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 Protein-protein interactions are essential to biological processes; 
therefore, developing methods to discover and characterize these interactions is 
of high importance to the scientific community.  Transcription, a fundamental 
cellular function, relies upon protein-protein interactions between a transcriptional 
activator and the protein complexes that are recruited to DNA in order to  
initiate the process. Given the relationship between transcription misregulation 
and disease, protein-protein interactions responsible for transcriptional regulation 
are attractive targets for therapeutic intervention. Despite considerable effort, the 
discovery of the direct and functionally relevant protein binding partners of 
transcriptional activation domains (TADs) of the amphipathic activator class has 
proven to be challenging, with a number of conflicting models. To create a detailed 
network map filling this void, an enhanced tRNA/tRNA synthetase pair has been 
developed to site specifically incorporate the photolabile nonnatural amino acid p-
benzoyl-L-phenylalanine (pBpa) in vivo (S. cerevisiae) into the amphipathic prototypical 
transcriptional activator Gal4 to capture the interactions through in vivo photo-
crosslinking. Applying this methodology, in vivo photo-crosslinking was used to 
detect a key binding partner of Gal4, the inhibitor protein Gal80.  This approach 
when followed by mass spectrometric analysis of crosslinked protein partners 
also resulted in identifying Gal80 as a protein in the purified crosslinked reaction 
mixture.  Using this technique other potential targets of Gal4 were identified 
under conditions where Gal80 is not inhibiting Gal4-activated transcription.  
Some of these potential targets, Ccr4, Mot2, Tra1, Ssl2, Mlp2, Abf1, Ctr9, Swi1, 
Hrr25, are consistent with previously suggested targets of amphipathic 
transcriptional activators while others are novel findings.  Further verification of 
these targets will be will be critical for elucidating the mechanism of 
 xii 
transcriptional activation, useful information for developing therapeutics designed 
















































     
 All cells have a unique transcriptional signature indicative of their overall 
function, cell cycle status and health.1 Although strategies are available to 
characterize these cells by their transcriptional signature(s), many fundamental 
questions exist surrounding the mechanistic details of activated transcription. 
One of the unanswered questions is what are the specific protein-protein 
interactions (PPIs) utilized by transcriptional activators.  The focus of my 
dissertation is aimed at answering this question by developing and implementing 
in vivo photo-crosslinking for uncovering the direct protein binding partners of the 
prototypical eukaryotic transcriptional activator Gal4.  
 
A.  Overview of transcriptional regulation 
 In the process of transcription, a cellʼs genetic material (DNA) is 
transcribed into mRNA which is then translated into proteins; as outlined above, 
appropriate regulation of this essential process is vital for the health and viability 
of the organism.  As a result, a variety of extra- and intracellular signal 
transduction cascades tightly regulate this process by controlling what proteins 
are localized at a gene promoter.2 A more detailed look at the mechanism of 
transcription initiation paints an exceedingly complicated picture of molecular 
recognition network that controls this process (Figure 1-1).2,3 Playing a central 
role in the process are transcriptional activators, proteins that are recruited to 
DNA in order to activate transcription. After the initial signal is relayed to the 
transcriptional activator, indicating transcription must be initiated, most activators 
interact with one or more enzymes that confer post-translational modifications. 
These modifications include phosphorylation, ubiquitylation, methylation, and 
sumoylation, all of which can alter the conformation, binding properties and   
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Figure 1-1:  General scheme of transcription.  Transcriptional activators are represented by 
blue circles connected to red squares.  Upon external signaling a transcriptional activator 
undergoes a post-translational modification, is shuttled to the nucleus and localized to DNA 
via the DNA binding domain.  Numerous proteins including chromatin modifying enzymes 
and the general transcriptional machinery including RNA polymerase are recruited to DNA 
for initiation of activated transcription.4  Reproduced with permission. 
 
cellular localization of the activator.5,6   If the activators are not already in the 
nucleus, they must be shuttled there in order to interact with DNA.  It is at the 
stage after the activator locates its cognate binding sequences in DNA that  the 
most complex and poorly understood binding interactions take place, as the 
activator must assemble the transcriptional machinery (RNA polymerase II and 
associated protein complexes) at the gene in order for transcription to be initiated 
through one or more direct binding events.2  Transcriptional activators are 
thought to possess a multipartner binding profile with proteins recruited to DNA.  
These proteins/complexes include a preinitiation complex (PIC) which is 
considered to be the general transcriptional machinery and is made up of TFIIA, 
TFIIB, TFIID (which includes TATA binding protein (TBP)), TFIIE, TFIIF,TFIIH, 
and RNA polymerase II.  Other proteins recruited are TBP-associated factors 
(Tafs), mediator, and proteins that aid in chromatin remodeling, SAGA and 
Swi/Snf complexes.3 Protein-protein interactions are essential to the regulation 
and function of transcriptional activation.  
 3 
 Misregulated gene expression leads to a disruption in the transcriptional 
signature of the cell and is a characteristic of disease. If misregulation should 
occur having a detailed map of the functional PPIs a transcriptional activator 
makes with proteins recruited to DNA for transcription initiation would be useful in 
designing transcription based-therapeutics designed to bring the transcriptional 
gene expression signature back to a healthy state.  The goal of my thesis 
research has been to develop tools and applying them to this system in order to 
capture these interactions in a cellular context. 
 
B. Misregulation and Disease  
 Gene expression profiling has shown that a hallmark of all diseases is 
aberrant gene expression.7 Due to this, transcription-based therapies intended to 
correct gene misregulation are being pursued by many researchers.8-12 One well-
characterized example is medulloblastoma, the most malignant pediatric brain 
cancer, that is proposed to stem from undifferentiated external granule-layer cells 
located in the cerebellum.  The mechanism of tumorigenesis is not fully 
characterized; however it is known that one protein, repressor element-1silencing 
transcription/neuron-restrictive silencer factor (REST/NRSF), is inappropriately 
expressed in these cells.  REST/NRSF acts as a repressor of a set of neuronal 
differentiation genes by binding to the promoter region where a transcriptional 
activator would bind, thereby inhibiting transcription.9,10 Conversely, in normal 
cerebellum tissue samples REST/NRSF is not expressed.  To compete with 
REST/NRSF binding to the promoter region an adenovirus vector for a fusion 
protein of the REST DNA binding domain and the viral transcriptional activator 
VP16 (REST-VP16) was used to infect mice with preformed medulloblastoma 
tumors.  After 4 weeks there was a visible decrease in tumor size (Figure 1-2).  In 
addition, gene expression of terminal neuronal differentiation genes and signs of 
apoptosis were present.10  
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Figure 1-2: A.  immuno-staining with anti-REST shows elevated REST protein expression in 
medulloblastoma cells.  B.  Mice infected with adenovirus containing REST-VP16 fusion 
protein results in a reduction in tumor size compared to the placebo after 4 weeks of 
treatment.10  Reproduced with permission. 
 
As discussed earlier the zinc finger motif is found in DBDs that bind DNA 
with high specificity.  To regulate gene expression, nonnatural zinc finger proteins 
(ZFPs) can be engineered to recognize a specific DNA sequence.  In one 
example a ZFP was designed to target a specific site on DNA upstream of the 
gene coding for vascular endothelial growth factor A (VEGF-A).  Aberrant gene 
expression of VEGF-A is associated with tumorigenesis, diabetic retinopathy, and 
ischemic heart and limb disease.  In this study, a designer ZFP fused to either 
VP16 or p65 transcriptional activator was able to activate endogenous gene 
expression of VEGF-A.11   Another study further demonstrated the utility of ZFP 
based transcription factors by infecting mice with an adenovirus vector containing 
the ZFP fused to VP16 resulting in induction of angiogenesis (Figure 1-3).12 
Currently, a ZFP is in Phase II clinical trials at Sangamo Biosciences, Inc.  It is 
being assessed for heath benefits in diabetic related illnesses.   
B. A. 
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A.        B.  
 
Figure 1-3:  Zinc finger protein transcription factor induces angiogenesis in mice. A) Mice 
injected with adenovirus coding ZFP transcription factor (right) shows visible 
neovascularization versus mice injected with adenovirus coding GFP on day 3.  B) Quantified 
vessel counts by immunohistochemistry. Day 3 for mVZ+509 and day 6 for mVZ+426 ZFP 
transcription factors.12 Reproduced with permission. 
 
C.  Transcriptional activator architecture 
 In order for transcription to be initiated a transcriptional activator must be 
localized to the DNA.13 Transcriptional activators are minimally composed of two 
modules or domains: a DNA binding domain (DBD) whose job it is to localize the 
activator to DNA in a site-specific manner and a transcriptional activation domain 
(TAD) which makes necessary contacts with the general transcriptional 
machinery recruited to the DNA in order for transcription initiation to occur.  
These two modules can exist within the same polypeptide or assemble through 
non-covalent interactions. Interestingly, these two modules may be separated 
where the TAD of one activator can be fused to the DBD of another and maintain 
function.4,13 One of the first examples of this domain swapping was done by 
Ptashne and co-workers where they fused the DNA binding domain of the 
bacterial repressor protein LexA to the TAD of the yeast transcriptional activator 
Gal4.  This fusion protein was able to activate transcription of a reporter gene 
only when the lexA operator was presented near the transcription start site.14 
This seminal experiment revealed the modular architecture of activators and lead 
NATURE MEDICINE • VOLUME 8 • NUMBER 12 • DECEMBER 2002 1429
ARTICLES 
Vegfa mRNA in mVZ+57-injected muscle as compared to adeno-
GFP-injected contralateral controls (Fig. 2e). In contrast, mVZ+57
did not activate Ldh1 or Glut1 and activated Pgk1 only slightly. As
a positive control, an adenovirus encoding the hypoxia-inducible
transcription factor HIF-1! was similarly tested and showed
markedly greater expression of all these genes (Fig. 2e).
Further studies investigated effects of mVZ+509 and mVZ+426
















































   
   

















































































Fold induction relative to control
j
Fig. 2 ZFP-mediated Vegfa activation and induction of angiogenesis in vivo.
a, Western blotting of smooth muscle cells transduced with adenovirus en-
coding Vegf-ZFP; the presence of FLAG epitope and VP16 transactivation do-
main (TAD) demonstrates effective expression of the Vegf-ZFP. b,c, Western
blots showing VEGF-A in the quadriceps muscle of CD-1 mice 3 d after intra-
muscular injection with 108 PFU of adenovirus encoding either mVZ+426 or
mVZ+57. VP16 TAD expression documents expression of the ZFP; actin ex-
pression documents equal loading. d, Western blot of Vegfa expression in
skeletal muscle 3 d after injection of plasmid DNA encoding either mVZ+426,
mVZ+509 or a control plasmid encoding a Vegfa-targeting finger region
without the VP16 TAD. e, Comparison of profiles of gene activation induced
by Vegf-ZFP mVZ+57 (light bars) and transcription factor HIF-1! (dark bars).
Real-time RT-PCR shows that injection of adenovirus encoding human HIF-1!
into the quadriceps muscle results in significant increases (P " 0.01) in the
amounts of mRNAs for phosphoglycerate kinase (Pgk1), t e glucose trans-
porter (Glut1) and the lactate dehydrogenase A chain (Ldha) as well as activa-
tion of Vegfa. In contrast, mVZ+57 activates Vegfa without activation of Glut1
or Ldh1 and with only a minimal increase in Pgk1 expression (n = 4 per group;
all values compared to contralateral control quadriceps injected with adeno-
GFP). f,g, Vegfa-activating ZFP expression induces angiogenesis in the mouse
ar. Subcutaneous injection f ad novirus encoding mVZ+509 results in visi-
ble neovascularization after 3 d relative to contralateral ears injected with ade-
novirus e coding GFP. Quantification by i munohistochemical vessel counts
3 d after mVZ+509 (n = 5) and 6 d after mVZ+426 (n = 4) corroborates the
neovascularization. In g, P < 0.001 (left); P = 0.001 (right). h, In similar exper-
iments, angiogenesis stimulated by mVZ+509 (top and middle right) does
not produce a hyperpermeable neovasculature as determined by Evans blue
dye extravasation (bottom right). The neovasculature induced by Vegfa164
adenovirus transduction (left) shows spontaneous hemorrhage and Evans
blue extravasation. i, Quantitative RT-PCR shows increases in mRNA of all 3
major Vegfa splice variants in vivo 3 d after VEGF-ZFP transduction. j, RT-PCR
shows increased total Vegfa mRNA, no substantial increases i  Agpt (an-
giopoietin), Vegfb or Vegfc mRNAs, and a moderate increase in Vegfd mRNA
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to an extensive effort toward understanding the structure and targets of each 
domain.2 
 
C.1  DNA binding domains 
 
 Of the two key domains, the DBD is better characterized.   It is the job of 
DBDs to bind DNA at a specific site where the TAD is then localized for up-
regulating a specific gene.15   A number of structural studies have revealed key 
features of their interactions with DNA and one can actually classify these 
domains structurally.16,17 This is in contrast to TADs, which are typically referred 
to in terms of primary amino acid content because there is so little known with 
regard to structure which will be discussed in the next section.  Common DNA 
binding structural motifs include helix-turn-helix, zinc finger and leucine 
zipper.16,17 For example, the DBD of the well studied transcriptional activator 
Gal4 binds DNA as a dimer through a Zn2Cys6 binuclear cluster (Figure 1-4).18 In 
many cases DBDs, like Gal4, bind DNA as oligomers.  They are regulated by 
post-translational modifications (phosphorylation, ubiquitylation, etc.) which may 
prevent DNA binding or protect them once on DNA from proteasomal 
degradation; this is the case with the Gal4 DBD when it is monoubiquinylated.5,6  
                           
Figure 1-4:  Crystal structure of Gal4 DBD (1-100) in complex with DNA.  The two subunits 
of the dimer are colored green and blue.  The zinc ion is yellow, DNA is gray and the two 
CGG DNA sites are in red.  11 base pairs are located in between the two CGG recognition 
sites.18 Figure from PBD 3COQ.  Reproduced with permission. 
 
and 3C, each of these mutants showed reduced DNA binding,
although the effects were relatively modest, with the most
debilitating L67A/I80A/L81A triple mutant showing only about
a 2-fold reduction in binding. We also prepared more drastic
mutations to glutamate residues of residues 67, 80, 81, 89, and
93; however, each of these mutant proteins were unstable and
could not be purified, arguing that more drastic mutations are
not tolerated (data not shown). Taking this result together with
the more dramatic reduction in DNA binding for Gal4(1–65) rela-
tive to Gal4(1–100), we conclude that dimer interactions are
not additive, but function cooperatively to facilitate Gal4 binding
to DNA.
Role of Gal4 Dimerization on Protein Stability
To investigate the role of Gal4 dimerization on protein stability,
we studied the wild-type and mutant Gal4(1–100) proteins with
differential scanning calorimetry (DSC). The wild-type protein
shows a complex thermal denaturation curve that is irreversible
and yields three melting transitions (Tm1, Tm2, and Tm3)
(Figure 4A and Table 2). We hypothesize that Tm1 corresponds
to melting of the Gal4 dimer, with Tm2 corresponding to melting
of the dimerization domain within a protein subunit, and Tm3
corresponding to the melting of the binuclear cluster domain.
The wild-type protein shows melting values of 69.4!C, 83.4!C,
and 88.0!C for Tm1, Tm2, and Tm3, respectively. Analysis of the
L67A/I71A, L67A/I80A/L81A, L67A/I89A, and L67A/L93A mu-
tants reveals decreased Tm values for each of the three transi-
tions, suggesting an overall reduced thermal stability of each
of the mutants. Interestingly, Tm1, which we hypothesize corre-
sponds to the dimer-monomer transition, shows the greatest
decrease in thermostability, with a decrease of between 8!C
and 14!C, depending on the specific mutant. The other thermal
Figure 1. Crystal Structure of the Gal4-
(1–100)/DNA Complex and Comparison to
Related Structures
(A) The structure of the Gal4(1–100)/DNA (green/
gray) and Gal4(1–65)/DNA (pink/orange) com-
plexes are superimposed.
(B) A view of the Gal4(1–100)/DNA complex look-
ing perpendicular to the 2-fold axis. The two
subunits of the dimer are colored in blue and
green, respectively, with zinc ions in yellow. The
DNA is colored gray with the CGG half-sites
colored red.
(C) A view looking down the 2-fold axis.
(D) Superimposition of the crystal structure of the
Gal4(1–100)/DNA complex with the NMR solution
structure of the Gal4(50–106) dimerization domain
(magenta).
transitions showmore modest decreases
in thermal stability of between 1!C and
6!C. This result demonstrates that the
dimerization domain of Gal4 plays an
important role in Gal4 thermostability.
We further evaluated the effect of di-
merization mutants (L67A/I71A, L67A/
I80A/L81A, L67A/I89A, and L67A/L93A)
on the mobility of the Gal4(1–100)/DNA
complex using molecular dynamic (MD) simulation to account
for protein flexibility within a simulated solution environment.
The starting structures for wild-type and mutants were directly
extracted or mutated from the wild-type crystal structure re-
ported here. All systemswere subjected to 600 psMD simulation
separately and the averaged root-mean-square fluctuation
(rmsf) values of each residue were used to measure the protein
stability and to gain insight into possible structural fluctuation.
The results of this analysis are presented in Figure 4B and reveal
that each of the protein mutants produces larger protein fluctu-
ations than the wild-type protein. Taking together the experi-
mental and theoretical results, our data are consistent with an
important role for theGal4 dimerization interface that is observed
in the structure of the Gal4(1–100)/DNA complex for protein ther-
mostability.
Gal4 Dimerization as a Function of DNA Binding
A surprising outcome of our studies is that the dimerization
domain of Gal4(1–100) bound to DNA shows considerable diver-
gence from the more elongated DNA-free dimerization domain,
as determined by solution NMR (Hidalgo et al., 2001; Figure 1D).
This comparison suggests that either the Gal4 dimerization do-
main might undergo a DNA-induced conformational change
from the DNA-free elongated NMR conformation to the more
compact DNA-bound conformation. Alternatively, the observed
solution NMR structure might be an artifact of the conditions
used in the NMR study, and, therefore, does not represent a
populated solution conformation in vivo.
Given the unusual elongated shape of the free Gal4 dimeriza-
tion domain, as measured by solution NMR, we first tested
whether the NMR solution structure represents the only dimer
conformation that could form in solution. To do this, we prepared
Structure
Structure of a Gal4 Dimer on DNA
Structure 16, 1019–1026, July 2008 ª2008 Elsevier Ltd All rights reserved 1021
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C.2 Transcriptional activation domains 
 TADs typically fall into one of three categories based on their primary 
amino acid sequence: amphipathic, proline-rich and glutamine-rich. The 
amphipathic class of activators, distinguished by their interspersion of 
acidic/polar and hydrophobic residues, is the most studied class.  Their function 
is generally considered to be conserved throughout eukaryotes based on their 
ability to maintain their function in different eukaryotic species,.19 For example, 
the yeast activator Gal4 functions in every eukaryote tested, from yeast to mice 
to human.12,20 Therefore, studying this class of activators in one eukaryotic 
system provides information about how they operate in other systems. Found in 
this class are the yeast activators Gal4 and GCN4, the herpes virus activator 
VP16 and the mammalian activator p53, all of which are highly studied and serve 
as models for how this class of activators operates. Mutagenesis studies of these 
TADs have lead to the identification of the minimal activation domain sequences 
of the protein that are essential for maintaining functional transcriptional 
activators (Figure 1-5).21-24 In the case of  
 
Figure 1-5:  Amino acid sequences of amphipathic TADs Gal4, Gcn4, VP16.  There is an 
interspersion of hydrophobic (black) and acidic/polar (green) residues.  Despite have little 
sequence homology all act as TADs. 
 
Gal4, Ptashne and co-workers performed experiments where they created 
truncated versions of Gal4 and found that minimally, the 881 amino acid protein 
requires the N-terminal DBD (1-147) fused to the last 30 amino acids (851-881) 
in order to maintain function.22 Further, fusing Gal4 (1-100) to the last 41 amino 
acids results in only a 2-fold reduction in activation of transcription when 
expressed from the ACT1 promoter, remarkable considering ~85% of the protein 
is deleted.25 This minimal transcriptional activator is fully functional in the sense 
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that it response to environmental cues.  Since Gal4 regulates the genes whose 
product is responsible for galactose metabolism it is sensitive to sugars in the 
enviroment.  For example, when glucose is present transcription is repressed by 
Gal4 interacting with an inhibitor a protein, Gal80.  Conversely when galactose is 
present Gal4 is no longer repressed and transcription may occur.13 
 
C.2.a  Structural studies of TADs 
 In contrast to DBDs, TADs have proven to be much more challenging to 
study due to being intrinsically unstructured and having a poorly characterized, 
multipartner binding profile.2   Several studies have suggested that TADs form an 
α-helix upon protein complex formation with proteins in the transcriptional 
machinery.26-28 One example is that of the TAD of CREB when it interacts with 
CBP/p300, a member of the transcriptional machinery.26 It is possible that TADs 
may form other secondary structures upon binding other protein targets.29 
 
C.2.b. Transcriptional activation domains interact with masking proteins 
 TADs not only contact proteins that are recruited to DNA to activate 
transcription they also interact with masking proteins that regulate this process by 
binding to them and inhibiting transcription.30 One such example is the well-
characterized p53-MDM2 interaction.  p53, a transcriptional activator, becomes 
inhibited when the MDM2 oncoprotein binds to its activation domain.  p53 
misregulation occurs in many types of cancer (>50%) and is a result of either a 
mutation that produces a functionally inert protein or MDM2 is over expressed.31-
33  Upon interacting with MDM2, p53 TAD forms an α-helix, burying its 
hydrophobic residues in MDM2ʼs hydrophobic cleft (Figure 1-5)   More recently,   
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Figure 1-6: X-ray crystal structure of p53 peptide in complex with MDM2.  p53 forms an 
amphipathic α-helix upon binding MDM2, with hydrophobic residues, Phe19, Trp23 and 
Leu26 on one face of the α-helix buried in the MDM2 binding cleft.30  Reproduced with 
permission. 
 
an NMR structure of the intrinsically disordered activation domain was solved.  In 
this experiment they used a full-length p53 that contains modifications, not in the 
TAD, that help to stabilize the protein.  This study suggests that p53 forms an α-
helix in the absence of MDM2.34,35 There is, however, conflicting evidence 
suggesting that upon binding to its masking protein Gal80, Gal4 TAD is capable 
of forming a β-hairpin.29,36 However, a recent x-ray crystallographic study of Gal4 
TAD complexed with Gal80, from Kluyveromyces lactis (K. lactis), defined an α-
helical conformation upon binding Gal80 but this was only a small fragment.37   
To conclude, TADs make contacts with the both masking proteins and 
protein complexes that are recruited to DNA for activated transcription. As 
discussed earlier, besides the general transcriptional machinery other proteins 
are localized to DNA for transcription to occur. Many genetic and biochemical 
approaches, which will be discussed in the next section, have been used to 
identify the direct protein targets of amphipathic TADs but because these have 
not clearly defined the targets, conflicting models exist.  It is the aim of my 
dissertation to develop a tool to study these interactions in a cellular environment 
resolving the complicated TAD-protein target interaction network.  
RESEARCH ARTICLES 
wide, deep pocket. The remaining portion, 
where the extended region of p53 makes 
only a few contacts, is narrower and shal- 
lower, and offers a smaller interaction area 
with little hydrophobic character. The 
asymmetry in the cleft results, in part, from 
the o2 helix in the first repeat being about 
one turn longer than the corresponding o2' 
helix in the second repeat, and the middle ,B 
sheet being larger than the terminal ,B sheet 
at the other end of the cleft (Figs. 2 and 3). 
Structure of the p53 peptide. The p53 
peptide used in the crystallization is 15 
amino acids long (residues 15 to 29), but 
only 13 amino acids (residues 17 to 29) are 
ordered in the crystals. Residues 18 to 26 
form an amphipathic a helix (Fig. 4A), 
and residues 17 and 27 to 29 at either end 
are in extended conformations (Fig. 4). 
The helix is a regular a helix until its 
COOH-terminal portion where it makes 
one 310 helical hydrogen bond. 
Contributing to the initiation of the a 
helix is a network of hydrogen bonds 
formed by the Thr'8 and Asp21 residues. 
The Thr'8 side-chain hydroxyl group hy- 
drogen bonds with the backbone amide and 
side-chain carboxyl groups of Asp21, and 
the Thr'8 backbone amide hydrogen bonds 
with the Asp21 carboxyl group as well. On 
the hydrophobic face of the amphipathic 
p53 helix, three of the hydrophobic amino 
acids (Phe19, Trp23, Leu26) have extended 
side-chain conformations and pack close to 
each other, making sequential van der 
Waals contacts (Fig. 4). Most noteworthy 
are the aromatic side chains of Phe'9 and 
Trp23, which stack face-to-face in a stag- 
gered arrangement (Fig. 4). The remaining 
two hydrophobic amino acids (Leu22 and 
Leu25) have less extended side chains and 
do not interact with any of the others, 
packing instead with the body of the a 
helix (Fig. 4A). The two charged amino 
acids of the helix (Asp21 and Lys24) are 
within salt bridge distance, although the 
amino group of the lysine is partially disor- 
dered, presumably because of the high ionic 
strength of the crystallization solution. Im- 
mediately after the a helix is Pro27, which is 
likely to contribute to its termination, and 
Glu28 and Asn29, which have extended 
backbone conformations. 
In the absence of MDM2, the a helix is 
readily digested by proteases, including 
cleavage at Trp23 (31), and it is possible 
that it is only loosely folded, or folded in 
only a fraction of the molecules. Stable 
helix formation may thus be induced by 
the fitting of the hydrophobic amino acids 
in the cleft of MDM2. 
Structure of the MDM2-p53 interface. 
The MDM2 cleft is lined with 14 conserved 
hydrophobic and aromatic amino acids that 
make multiple van der Waals contacts to 
p53 (Met50, Leu54, Leu57, dGy58, Ile61, and 
Met62 from the o2 helix, Tyr67, His73, 
Val75, Phe91, and Val93 from the middle ,B 
sheet, and His96, Ile99, and Tyr'00 from the 
o2' helix, Fig. 4). The p53 helix binds at 
the entrance of the cleft, packing, on one 
side, with the x2 helix of MDM2 in an 
antiparallel orientation and, on the other 
side, with the ends of the MDM2 middle 3 
sheet (Fig. 4). The ,B sheet ends contain 
reverse turns (two turns between ,B3 and 
(31' and one between 132' and o2') and they 
provide a rigid surface on which the p53 
helix packs (Fig. 4B). The position of the 
p53 helix allows Phe19, Trp23, and Leu26, 
which are aligned along its hydrophobic 
face, to insert deep inside the MDM2 cleft 
(Fig. 5A), and pack with the cleft in a 
complementary fashion (Fig. 5B). The clos- 
est approach at the interface occurs be- 
tween Phe19 and Trp23 of PS3 and the body 
of the x2 helix of MDM2. Phe19 makes van 
der Waals contacts to Ile61 and Gly58 of 
MDM2, while Trp23 makes van der Waals 
contacts to Gly58 and Ile61 (Fig. 4). Addi- 
tional van der Waals contacts are provided 
by Leu22 of p53, which packs against the 
side of the MDM2 cleft (13 sheet). 
After the a helix, the extended region of 
p53 (residues 27 to 29) packs against the 
shallow end of the MDM2 cleft (Figs. 4 and 
5A). There are only a few van der Waals 
contacts in this region, and they primarily 
involve the Pro'9 side chain of p53. The 
COOH-terminal Glu28 and Asn29 residues 
also pack against MDM2, but they are par- 
tially disordered, and we presume that they 
do not contribute significantly to binding. 
The p53-MDM2 interface buries 1498 
A2 of surface area, most of which is hydro- 
phobic. The van der Waals contacts at the 
interface are augmented by only two inter- 
molecular hydrogen bonds: one between 
the Phe19 backbone amide of p53 and the 
Gln72 side chain of MDM2 at the entrance 
of the cleft (Fig. 4), and another between 
the p53 Trp23 indole group and the MDM2 
Leu54 backbone carbonyl deep inside the 
cleft (Fig. 4). 
Fig. 5. The MDM2 cleft contains, in its p53 binding portion, a deep pocket 
where a triad of hydrophobic and aromatic p53 amino acids-Phe19, Trp23, 
and Leu26 -insert into. (A) Surface representation of the MDM2 cleft with gray 
concave regions highlighting its pocket-like characteristics. The p53 amino 
acids that interact with this surface are shown in yellow, and are labeled. 
Orientation is similar to Fig. 2A and the regions corresponding to the o2 helix 
and ,B sheet of MDM2 are labeled. (B) Phe19, Trp23, and Leu26 of p53 form a 
structure that is highly complementary to the MDM2 pocket, and fit tightly in it. 
A cross section of the interface showing the complementarity of p53 with the 
MDM2 pocket. The MDM2 surface is represented as a blue wire mesh and p53 
residues 18 to 27 are in space filling representation. The orientation is similar to 
that of Fig. 4B [prepared with the program GRASP (52)]. 
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D.  Transcriptional activation domains and their direct protein binding 
partners 
As outlined in section B, knowledge about transcription mechanisms can 
lead to the development of new therapeutic strategies that are dependent on the 
DNA sequence for delivery of the transcription-based therapy, a work still in 
progress.  Likewise, researchers have been working to uncover the direct protein 
partners of TADs, information that would be very useful when trying to design 
new methods for controlling gene misregulation and disease.38-40 One could use 
this information to make TAD mimics, that could be used to activate or inhibit 
transcription depending on the context. 
 When transcriptional activators are localized to DNA through their DBD 
they are then poised for making the necessary contacts with proteins that are 
recruited to the DNA, needed to initiate transcription.  Transcriptional activators 
need to recruit many proteins with different enzymatic functionalities to promoters 
and they are thought to make contacts with several of these proteins however, 
which ones they are directly contacting for activating transcription are not clearly 
defined. Considerable effort has been made toward uncovering these protein-
protein interactions, however conflicting models still exist (Figure 1.7).  This 
section outlines a history of the techniques used and the resulting proteins 
identified as potential targets of amphipathic TADs.  It also shows that despite all 
the efforts thus far, clear targets have not been defined.   
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Figure 1-7:  Timeline of proteins and protein complexes discovered as potential targets of 
TADs.  The direct and functional targets of TADs are still debatable.2 Reproduced with 
permission. 
 
D.1 General transcriptional machinery as targets of transcriptional 
activators 
 Starting in the 1980s, in vitro studies were carried out to discover the 
proteins that interact with amphipathic TADs.  In an early study it was found that 
VP-16 and the mammalian activator ATF interact with the TATA box binding 
protein (TBP) in TFIID.41,42   This was followed by the discovery that TFIIB, a 
protein that stabilizes the TBP-TATA complex, was a potential target.43,44 Next, a 
mutagenesis study suggested that TFIIA was important for transcription induced 
by amphipathic activators.45 Also, through affinity chromatography of mammalian 
whole cell extracts interacting with amphipathic activators, p53 and Vp16, TFIIH 
was isolated, thus adding this protein to the fast-growing list of potential protein 
targets of TADs.46 By the mid-1990ʼs nearly every component of the general 
transcriptional machinery that makes up the transcription preinitiation complex 
(PIC) were considered targets of amphipathic TADs.   
 A detailed study by Pugh and Tijan revealed that proteins that are 
complexed with TBP and TFIID, known today as TBP-associated factors (Tafs), 
in fact act as the adaptors between the TADs and the general transcriptional 
machinery.47 This was further confirmed by Poon and Weil who immunopurified 
TBP in complex with Tafs.48 These factors were then thought to be essential for 
Proteasome 
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activator-mediated transcription and thought to be targets of TADs.49 In vitro 
studies have showed that TAFs are not necessary for basal transcription but are 
needed for activated transcription.50 51 However, the idea of Tafs acting as 
adaptor proteins between TADs and the general transcriptional machinery was 
questioned based on results from in vivo studies.  In these experiments TAF 
depletion had little affect on transcription initiated by transcriptional activators 
such as GCN4 and Gal4.  These findings indicated that TAFs are not a general 
requirement for transcriptional activation in yeast.50,51 This information drove 
researchers to focus their attention toward discovering protein complexes other 
than those associated with TBP and that are localized to DNA during activated 
transcription for TAD-protein target identification.  It was observed in vitro that 
dosing in excess transcriptional activator caused an inhibition of transcription 
also known as “squelching” and that adding additional amounts of the general 
transcriptional factors did not relieve the inhibition.21,52,53 This indicated that the 
transcriptional activators are competing for a target, perhaps a generally 
unknown factor, and that the general transcription factors are not the clear 
target.54  
 
D.2 The Mediator complex and the proteasome as targets of 
transcriptional activators 
 The Mediator is one of the protein complexes that is localized to DNA for 
transcription to take place.  It was identified, then called Srb/Mediator, through 
purifying RNA polymerase II and functional assays on purified systems.55,56 This 
complex was thought to form stably with RNA polymerase II and in this form it 
was thought to be recruited to DNA and make contact with transcriptional 
activators, those tested were of the amphipathic class.57,58 Although the 
discovery of the Srb/Mediator complex was considered a huge step forward 
toward as this complex was thought to bridge or “mediate the TAD interaction to 
the RNA polymerase, much speculation arose when one protein, Sug1 an 
ATPase, originally thought to be a target and component of the Mediator/RNA 
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polymerase II, was found to actually be a part of the 26S proteasome.59,60 61 
Indeed, the proteasome is not considered a member of the transcriptional 
machinery; however, it is thought to play an important role in regulating 
transcription by controlling the activator stability in the cell or abundance through 
activator turnover by proteolytically degrading the activator after it initiates 
transcription.62 More recently Sug1 and Sug2, components of the 19S 
proteasome, have been thought to actually play a role in transcription elongation 
both in vitro and in vivo, contrasting the original functional role of the proteasome, 
that it is strictly associated with proteolysis mediated transcriptional regulation, 
thereby making it a potential target of activators.63-68    
 
D.3  Chromatin-remodeling complexes as targets of transcriptional 
activators 
 As the Mediator complex was being questioned for its validity of being a 
functional activator target other classes of proteins were being studied for their 
role in transcription initiation by activators, chromatin remodeling and chromatin 
modifying complexes. Chromatin remodelers and modifiers play a role in 
regulating transcription because DNA structural change allows the promoter 
region to be accessible for activator binding and recruitment of the general 
transcriptional machinery.69,70 It was thus not surprising when Workman et al. 
found that TADs were able to recruit the SWI/SNF complex, an ATP-dependent 
nucleosome remodeling enzyme, to promoters.39,71 Likewise, chromatin 
modifying enzymes, like those located in the SAGA complex are histone 
aceltyltransferase (HATs) which modify lysine side chains found in the histone 
proteins that compose the nucleosomes, have also been thought to be recruited 
to DNA via TADs.72 The SAGA complex participates in at least five functions 
including: activator binding, making contacts with TBP, recognizing methylated 
histone H3, HAT activity and deubiquitinating actions therefore this 
macromolecular complex was not to be dismissed when trying to understand 
transcriptional activator interactions and mechanisms.66 Acetylation by HATs is 
 14 
reversed by histone deacetylases (HDACs) which is associated with gene 
repression and have been studied for their role in gene expression.73 Rpd3 the 
yeast HDAC will be discussed further in Chapter 5. 
 In summary, this section outlines 25 years of scientific research aimed 
toward a single goal of determining the transcriptional mechanism surrounding 
the protein-protein interactions that transcriptional activators make with proteins 
that participate in transcription regulation.  As techniques improved over the 
years some initial studies were proven false only to uncover more uncertainty in 
the field with each new target identified as a player in activated transcription.  In 
the recent past new technology has set the stage for successfully painting a 
clearer picture of what contacts are being made between TADs and the library of 
potential protein targets.  The next section will outline the current stage of the 






















Protein complex Protein Methods used 
TFIID TBP 
Taf12 
Affinity chromatography (41) 
DNase footprinting (42) 
ChIP(76) 
125I-PEAS (38,40,80) 
TFIIB  Affinity chromatography(43, 44) 
 
TFIIA  Mutagenesis (45) 







Protein deletion (74) 
125I-PEAS crosslinking (38,40, 80) 
Proteasome Sug1, Sug2 Pull-down(59,63) 





















125I-PEAS crosslinking (38,40, 80) 
 Mbf1 Protein deletion (78) 
RSC complex Rsc1 Protein deletion (78) 
Paf complex Cdc73 
Hpr1 
Protein deletion (78) 
CCR4-NOT complex Ccr4 
Dbf2 
Caf1 
Protein deletion (78) 
Table 1-1:  Transcription proteins and complexes identified with various techniques as interacting 
with amphipathic TADs. 
 
E.  The search continues:  current methods used to identify activator-
targets  
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Traditional biochemical and genetic techniques have principally answered 
questions regarding what proteins are present at the time that transcription is 
occurring and the function of these proteins in relationship to regulating activated 
transcription. Due to the complex nature of transcription however, these 
techniques did not answer a more specific question surrounding the direct and 
functional targets of TADs.  Traditional genetic deletions can make it difficult to 
determine if the effect of the deletion on transcription is directly or indirectly 
related to loss of TAD contacts, especially if the protein is in a complex. The 
change in transcription can be a direct result of the TAD not being able to make 
contact the deleted protein or a result of the complex becoming destabilized as a 
result of the absent protein.  Due to this, the data from genetic deletions of 
transcription proteins can be difficult to analyze.   For example Swanson et. al. 
performed extensive protein deletions and studied the effect these deletions had 
on GCN4 transcription.  Not surprisingly, they report many proteins found in 
Swi/Snf, SAGA and mediator complexes as well as several other 
proteins/complexes as a requirement for GCN4 transcription.74   Whether these 
are relevant targets is yet to be fully understood. Biochemical colocalization 
technology is difficult to interpret as well because many times the experiments 
were carried out in vitro and using a purified system.  Even chromatin 
immunoprecipitation (ChIP), which can be performed in vivo shows protein 
occupancy on DNA, does not determine whether two proteins are direct partners 
but rather if they are colocalized to DNA.   In the last 5-10 years there has been a 
surge of development and application of new methods for studying these 
interactions in live systems making the interpretation of the results much more 
clear and moving the field forward.  
  
E.1 Chromatin Immunoprecipitation for identifying targets of transcriptional 
activators 
 As described earlier, the amphipathic class of activators is the most well 
studied and the three members that are used in recent studies are Gal4, GCN4 
 17 
and VP16.  Towards identifying their direct protein targets, ChIP experiments 
have been used by researchers.  ChIP is an experiment that is designed to study 
proteins that are localized to DNA.  In these experiments formadehyde is used to 
crosslink proteins to DNA.  Next, the cells are sonicated to shear the DNA.  The 
proteins are immunopurified and then they can be analyzed by Western blots and 
polymerase chain reaction can be used to determine the DNA that was 
associated with the proteins bound.   Whether or not the proteins are actually 
contacting one another would require many more experiments.  ChIP assays 
carried out with GCN4 in vivo revealed the HAT GCN5, a member of the SAGA 
and ADA complex, was targeted to the promoter region by GCN4.75 In a similar 
experiment, a ChIP assay was performed in yeast to identify targets of VP16 
resulting in TBP, multiple TAFs and Tra1 being observed.76 Likewise, Bhaumik 
and Green found SAGA to be localized to the  Gal4 upstream activation 
sequence (UAS), a section of the promoter that bears Gal4-binding sites, using 
this technique.77 ChIP experiments do not help determine if the activator is 
interacting with the proteins directly or if they are simply neighboring each other 
with another adaptor protein bridging the two. 
 
E.2 Förster resonance energy transfer and in vitro photo-crosslinking 
techniques for detecting targets of TADs  
 A few years later more evidence was presented for components of SAGA  
to potentially interact with TADs through in vivo FRET, a technique used to study 
proteins that are in close proximity through the use of a pair of fluorophores.  
Specifically, they found that Tra1, a subunit of the SAGA complex interacts with 
Gal4 in yeast.78 Although FRET is a powerful technique in that one can visualize 
the interactions in vivo, it too has limitations in capturing protein-protein 
interactions in this context.  One limitation is that false-positives occur by two 
proteins being brought together by a bridging protein and the two proteins are not 
directly interacting.  Likewise, false-negatives may occur if the fluorophore is not 
positioned in such a manner to make it capable of interacting with its fluorophore 
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partner.  Further, when proteins are in complexes, as is the case of many 
transcription proteins, interpreting a positive FRET signal becomes very 
challenging as it is difficult to say what is bridging the two fluorophores.  
Additionally, when proteins, like those related to transcription, are found in low 
abundance in the cell, a FRET signal may be difficult to detect.79   
 Another technique used to study these interactions is in vitro photo-
crosslinking.  The advantage of this technique is that one has the possibility of 
identifying the direct binding partner and, in some cases, even the actual binding 
site. In this experiment, a crosslinking capable label is placed on the 
transcriptional activator and upon UV irradiation covalent bonds are formed 
between the TAD and any protein(s) that are in close proximity.  In the case of 
transcriptional activators, this had only been accomplished in vitro prior to the 
work outlined in this dissertation. For example, Hahn and coworkers identified 
direct binding partners of the yeast activator Gcn4 by labeling the protein with 
125I-PEAS, an aryl azide photo reactive crosslinker at the end of a linker that 
attaches to proteins through disulfide bond formation with cysteines, discussed in 
more detail in Chapter 4 (Figure 1-8).40,80 They found that in the promoter-bound                               
                            
                  Figure 1-8:  Structure of PEAS aryl azide photo-crosslinking moiety. 
state in the presence of purified preinitiation complex (PIC), GCN4 formed 
crosslinks with Tra1, a component of SAGA, Med15(Gal11), part of mediator and 
Taf12, part of TFIID.40,80   Tra1 is part of SAGA complex, Med15 is a component 
of the Mediator.  Based on previous studies, see above, all of these are 
components of larger complexes that all have been suggested to interact with 
amphipathic TADs.  Also, Sin4/Med16 was identified as a target of only the N-
terminal Gcn4 activation domain.80 Using 125I-PEAS labeling and Gal4 as the 










photo-crosslinking was carried in the presence of purified PIC and TAD.38   It is 
interesting that the same binding partners were identified, given the lack of 
sequence homology of the sequences. This strengthens the idea that identifying 
the direct targets of an amphipathic TAD, like Gal4 in my thesis research, can be 
applicable to other amphipathic activators of particular interest in higher 
eukaryotic organisms.  125I-PEAS contains a linker that extends the crosslinking 
moiety 14 Å from the α carbon of the cysteine to which it is attached so the 
crosslinker could possibly capture indirect partners that are bridging the TAD to 
the actual direct partner rather than the direct protein partner itself.81 Additionally, 
these experiments were performed in vitro where the crosslinking may not yield 
true protein targets in the absence of a complex cellular environment.  
 The above experiments were groundbreaking in that it was the first time 
that the binding preferences of DNA-bound activators had been defined through 
crosslinking. There have, however, been a number of studies in which in vitro 
photocrosslinking was used to investigate the binding behavior of isolated TADs. 
Sulfo-SBED is a crosslinking reagent that had been used to identify targets of 
GCN4 and VP16 and components of purified Swi/Snf complex.  Sulfo-SBED is 
conjugated to the lysines on the TAD and contains a photoreactive aryl azide, a 
disulfide bond and a biotin label.  Upon UV irradiation, crosslinks are formed via 
the aryl azide.  DTT is then added to disrupt the disulfide bond, thereby removing 
the activator and leaving the biotin handle on the target which is used for 
Western blotting with a streptavidin antibody for detection of crosslinked targets.  
From these experiments subunits of the Swi/Snf complex, Swi1, Swi2/Snf2 and 
Swf5, were thought to interact with both GCN4 and VP16.82 A disadvantage of 
using Sulfo-SBED for crosslinking experiments is that it nospecifically labels all 
lysines in a protein which can result in many proteins not related to the question 
at hand being crosslinked.  Further nonspecific labeling is not compatible with in 
vivo studies because all proteins would be susceptible to labeling resulting in 
everything being crosslinked and little information about direct targets of TADs 
would be resolved.    
 20 
 Although technically challenging, progress has been made toward 
capturing the interactions that take place between TADs and proteins recruited to 
DNA for activated transcription.  All of the methods presented here have helped 
to move the field forward, but they all have limitations in their capabilities to 
capture the relevant interactions taking place in vivo.  Due to the complex nature 
of transcription and limitations of the current methods used to capture these 
direct interactions there was a need for a new tool to study these problems. 
 
F.  Thesis Overview 
 Outlined in this Chapter is a description of the general architecture of 
transcription and the progress that has been made by researchers toward 
understanding what interactions takes place between the numerous proteins that 
are recruited to DNA for transcription to occur.  Methods intended to control 
misregulated gene expression however, are limited by the lack of an accurate 
map of the TAD-protein network involved in transcription regulation.  To this end 
Chapter 2 describes the development and implementation of a new tool, in vivo 
photo-crosslinking using p-benzoyl-l-phenylalanine (pBpa).  After verifying the 
utility of our chemical biology tool by capturing a known TAD-protein interaction, 
we extended our study in Chapter 3 to identifying unknown relevant protein 
targets of Gal4 by analyzing photo-crosslinked samples with mass spectrometry.  
Finally, in Chapter 4 an analysis of two photo-crosslinking moieties, pBpa and p-
azido-l-phenylalanine (pAzpa) for capturing PPIs is studied based on their 
reaction mechanism and amino acid propensity at hetero-complex interfaces.  In 
summary, this research is aimed at developing and implementing an in vivo 
method for mapping the protein-protein interactions between Gal4 TAD and its 
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Development of in vivo photo-crosslinking for capturing transcriptional 
activator Gal4•protein interactions* 
A. Project focus 
 Given the central role of protein-protein interactions in biological functions, 
the development of methods for the discovery and characterization of such 
interactions has been of paramount importance in the scientific community.1-4 
Ideally these methods are compatible with live-cell studies so that protein-protein 
interactions can be investigated in their native environment.  Towards this end, 
recent advances in nonsense suppression technology have enabled the site-
specific incorporation of amino acids bearing moieties for photoactivatable cross-
linking reactions into proteins in bacteria, yeast and human cells.5,6 However, 
there have been few applications of this technology in eukaryotes, perhaps due 
to challenges in obtaining efficient incorporation of the nonnatural amino acids as 
well as limited knowledge about the impact of these changes on structure and 
function.7-10 To study the affect of incorporating nonnatural amino acids into the 
Gal4 in live yeast and to directly uncover the protein-protein interactions between 
Gal4 TAD and its protein partners, our goal was to implement this methodology.   
To this end, p-benzoyl-l-phenylalanine (pBpa), a nonnatural amino acid with 
photo-crosslinking capabilities, was incorporated in vivo (S. cerevisiae) into 
various positions throughout the amphipathic transcriptional activator Gal4 with 
photo-crosslinking reactions resulting in a capture of the Gal4 repressor protein, 
Gal80.11     
 
 
*portions of this chapter have been published:  Majmudar, C.Y., Lee, L.W., Lancia, J.K., 
Nwokoye, A., Wang, Q.,Wands, A.M., Wang, L., Mapp, A.K., J Am Chem Soc 2009, 131, 14240. 
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B.  Background 
 With few exceptions, Nature selects from 20 natural amino acids for 
protein construction.6,11 The side chains of the constituent amino acids contribute 
to the both the structure and function of a protein, participating in intra- and 
intermolecular interactions as well as functioning directly in chemical reactions. 
Therefore, perturbations in the amino acid sequence of a protein can have 
profound effects.  Indeed, amino acid mutagenesis is a strategy widely used to 
characterize the molecular interactions and functions of a protein as well as study 
the role of individual amino acids in those processes.12-14 Both to further expand 
the utility of mutagenesis for protein study and to potentially enhance the function 
of proteins, there has been a great deal of effort aimed at expanding the group of 
amino acids that can be incorporated into proteins beyond the typical twenty. 6,15  
In the following sections, approaches towards accomplishing this are outlined. 
 
      B.1 Genetically encoding nonnatural amino acids in bacteria 
 Incorporating nonnatural amino acids with unique functionality, like photo-
caged or photoactivatible moieties, into proteins is useful for studying biological 
systems.   In order to genetically encode a nonnatural amino acid in a living 
system, several things must be considered.  For example, site-specific 
incorporation of nonnatural amino acids into proteins requires a unique codon for 
the nonnatural amino acid.  In early efforts towards this end, the amber stop 
codon (TAG) was initially chosen because it possesses two desirable qualities. It 
is the least used stop codon from bacteria (present at ~7% coding genes) to 
eukaryotes.5,16 During translation, a tRNA that recognizes a certain codon coding 
for an amino acid is charged with the appropriate amino acid by its cognate tRNA 
synthetase (Figure 2-1).  There is a unique tRNA/synthetase pair in nature for 
each of the 20 natural amino acids and none that recognize the amber 
suppressor stop codon.  Therefore, a unique tRNA/synthetase pair was 
engineered, that utilized the endogenous translational  
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Figure 2-1:  General nonsense suppression method for site-specifically incorporating 
nonnatural amino acids in vivo (S. cerevisiae).5  Orthogonal tRNA/synthetase pairs are 
engineered to charge the tRNA, that recognizes the amber stop codon, with a nonnatural 
amino acid that goes on the to work with the endogenous translational machinery for 
incorporporating nonnatural amino acids into proteins. Reproduced with permission. 
 
machinery, to incorporate the nonnatural amino acid at the TAG codon instead of 
stopping translation or incorporating one of the naturally occurring amino acids 
into the site.6,15   
Designing a new tRNA/synthetase pair de novo is exceedingly challenging 
because one of the endogenous synthetases may charge the newly designed  
tRNA with a natural amino acid in the absence of the nonnatural amino acid and 
cause misincorporation to occur.  Schultz et. al. developed the first orthogonal 




Tyr /MjTyrRS) from Methanococcus jannaschii (M. jannaschii).15 To do 
this they generated a library of tRNAs by randomly mutagenizing specific 
Figure 1.
A general method for genetically encoding unnatural amino acids in live cells.
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nucleotides on the tRNA containing the already mutated CUA anticodon that 
recognizes the amber stop codon, UAG; likewise, a library of tRNA synthetases 
were created.  A series of positive and negative selections were then used to 
identify an efficient and selective pair. Using the endogenous translational 
machinery, this new pair was evolved to incorporate the nonnatural amino acid, 
O-methyl-L-tyrosine, in E. coli.15 Since then, ~30 nonnatural amino acids have 
been genetically incorporated into proteins in various organisms with varying 
efficiency (Figure 2-2).5,6 Each nonnatural amino acid has an engineered 
tRNA/synthetase pair designed for their incorporation.  
 
 
Figure 2-2:  Some of the nonnatural amino acids that have been incorporated into proteins 
in S. cerevisiae in vivo.  1. p-propargyloxy-L-phenylalanine (pPpa) 2.  p-methoxy-L-
phenylalanine (pMpa) 3.p-azido-L-phenylalanine (pAzpa)  4. p-acetyl-L-phenylalanine (pApa) 
5. P-benzoyl-L-phenylalanine. 
 
B.2 From E.coli to eukaryotes-Using E. coli tRNA/synthetase pairs for 
nonsense suppression in S. cerevisiae 
 Initially E.coli tRNA/synthestase pairs (
€ 
tRNACUA
Tyr /TyrRS) were used to 
generate functional pairs in yeast by applying a similar selection method 
described above.17 Although this was successful, when human superoxide 
dismutase (hSOD) was expressed in yeast with the nonnatural amino acid p-
Acetyl-L-phenylalanine present for incorporating at the amber codon, the yield of 
full-length protein was approximately five-fold lower than wild-type hSOD 
expression under the same conditions (~50 ng/mL versus 250 ng/mL)18 
Incorporation of the nonnatural amino acid into hSOD was verified by digesting 
the protein with trypsin and using mass spectrometry to analyze the peptide 
fragments. Thus, the next step was to optimize incorporation yields.  Strategies 
used to increase yields include using different promoters and incorporating 
increase in tRNAexpression relative to pPR1-3SUP4-
tRNACUA (Figure 2(a), lanes 6 and 8): the plasmid
pPR1-PGK1+3SUP4-tRNACUA gave an overall N50-
fold increase in tRNA levels compared to the original
construct pPR1-tRNACUA (Figure 2(a), lanes 6 and
7). Regardless of which promoter was used to
express the tRNA, the final transcripts appeared to
be processed to the expected size. No intermediate,
pre-tRNA or shorter tRNA (possibly without the
CCA acceptor stem) transcripts were detected.
Western blot analysis was used to determine the
expression levels of the hSOD-His6 Trp33 to pPpa
mutant (with over-expression of hSOD (SCY4/pC1-
hSODW33) and the new pPR1 plasmids). Cells
were grown under the same conditions and lysate
from the same volume of cells was analyzed (Figure
2(b)). Plasmid pPR1-3SUP4-tRNACUA afforded an
approximate threefold increase in the yield of
mutant protein, and plasmid pPR1-PGK1+3SUP4-
tRNACUA increased the yield seven- to eightfold
over the original plasmid pPR1-tRNACUA (Figure
2(b), lanes 2–4). Six copies of SUP4-tRNACUA genes
on one plasmid pPR1-6SUP4-tRNACUA slowed cell
growth and resulted in a lower yield of total
proteins and the mutant protein (Figure 2(b), lane
1). Therefore, the construct PGK1+3SUP4-tRNACUA
appears to be optimal for expression of mutant
proteins.
Optimized expression of the E. coli
aminoacyl-tRNA synthetase gene in yeast
We examined the effects of different promoters on
aaRS gene expression levels. The aaRS gene was
expressed originally behind the strong pADH1
promoter. Seven promoters for mRNAs that are
highly expressed in yeast were examined: RPP15,
ENO2, FBA1, RPP2B, TDH3, RPS2 and RPL5.14 The
Figure 1. Plasmids for protein expression in yeast and the structures of unnatural amino acids. (a) Plasmid pPR1-
PGK1+3SUP4-tRNACUA encodes the orthogonal E. coli tRNACUA and the -propargyloxyphenylala ine-specific tRNA
synthetase PR1; plasmid pC1 encodes hSOD. (b) Structures of p-propargyloxyphenylalanine (pPpa) 1, p-methoxyphe-
nylalanine (pMpa) 2, p-azidophenylalanine (pAzpa) 3, p-acetylphenylalanine (pApa) 4 and p-benzoylphenylalanine
(pBpa) 5.
114 Mutant Proteins Containing Unnatural Amino Acids
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elements of tRNA processing elements, described below, that differ in E.coli and 
yeast.  One concern associated with increasing incorporation yield is that this 
may concomitantly increase the amount of read-through.  Read-through is when 
the specialized tRNA/synthetase pair read the amber stop codon in the absence 
of the nonnatural amino acid, placing a naturally occurring one at this site.    
 Initially two groups made modifications to the tRNA/synthetase expression 
plasmid with the goal of increasing incorporation yields.  The Hahn laboratory 
tested strong, medium and weak Pol III promoters driving tRNA production and 
found that a strong promoter reduced the yeast growth rate; however, the 
medium-strength N(GTT)PR promoter was reported to produce “normal” levels of 
proteins with nonnatural amino acid incorporated.19 The Schultz laboratory 
modified the tRNA expression plasmid by adding the strong Pol II promoter, 
pPGKI, that drove transcription of the tRNA and they also included the SUP4 5ʼ 
and 3ʼ- flanking sequences, an endogenous yeast suppressor tRNA gene, in front 
of the tRNA. This was included because, unlike E. coli tRNAs that are transcribed 
from a promoter located upstream of the gene, yeast tRNAs are transcribed 
through promoter elements that are located within the tRNA known as the A- and 
B-boxes (Figure 2-3A).5 SUP4 has a Pol III promoter with internal A and B boxes                          
and flanking regions.20 Additionally they removed the 3ʼ CCA nucleotides from 
the original E. coli tRNA.20 This change was justified by the difference in how 
E.coli and yeast process tRNA.  The E. coli tRNA gene codes for the entire, fully 
processed tRNA whereas in yeast the initially transcribed tRNA lacks the 3ʼ-CCA 
sequence (Figure 2-3A). The modified plasmid resulted in >50 fold increase in 
tRNA levels compared their original plasmid and a yield ranging 3-10mg/L of 
hSOD protein when p-propargyloxyphenylalanine was incorporated at three 
different positions in the protein.20  
 More recently, Wang and co-workers further improved the 
tRNA/synthetase expression plasmid.  It is known that transcription and 
processing of tRNAs are different between prokaryotes and eukaryotes.17,21 
Because generating an A-box and a B-box in E. coli tRNA was thought to result  
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Figure 2-3:  tRNA promoter architecture. A. The basic promoter architecture for expressing 
naturally occuring E.coli and eukaryotic tRNAs.  B. Wang et. al. construct design for 
expressing tRNA for nonsensense suppression.5,22  Reproduced with permission. 
 
in distorted mature tRNA Wang and coworkers added a promoter containing the 
consensus A- and B-boxes upstream of the E. coli tRNA that would be post-
transcriptionally cleaved to yield the final tRNA.22 Two yeast genes, SNR52 and 
RPR1, that are transcribed by Pol III share a promoter arrangement with the A- 
and B-box promoter elements situated as described above and therefore, it was 
reasoned that these promoters could be used to enhance production of functional 
tRNA.22 Similar to Schultz, Wang and co-workers inserted the E. coli tRNA 
lacking the 3ʼ-CCA into the plasmid and the SUP4 3ʼ-flanking sequence was 
present in their yeast expression plasmid as well (Figure 2-3B).20,22 This newly 
designed tRNA/synthetase expression plasmid yielded tRNA transcripts and the 
mature tRNA was functional for encoding amber codons in yeast with an increase 
in protein yield, 6-9 fold compared to the constructs with the SUP4 5ʼ-flanking 
sequence alone and with little reported read-through (~7%).22 Although having 
SUP4 5ʼ-flanking sequence alone produced more tRNA than the plasmid with the 
SNR52 promotor driving tRNA transcription, the latter produced more 
Figure 3.
General methods for efficient expression of prokaryotic tRNAs in eukaryotic cells using special
Pol III promot rs. (A) Gene element  for tRNA transcription in E. coli and eukaryotic cells.
(B) Expression of prokaryotic tRNAs in yeast using an external SNR52 or RPR1 Pol III
promoter, which contains the consensus A- and B-box sequences and is post-transcriptionally
cleaved from the primary transcript. (C) A type-3 Pol III promoter, such as the H1 promoter,
with a defined transcription initiation site is used to express prokaryotic tRNAs in mammalian
cells.
Wang et al. Page 21

























incorporated protein product. This result indicates that tRNA processing is an 
important consideration for tRNA function.   
Overall, utilizing this enhanced tRNA/synthetase pair allows one to expand 
the functionality of amino acid side chains that do not exist in nature to probe 
eukaryotic biological systems and answer questions yet unresolved.  All of the 
tRNA/synthetase pairs described here were used in the optimization of 
incorporating a nonnatural amino acid into Gal4 discussed in the next section. 
 
C. Optimizing the incorporation of p-benzoyl-L-phenylalanine into a 
transcriptional activator 
 The direct protein targets of the transcriptional activators have not been 
clearly defined.23 Implementing nonsense suppression technology for 
incorporating a photo-crosslinking nonnatural amino acid into the prototypical 
activator Gal4 will be used to identify these targets. Of the two photoactivatible 
nonnatural amino acids that have been successfully incorporated into proteins in 
yeast, pBpa and p-azido-l-phenylalanine (pAzpa), pBpa was initially selected for 
incorporation into Gal4 because its excitation wavelength is less damaging to 
biomolecules than pAzpa excitation wavelength (~365nm versus ~250nm).2,5 
Briefly, pBpa forms a diradical upon excitation and inserts into C-H bonds within 
the ~3 Å reactive radius (Figure 2-4).2 A detailed analysis of the pBpa and pAzpa 
crosslinking mechanism is provided in Chapter 4.                               
 






C.1 Towards p-benzoyl-L-phenylalanine incorporated into Gal4  
 Gal4, a 881 residue protein, is one of the most well studied transcriptional 
activators.  Gal4 is responsible for regulating the GAL genes, whose products are 
responsible for galactose catabolism.24-28 As a result, Gal4 is highly sensitive to 
the nutrient environment, such that only under galactose growth conditions does 
it function as an activator.  The environmental sensitivity of Gal4 is largely 
regulated via a strong (nanomolar Kd) interaction between the repressor Gal80 
and a portion of the C-terminal transcriptional activation domain of Gal4 (Figure 
2-5).13,26-29 Conventional mutagenesis and structural studies suggest that the  
                                     
Figure 2-5:  Structure of Gal4 peptide in complex with Gal80.  Red and yellow highlights the 
Gal4 peptide (yellow are residues used in this study) and gray represents Gal80 both from K. 
lactis.  The residue numbering is from S. cerevisiae. PDB ID 3EIK30 Reproduced with 
permission. 
 
middle region of the transcriptional activation domain (amino acids 851-871) 
comprises the binding site for Gal80, yet the Gal4-Gal80 complex impacts the 
function of the entire activation domain (840-881).13,30-32 We hypothesized that in 
vivo crosslinking would provide molecular-level detail regarding this important 
regulatory interaction. In addition to the interaction with Gal80, the Gal4 TAD 
engages in a set of interactions with coactivators in the transcriptional machinery 
to stimulate transcription under restrictive growth conditions (galactose).13,23,29-
31,33-42 Thus, the impact of pBpa mutations on the binding modes and function of 
Gal4 can be assessed by examining transcriptional activity under restrictive and 
permissive growth conditions (Figure 2-6). 
Impact of Nonnatural Amino Acid Mutagenesis on the in Vivo Function and
Binding Modes of a Transcriptional Activator
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Given the central role of protein-protein interactions in biologi-
cal functions, the development of methods for the discovery and
characterization of such interactions has been of paramount
importance in the scientific community.1 Ideally these methods are
compatible with live-cell studies so that protein-protein interactions
can be investigated in their native context. Toward that end, recent
advances in nonsense suppression technology have enabled the site-
specific incorporation of amino acids bearing moieties for photo-
activatable cross-linking reactions into proteins in bacteria, yeast,
and human cells.2 However, there have been few applications of
this technology in eukaryotes, perhaps due to challenges in obtaining
efficient incorporation of the nonnatural amino acids as well as
limited knowledge about the impact of these changes on structure
and function.3 Here we demonstrate an enhanced tRNA/synthetase
system for efficient incorporation in vivo (S. cereVisia ) of the
photoactivatable amino acid p-benzoyl-L-phenylalanine (pBpa)
throughout the transcriptional activation domain of the prototypical
eukaryotic transcriptional activator Gal4. The pBpa-containing
proteins maintain the key functions of Gal4, suggesting that this
nonnatural amino acid has minimal impact on a critical binding
surface within the protein. In vivo cross-linking with these mutants
captured a key binding partner of Gal4, Gal80, and defined the
binding interface of this complex beyond that predicted by
conventional approaches. More broadly, this strategy should be
suitable for the characterization and discovery of transcription factor
binding partners in the native cellular environment.
The multipartner binding profile and intrinsically disordered
nature of the transcriptional activation domains (TADs) of amphi-
pathic activators produce significant roadblocks in studies of the
function and structure of these essential proteins.4,5 The most well-
studied member of this family, Gal4, is a yeast transcriptional
activator that regulates the GAL genes, whose products are required
for galactose catabolism.6,7 As a result, Gal4 is highly sensitive to
the nutrient environment, such that only under galactose growth
conditions does it function as an activator. The environmental
sensitivity of Gal4 is largely regulated via a strong (nanomolar KD)
interaction between the repressor Gal80 and a portion of the
carboxy-terminal transcriptional activation domain of Gal4.7-9
Conventional mutagenesis and structural studies suggest that the
middle region of the transcriptional activation domain (amino acids
851-871) comprises the binding site for Gal80, yet the Gal4•Gal80
complex impacts the function of the entire activation domain
(840-881) (Figure 1).9-11 We hypothesized that in vivo cross-
linking would provide molecular-level detail regarding this impor-
tant regulatory interaction. In addition to the interaction with Gal80,
the Gal4 TAD engages in a set of interactions with coactivators in
the transcriptional machinery to stimulate transcription under
restrictive growth conditions (galactose).5,8-14 Thus, the impact
of pBpa mutations on the binding modes and function of Gal4 can
be assessed by xamining transcriptional activity unde restrictive
and permissive growth conditions.
As has been detailed previously, the nonsense suppression
strategy typically utilizes the amber stop codon to encode the
nonnatural amino acid.2,15,16 Thus, to investigate the effect of
p-benzoyl-L-phenylalanine incorporation on the binding and function
of the Gal4 TAD, 10 individual Gal4 mutants were created in which
am er stop codons (TAG) replaced the natural codons at specified
positions within this sequence; in addition to the sequence encoding
the mutant Gal4 TAD, each plasmid bears the sequence for the
LexA DNA binding domain (Figure 2a). Six of the positions within
Gal4(840-881) (W840, Y846, F849, F856, Y867, F869) are
hydrophobic aromatic residues at which replacement with pBpa
might be expected to have minimal impact. In contrast to this were
positions T852, T859, and D871, all of which are polar residues.
These plasmids were introduced into S. cereVisiae along with a
plasmid encoding a mutant E. coli tRNA/synthetase pair (tRNATyr-
CUA/TyrRS) for pBpa as previously reported.16 However, very low
yields of full-length protein were observed by Western blot analysis,
likely due to low expression levels of the mature tRNA (Figure
2b). To address this, a yeast polIII promoter (SNR52) was inserted
upstream of the E. coli tRNATyrCUA which enables the efficient
expression of functional E. coli tRNATyrCUA in yeast.17 We first
examined the Phe849pBpa mutant and observed that expression
increased from undetectable to >20% of unmodified LexA+
Gal4(840-881) (Figure 2b and c). Significantly, read-through in the
absence of pBpa was minimal, consistent with previous reports.16
Next, we examined the functional impact of incorporating pBpa
into LexA+Gal4(840-881) using quantitative !-galactosidase
assays. Truncation of protein synthesis at residue 849 would result
in a protein with little transcriptional activity;12 thus activity
† Department of Chemistry, University of Michigan.
‡ Program in Chemical Biology, University of Michigan.
§ Department of Medicinal Chemistry, University of Michigan.
| The Salk Institute.
Figure 1. (a) Stru ture of a short region of the Gal4 TAD (red and gold)
bound to the inhibitor protein G l80 (gray). Four of the mino acids replaced
with pBpa in this study a highlighted in gold. Labels c rrespond o S.
cereVisiae numbering. PDB ID 3E1K.11 (b) Structure of p-benzoyl-L-
phenylalanine (pBpa).
Published on Web 09/18/2009
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 Previously it was not known if incorporating pBpa at different positions on 
the Gal4 TAD was possible and how changes in the amino acid  
 
 
Figure 2-6:  Construct used in this study LexA-Gal4(840-881)-FLAG and the environmental 
sensitivity of Gal4.  In the present of glucose transcription is repressed by Gal80 and under 
galactose growth conditions Gal4 is no longer repressed and transcription may take place. 
 
sequence would affect the function of said activator, since mutagenesis of 
proteins can disrupt the natural PPIs required to maintain protein function.13 To 
this end, two colleagues in my laboratory performed a study to first optimize the 
conditions needed for successful incorporation.  Some criteria for incorporating 
pBpa into Gal4 were that incorporation efficiency needed to be high so that 
protein could be detected via Western blot and with little read-through and low 
truncated protein yields.  ʻRead-throughʼ refers to incorporation of a naturally 
occurring amino acid at the amber stop codon, a common problem in nonnatural 
amino acid mutagenesis. Truncated protein occurs when the amber stop codon is 
not ʻreadʼ at all which results in termination of translation. A fusion protein 
consisting of a LexA DBD, the well studied bacterial repressor protein, and the 
Gal4 TAD (840-881) was used in this study.11 LexA+Gal4 had previously been 
used in our laboratory with much success.  Because the yeast strain that is used, 
LS41, contains LexA DNA binding sites upstream of a LacZ reporter, we are able 
to assess protein function when pBpa is incorporated.  A variety of 
tRNA/synthetase pairs were tested in S. cerevisiae for in vivo incorporation 
efficiency of pBpa into the Gal4 TAD (Figure 2-7).  To achieve full-length protein 
with pBpa incorporated at pre-determined positions, the tRNA/synthetase 
Gal4(840-881)LexA(1-202) Flag






















plasmid is co-transformed into yeast along with the plasmid coding for the 
LexA+Gal4 fusion protein. Position 849 of the Gal4 TAD, a phenylalanine, was 
chosen for the first site for pBpa  
 
Figure 2-7:  Different tRNA/sythetase pairs (as described above) were used to determine 
which yielded the highest amount of full-length LexA-Gal4(849 TAG) protein and minimilzed 
the amount of read-through.  The Wang plasmids produced the most protein with least read-
through (red box). Experiment by Dr. Chinmay Majmudar and Adaora Nwokoye. 
 
incorporation because its large hydrophobic aromatic character is most 
reminiscent of the pBpa structure and therefore would minimize the disruption to 
the primary sequence.  Utilizing this construct in live yeast, they were able to 
incorporate pBpa into LexA+Gal4 with ~20% efficiency compared to wild-type by 
using the tRNA/synthetase pair driven by the Pol III pSNR52 promotor and with 
little read-through.11 This tRNA/synthetase construct therefore, was used in the 
remainder of the study. 
 
D.  Expanding p-benzoyl-L-phenylalanine incorporation throughout the 
Gal4 transcriptional activation domain 
 We extended this study to test a broader range of mutations throughout 
the Gal4 TAD.  Using the enhanced tRNA/synthetase pair we tested for 
incorporation at various positions.  The goal was to determine (i) does the type of 
residue (hydrophobic v. polar) affect incorporation efficiency (ii) does 
incorporating pBpa into Gal4 affect its function and (iii) can we incorporate pBpa 
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into residues shown by other groups to be important for Gal4 TAD-protein target 
interactions to capture these interactions via photo-crosslinking.  
 
D.1 Selecting residues along Gal4 TAD for p-benzoyl-L-phenylalanine 
incorporation  
 In case mutating the key residue disrupts Gal4 from making key contacts 
with its protein target(s) we also mutated residues nearby these key residues so 
as to not disrupt the natural interaction. Table 2-1 outlines the residues where 
pBpa is incorporated. Thr859 was selected as an incorporation site based on the  
 




Residues thought to be 
outside the Gal80 binding 
site, selected to study 
proteins outside this area 
Ptashne and Gann, 
2002 
Phe856 Reduced Gal80 interaction 
in gel shift 
Ansari et. al. 1998 
Thr859 Reduced Gal80 interaction 
in gel shift 
Ansari et. al. 1998 
Met861 Adjacent to residue thought 
to be important for Gal80 
binding 
Ansari et. al. 1998 
Tyr867 Adjacent to residue thought 
to be important for Gal80 
binding 
Ansari et. al. 1998 
Asp869 Adjacent to residue thought 
to be important for Gal80 
binding, 
shown to crosslink to Tra1, 
Gal11, Ste12, Taf12 and 
Gal80 using 125I-PEAS 
 
Reeves and Hahn, 
2005 
Asp871 Adjacent to residue shown 
to crosslink to Tra1, Gal11, 
Ste12, Taf12 and Gal80 
using 125I-PEAS 
Reeves and Hahn, 
2005 
             Table 2-1:  Residues selected for pBpa incorporation along Gal4 TAD. 
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work done by Ptashne et. al. that suggested this residue was important for Gal4-
Gal80 binding.13 They found that mutating Thr859 to cysteine resulted in a 
decrease in Gal4-Gal80 interaction in a protein gel shift experiment.   Similarly, 
when Phe856 was mutated to cysteine, a reduction in Gal4-Gal80 gel shifting 
was observed, indicating that this residue likely makes important contacts with 
Gal80.13 In the same study they observed that point mutations at residues 
Thr860, Val864 and Leu868 to Pro resulted in a decrease in Gal80-mediated 
transcriptional repression, suggesting that these positions also play an important 
role in mediating the Gal4-Gal80 complex.  We therefore selected residues 
adjacent to Thr860 or Leu868, those thought to be important for maintaining 
Gal4-Gal80 interaction (Met861, Tyr867, and Asp869). Further, Reeves and 
Hahn demonstrated through in vitro crosslinking with 125I-PEAS at positions 
Phe869, Asp870 and Asp873 crosslinking with Tra1, Gal11, Ste12, Taf12 and 
Gal80, although with varying intensities.  Crosslinking to Gal80 was also 
observed when the crosslinker was attached at Asp871.36 This data supported 
selecting Phe869 and Asp871 for pBpa crosslinking.  Other residues, outside the 
middle region Gal4(851-871) that makes-up the Gal80 binding site, were chosen 
to study other proteins targets of Gal4 outside of this region.13 
 
D.2  p-benzoyl-L -phenylalanine incorporation along Gal4 TAD 
 Applying the same procedure used for Phe849pBpa incorporation we 
observed full-length protein in the presence of pBpa at all positions tested (Figure 
2-8).  The incorporation efficiency was not equal at all positions tested.  It 
appears that position on the protein (N-terminal versus middle region versus C-
terminal) has a greater influence on the incorporation rather than an individual 
residue being more permissive to pBpa incorporation over another. This is 
exemplified by Phe869 having significantly less full-length protein than Phe849 




   
Figure 2-8:  Site-specific incorporation of pBpa at positions along the Gal4 TAD.11 
 
E.  Functional impact of incorporating p-benzoyl-L -phenylalanine into Gal4  
Transcriptional activation domain 
 Next, we examined the functional impact of incorporating pBpa into all 
positions along LexA+Gal4(840-881) using quantitative β-galactosidase assays. 
The interaction of the Gal4 TAD with Gal80, an inhibitor protein that interacts with 
Gal4 when glucose is present, is tighter and more specific than the Gal4-
transcriptional machinery interactions. To assess if this interaction was impacted 
upon pBpa incorporation, the transcriptional activity of each mutant protein was 
assessed in media containing different sugar sources.  When glucose is present 
Gal4 is repressed by Gal80 and when galactose is present Gal4 is able to 
activate transcription as Gal80 no longer represses Gal4.  What was observed 
was that under glucose or raffinose growth conditions, little transcriptional activity 
was observed, indicating that the mutant retained its ability to interact with Gal80 
and thus maintain its environmental sensitivity.  When galactose was present 
transcriptional activity increases as it is free to interact with the necessary 
proteins for up-regulating transcription (Figure 2-9). Based on this data, Gal4 
maintains its function when pBpa is incorporated at all positions tested.  Also, it 
was concluded that little read-through occurs since truncation of  
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Figure 2-9: β-galactosidase assays showing the functional impact of incorporating pBpa into 
Gal4 TAD. β-gal assays at all positions tested for pBpa incorporation with different sugar 
sources.11 
 
protein synthesis at residue 849 would result in a protein with little transcriptional 
activity;33 thus activity observed in yeast grown without pBpa would be an 
indicator of read-through. 
 
F.  In vivo photo-crosslinking with Gal4 transcriptional activation domain 
 The incorporation and functional results encouraged us to move forward in 
trying to capture the Gal4-Gal80 interaction in vivo by applying photo-
crosslinking. Being able to capture a known binding partner of Gal4 would 
demonstrate the utility of this technique for capturing TAD-protein interactions in 













































mutants were irradiated at 365 nm to create direct Gal4-protein crosslinks (Figure 
2-10). Upon lysis and Western blot analysis we observed that all Gal4 mutants  
 
Figure 2-10:  In vivo crosslinking of pBpa-containing Gal4 mutants.  Only in the presence of 
UV light are crosslinking products observed.  One band is present at all positions at a 
molecular weight of 80 kDa indicative of Gal4•Gal80 crosslinked product (red box).11 
 
formed several crosslinked products, consistent with the multi-partner binding 
model proposed for their function.34-38 More specifically, all formed a crosslinked 
product with a molecular weight of ~80 kDa, consistent with a LexA+Gal4•Gal80 
product (Figure 2-10, red box). This was confirmed by the introduction of a c-
Myc-tagged version of Gal80 into yeast and visualization of the cross-linked 
products with a c-Myc antibody (Figure 2-11a). Further supporting this, 
incorporation of pBpa into Gal80 at residue 245 leads to crosslinking with 
LexA+Gal4(Figure 2-11b). Although all mutants formed crosslinks with Gal80, the 
extent varied with  
















Figure 2-11: Gal4 crosslinks to c-Myc-Gal80 in vivo.  a.  yeast were cotransformed with a 
plasmid coding c-Myc-Gal80 and Gal4 with pBpa at position 849.  Crosslinking is only 
observed when both contructs are present and UV light is applied. b.  yeast were 
cotransformed with a c-Myc-Gal80 containing a site for pBpa incorporation and wild-type 
Gal4 (lanes 1-4) or the same two plasmids used in a (lane 5).  Crosslinking was observed in 
one of the two positions selected for pBpa incorporation on Gal80 (lane 4) at the same 
molecular weight of the crosslinking experiment in a (lane 5).11 
 
position. Seven of the positions lie within the previously identified binding site for 
Gal80 (852, 856, 859, 861, 867, 869 and 871).13 Most striking is the Phe856pBpa 
mutant in which little crosslinked product is observed despite considerable 
evidence that this residue makes key contacts with Gal80.13,30 This is not due to 
attenuated binding affinity, as the pBpa-containing TAD exhibits a KD for Gal80 
nearly identical (0.7 ± 0.2 µM) to that of the native sequence (1.2 ± 0.1 µM) as 
demonstrated by my coworker Dr. Chinmay Majmudar with fluorescence 
polarization of Gal4 TAD peptides containing pBpa with interacting with Gal80.  In 
this instance, the benzophenone moiety at position 856 may be poorly positioned 
for cross-linking, particularly as the efficiency of benzophenone crosslinking is 
well-known to vary with amino acid identity (discussed in detail in Chapter 4).43 
Similarly, the enhanced cross-linking observed with theThr852pBpa and 
Tyr867pBpa mutants is not due to an altered affinity for Gal80 (Thr852pBpa: 0.8 
± 0.3 µM; Tyr867pBpa: 0.8 ± 0.1 µM).  Somewhat surprising was that positions 
beyond the previously defined Gal80 binding sequence (residues 851-871) also 




























exhibited effective cross-linking. At the amino terminus of the sequence, for 
example, the Phe849pBpa and Tyr846pBpa mutants both produce strong bands 
corresponding to the Gal4•Gal80 crosslinked product (Figure 2-10). To probe this 
further, we also examined pBpa mutations at positions Pro875 and Lys879 and 
upon irradiation of yeast bearing these mutants, crosslinking with Gal80 was 
observed (Figure 2-12).  Crosslinking efficiency was attenuated with the  
                                
Figure 2-12:  In vivo crosslinking with pBpa incorporated at positions near the N-terminal 
866, 875, 879.  A band at 80 kDa indicated that a more extended surface contacts Gal80 
than previously thought (positions (851-871).11,13 
 
Lys879pBpa mutant, similar to the Phe840pBpa mutant, and this may indicate 
limited binding interactions at the extreme amino- and carboxy-terminus of the 
Gal4 TAD. This cross-linking pattern reveals an extending binding interface 
between Gal80 and Gal4 not previously identified through conventional deletion 
and mutagenesis experiments, highlighting the higher resolution information 
accessible by this approach. 
 In conclusion, we showed the facile incorporation of the nonnatural and 
photoactivatable amino acid pBpa into a transcription factor (Gal4) in vivo using a 
modified tRNA/synthetase system. Importantly, the function and binding 
interactions of Gal4 remain largely intact with this substitution as all mutant 
proteins retained their ability to activation transcription and to respond to 


























masking protein, Gal80, and characterization of the binding interface with this 
protein. The improved expression yields observed with this system will be 
particularly valuable for identifying novel and functionally relevant binding 
partners of transcription factors that often have high turnover and are present in 
low abundance inside the cell. 
 
G. Methods 
LS41 [JPY9::pZZ41, Matα his3Δ200 leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 gal4 
URA::pZZ41] yeast was used for all experiments. pBpa was purchased from 
Chem-Impex International (Wood Dale, IL). All plasmids described below were 
constructed using standard molecular biology techniques and the sequences of 
all the isolated plasmids were verified by sequencing at the University of 
Michigan Core Facility (Ann Arbor, MI). 
 
Table of Plasmids used in this study 
 
Plasmid name Function 
pLexAGal4 Expresses LexA(1-202)+Gal4(840-
881)+FLAG tag 
pLexAGal4 840TAG, pLexAGal4 846TAG, 
pLexAGal4 849TAG, pLexAGal4 852TAG, 
pLexAGal4 856TAG, pLexAGal4 859TAG, 
pLexAGal4 861TAG, pLexAGal4 867TAG, 
pLexAGal4 869TAG, pLexAGal4 871TAG 
Express LexA(1-202)+Gal4(840-
881)+FLAG tag with a TAG 
replacing the codon of the existing 
amino acid 
pSNRtRNA-pBpaRS  Expresses tRNA under the control 
of the SNR52 promoter and 
contains synthetase specific for 
pBpa 
ptRNA-pBpaRS Expresses tRNA with no eukaryotic 
Pol III promoter and contains 
synthetase specific for pBpa18 
pMycGal80 Expresses Gal80 fused to c-Myc 
tag 
pMycGal80 234 TAG, pMycGal80 245 
TAG 
Expresses Gal80 fused to c-Myc 
tag with a TAG replacing the codon 
of the existing amino acid 
pmOCR-Gal80 Expresses Gal80 fused to the 




A high copy plasmid expressing LexA(1-202)+Gal4(840-881)+FLAG tag under 
the control of the ADH1 promoter was created from pNLexA (Origene). First, site-
directed mutagenesis was used to mutate the existing EcoRI and BamHI sites at 
the N-terminus of LexA and subsequently to insert EcoRI and BamHI sites at the 
C-terminus of LexA, producing the plasmid pCLexA. Primers (5ʼ- TTA CGA ATT 
CTG GAC GGA CCA AAC TG -3ʼ) and (5ʼ- AGT GGA TCC TTA TTT GTC GTC 
GTC GTC TTT ATA GTC CTC TTT TTT TGG G -3ʼ) were used to amplify 
Gal4(840-881) from EGY48 yeast genomic DNA. The amplified PCR product was 
digested with EcoRI and BamHI and inserted into pCLexA digested with EcoRI 
and BamHI and calf intestinal phosphate treated to create pLexAGal4.  
  
pLexAGal4 840TAG, pLexAGal4 846TAG, pLexAGal4 849TAG, pLexAGal4 
852TAG, pLexAGal4 856TAG, pLexAGal4 859TAG pLexAGal4 861TAG, 
pLexAGal4 867TAG, pLexAGal4 869TAG and pLexAGal4 871TAG  
Plasmids containing various amber mutants in the Gal4 TAD were derived from 
pLexAGal4. To create each plasmid, site-directed mutagenesis was used to 
replace an existing amino acid codon with TAG within the Gal4 TAD. In general, 
PCR primers were designed to have ~15 bases of homology on either side of the 
TAG mutation. QuikChange (Stratagene, La Jolla, CA) was used to incorporate 
the TAG mutants using manufacturer recommended conditions.  
pSNRtRNA-pBpaRS 
The previously described pSNRtRNA-TyrRS plasmid incorporating tyrosine at the 
amber position was used to generate a plasmid pSNRtRNA-pBpaRS to 
incorporate pBpa at the amber position.22 This plasmid was generated by 
insertion of the pBpa-specific E. coli tyrosyl synthetase (amplified from ptRNA-
pBpaRS (p-benzoylPheRS-2)18 obtained from Dr. P. G. Schultz, Scripps 
Research Institute, La Jolla, CA) using primers 5ʼ- AGT TCA ACT AGT ATG GCA 
AGC AGT AAC TTG ATT -3ʼ and 5ʼ-TCG ATC TCG AGT TAT TTC CAG CAA 
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ATC AGA CA-3ʼ) into SpeI and XhoI digested and calf intestinal phosphate 
treated pSNR TyrRS. 
pMycGal80, pMycGal80234TAG and pMycGal80245TAG 
A plasmid expressing Gal80 fused to the c-Myc tag under the control of the 
ADH1 promoter was generated by insertion of DNA encoding S. cerevisiae Gal80 
into the high copy plasmid pADT7 (Clontech, Mountain View, CA). Primers 5ʼ- 
TGT GAA GCT TAT GGA ACA AAA GTT GAT TTC TGA AGA AGA TTT GGA 
CTA CAA CAA GAG ATC TTC G -3ʼ and 5ʼ CGT CAA GCT TTT ATA AAC TAT 
AAT GCG AG -3ʼ were used to amplify Gal80 from LS41 yeast genomic DNA. 
The amplified PCR product was digested with HindIII and inserted into HindIII 
digested and calf intestinal phosphate treated pADT7. pMycGal80234TAG and 
pMycGal80245TAG were constructed by performing site-directed mutagenesis to 
incorporate a TAG codon to replace the codon of the existing amino acid 
Incorporation of pBpa into LexA(1-202)+Gal4(840-881)  
LS41 yeast was transformed with various pLexAGal4 TAG mutant plasmids and 
pSNRtRNA-pBpaRS or ptRNA-pBpaRS. Individual colonies were grown in 5 mL 
SC media containing 2% glucose but lacking histidine and tryptophan for 
selection. The cultures were incubated overnight at 30 °C and agitated at 250 
rpm. Following incubation, these cultures were used to inoculate 5 mL cultures of 
SC media containing 2% glucose, with or without 2 mM pBpa (dissolved in 50 μL 
of 1M NaOH), and 50 mL 1M HCl which were subsequently incubated overnight 
at 30 °C with agitation to an OD660 of 1.5. 3 ODs of cells were isolated, washed 
with cold, sterile water and stored dry at -20 °C. The samples were lysed in 10 
mL 4x NuPAGE LDS Sample buffer (Invitrogen), 15 mL Lysis Buffer (50 mM Tris-
Acetate, pH 7.9, 150 mM KOAc, 20% glycerol, 0.2% Tween-20, 2 mM b-
mercaptoethanol, 2 mM MgOAc) 5 mL 1M DTT and analyzed using Western blot 
with the anti-FLAG(M2) antibody (Sigma). 
In vivo cross-linking 
To perform in vivo cross-linking, individual colonies of each pLexAGal4 TAG 
mutant were grown in 5 mL SC media containing 2% glucose but lacking histidine 
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and tryptophan for selection. The cultures were incubated overnight at 30 °C and 
agitated at 250 rpm. Following incubation, these cultures were used to inoculate 
50 mL cultures of SC media containing 2% glucose, with 2 mM pBpa (dissolved 
in 0.5 mL of 1M NaOH), and 0.5 mL 1M HCl, which were subsequently incubated 
overnight at 30 °C with agitation to an OD660 of 1.5. For each mutant, 50 ODs of 
cells were isolated, washed with water and either resuspended in 2 mL water and 
irradiated for 1 h with 365 nm light (Eurosolar 15 W UV lamp) with cooling or kept 
in the dark at 4 °C. Following irradiation, all the cells were pelleted and stored at -
80 °C until lysis. For lysis, cells were resuspended in 600 mL Lysis buffer (50 mM 
Hepes-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-
Deoxycholate and 2X Complete Mini, EDTA Free Protease Inhibitor (Roche) and 
lysed using glass beads by vortexing at 4 °C. Subsequently, the lysate was 
pelleted and the supernatant incubated with 10 mL of LexA antibody (N-19, 
Santa Cruz Biotechnologies) for 2 h at 4 °C for immunoprecipitation. The protein 
bound to the antibody was isolated by incubation for 1 h with ~50 mL of 
prewashed protein G magnetic beads (Dynal Corporation, Invitrogen, Carlsbad, 
CA) at 4 oC. The beads were washed  3X with 1 mL Wash Buffer (10 mM Tris-
HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 1% Na-Deoxycholate and 1 mM EDTA) 
and stored dry at -20 oC. The protein was eluted from the beads by heating at 95 
oC for 10 min in NuPAGE LDS Sample buffer  (Invitrogen, Carlsbad, CA) 
containing DTT and probed using Western Blot analysis using anti-FLAG (M2) 
antibody (Sigma, St. Louis, MO). 
β-Galactosidase assays 
To evaluate the ability of each LexA+Gal4 TAG mutant in the absence or 
presence of 2 mM pBpa to activate transcription, saturated cultures (SC media + 
2% raffinose) of each mutant were used to inoculate 5 mL SC media lacking 
histidine and tryptophan supplemented with 2% glucose or 2% raffinose + 2% 
galactose or 2% raffinose and grown to an OD of 1.5-2.0 before being harvested. 
The activity of each construct was monitored using β-galactosidase assays as 
previously described.44  
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Expression of Gal80 
Expression of Gal80 fragments fused to the His6-mOCR solubility 
tags was carried out in Rosetta2 (DE3) pLysS E. coli cells (Novagen). Briefly, 
cultures (50 mL) from single colonies were grown overnight at 37°C (300 rpm) in 
Select APS Super Broth (Difco) supplemented with ampicillin (100μg/mL) and 
chloramphenicol (34 μg/mL) before addition to 1L of Select APS Super Broth 
supplemented with ampicillin (100 μg/mL). After an OD600 of 0.8 was reached, the 
cultures were cooled on ice for 30 m, and expression was induced with IPTG 
(final concentration 0.1 mM) for ~14 h at 20 °C. The cell pellet was resuspended 
in Buffer A (100 mM Tris pH 7.5 at 4 °C, 10% glycerol (v/v), 150 mM NaCl, 10 
mM β-ME and Roche Complete Protease Inhibitor Cocktail), lysed using 
sonication, and the His-tagged protein was isolated using Ni NTA-Agarose 
(Qiagen). The Ni-NTA beads were washed 6 times with Wash buffer (100 mM 
Tris pH 7.5 at 4 °C, 10% glycerol (v/v), 150 mM NaCl, 10 mM β-ME, 30 mM 
imidazole). The protein was eluted from the beads at 4 ºC 3 times using Elution 
buffer (100 mM Tris pH 7.5 at 4 °C, 10% glycerol (v/v), 150 mM NaCl, 10 mM β-
ME, 300 mM imidazole). The resulting mixture was placed in dialysis tubing 
(Pierce) and the buffer exchanged to a low salt buffer (50 mM Tris pH 7.5 at 4 °C, 
10% glycerol (v/v), 
50 mM NaCl, 10 mM β-ME) overnight at 4 °C. The solution thus obtained was 
loaded onto an anion-exchange column (Q sepharose, GE Healthcare) and 
eluted with a NaCl gradient from 0-1 M. Fractions containing Med15(1-416) were 
pooled and buffer exchanged to Storage buffer (10 mM PBS pH 7.4, 10% 
glycerol, 0.01% NP-40, 1 mM DTT) using a PD-10 column (GE Healthcare) and 
concentrated using a 30K centrifugal filter device. The protein concentration was 
measured using absorbance at 280 nm. The identity and purity of the protein was 
verified by reducing SDS-PAGE with appropriate molecular weight standards. 
Peptide Synthesis 
Gal4(840-870) peptides with pBpa at various positions were synthesized using 
solid phase peptide synthesis in accordance with standard protocols. FMOC-
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pBpa was purchased from Chem-Impex International. The peptides contained a 
b-alanine linker at N-terminus and they were labeled using fluorescein 
isothiocynate on solid phase and subsequently cleaved using 95% TFA, 2.5% 
TIS, 2.5% H20. The products were purified to homogeneity using reversed-phase 
HPLC on a C18 column with a gradient solvent system (buffer A: 20 mM 
Ammonium Acetate, buffer B: MeOH) and stored at -80 ºC. The identity was 
verified using electrospray mass spectrometry (LCT Micromass). 
Fluorescence Polarization  
Dissociation constants for fluorescein labeled Gal4 TADs and Gal80 were 
determined using fluorescence polarization as previously described. For each 
experiment, 50 nM TAD was incubated with varying concentrations of Gal80 in 
100 mM PBS pH 7.2, 10% glycerol, 0.01% NP-40, 1 mM DTT and incubated for 
10 min in 384 well low volume plate (Corning) before being detected using a 
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Identifying the direct binding partners of the Gal4 transcriptional activation 
domain via in vivo crosslinking and MudPIT analysis 
 
A.  Project Overview 
 In the previous chapter, it was demonstrated that capturing a known 
protein-protein interaction, Gal4-Gal80, is possible using an in vivo crosslinking 
strategy with a genetically encoded crosslinker.1 Initially, we used Western blot 
analysis of the crosslinked proteome for identifying the crosslinked products; 
however, this method is limited since one must have some prior knowledge 
regarding likely binding partners in order to appropriately select antibodies. In 
addition, many of the potential protein binding partners of transcriptional 
activators do not have available antibodies (commercial or academic). Because 
the goal of our study is to use in vivo crosslinking for identifying the complete 
suite of direct binding partners of Gal4 in order to resolve the conflicting models 
surrounding activator-initiated transcription, we needed to analyze our 
crosslinked sample by a different and more unbiased method.  Towards this end, 
in vivo photo-crosslinking of Gal4 coupled with mass spectrometry (MS) analysis 
of the resulting crosslinked proteome was undertaken.  In this Chapter, we 
demonstrate that this technique was used to identify nine binding partners of 
Gal4, including several previously unidentified binding partners. 
  
B.  Background 
 Mass spectrometry was selected for this study over other methods 
because it is a proven to be a highly sensitive and powerful method to study 
proteins in complex samples.  To identify the direct protein targets of Gal4 using 
in vivo photo-crosslinking followed by mass spectrometry it was necessary to 

















a general scheme for preparing a sample for mass spectrometric analysis with 
crosslinked Gal4.  A major challenge in these experiments is that transcription 
proteins are typically low abundant proteins (Table 3-1), so large culture volumes 
are required. Even though we typically utilize a high copy plasmid expressing 
Gal4 from a strong promoter we are incorporating a nonnatural amino acid which 
adds to the low abundance issue, as these proteins typically express only ~20% 
of what wild-type protein expressed under the same conditions. In addition, 
activators such as Gal4 are often rapidly degraded. Developing optimal 
conditions for lysing procedures with such large volumes (6-12L) is also difficult 
as yeast are notoriously difficult to lyse.2 Since TADs are known to have a 
multipartner binding profile, one would expect that many proteins are crosslinked.  
An additional challenge is that effective washing conditions in the 
Figure 3-1:  General strategy for preparing a photo-crosslinked of Gal4 for mass 
spectrometric analysis.  
 
Gal4 in vivo crosslinking 
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conditions 
 
Crosslinked protein purification 
-Optimize wash steps and order of two affinity column 
purifications to maximize protein yields and minimize 
nonspecific/low affinity binding proteins in sample 
-Reassess culture size based on purified protein yields  
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immunoprecipitation steps must be identified in order to minimize the chance of 









Gal11 (Med15) 606 
Gal80 784 





















Taf5 14800 ± 203 
Mbf1 47300 
TBP low signal 
Srb9 low signal 
Tra1 not visualized 
SRB10 not visualized 
Hpr1 not visualized 
Sug2 not visualized 
Table 3-1: Protein copies/cell of potential targets of amphiphatic activators (discussed in 
Chapter 1) based on the yeast GFP fusion database (http://yeastgfp.yeastgenome.org/). Low 
abundance proteins are <5,000 copies/cell.3 Not visualized means either the tagging was 
unsuccessful or no signal was detected.  Low signal means tagging was successful but the 
signal was not sufficiently high above background to permit accurate quantitation.  
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the final sample to be analyzed.  Finally, choosing a MS ionization strategy is 
important since the sample is complex and contains low abundance proteins. 
 
B.1 Mass spectrometric analyses of complex proteomes 
 To analyze complex protein sample mixtures many analytical techniques 
involving mass spectrometry have been developed.4-7 These techniques vary 
with regards to their degree of reproducibility, resolution/sensitivity, throughput, 
biases and limitations.  High resolution and sensitivity with little bias and 
limitations are desired for analyzing a sample where protein composition is 
unknown.  This will maximize protein coverage so that both low and high 
abundance proteins are identified.  It is also important to consider the 
reproducibility and throughput of the technique used.  Low throughput on 
complex samples may limit the data collected and ultimately may be 
unreasonable for such studies. 
 
B.1.a  MALDI versus ESI for analyzing proteomes 
 There are primarily two methods used to ionize biomolecule for MS 
analysis.  Matrix-assisted laser desorption/ionization (MALDI) is a one method for 
ionization and another used in proteomic analysis is electrospray ionization (ESI).  
MALDI is a solid-state method where the sample is dried on a metal matrix plate 
and a laser is used to vaporize the sample.8 ESI is flow-based where a sample in 
solution is aerosolized and droplets become ionized.  The liquid in the drops 
evaporate producing gas-phase ions.8 A major advantage of ESI over MALDI is 
that the flow source can come directly from an attached liquid chromatography 
column, making it very convenient for analysis of complex mixtures that can be 
resolved prior to analysis.   To achieve a similar type of experiment using MALDI, 
plate spotters can be coupled to a liquid chromatography system. However, the 
quality of the separation will be attenuated because several spectra of data will 
be “summed” in collected fractions rather than a sample coming directly off the 
separation system to the ionizer where no fractions are collected for analysis.  A 
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disadvantage of ESI is that a sample cannot be reanalyzed, which is not the case 
with MALDI.  Some researchers use both techniques to analyze a similar sample 
in a complementary approach.9-12  
 
B.1.b.  Top-down versus bottom-up proteomics 
Two approaches are primarily used for studying biomolecules with MS.  
The bottom-up approach (Figure 3-2) is a widely used method that involves  
                             
                              
Figure 3-2:  General schemes for bottom-up and top-down proteomics.13 In bottom-up 
approach (top panel) proteins are enzymatically digested before MS analysis.  In top-down 
approach (bottom panel) intact proteins are analyzed by MS.  
 
digesting a protein sample mixture to generate peptides that are then subjected 
to MS analysis. In this analysis, the peptide ions are fragmented, enabling 
peptide sequences to be determined, ultimately leading to protein identification.  
The peptide fragments are more easily solublized and separated compared to the 
parent proteins which is an advantage of the bottom-up technique for protein 
identification. A disadvantage of this method is that only a fraction of the peptides 
are detected, so mapping post-translational modifications (PTMs) found on the 
parent protein is not straightforward.13 Conversely, in the top-down approach 
intact proteins are subjected to MS analysis where they fragment yielding 
identification of the protein.13 An advantage of this technique over the bottom-up 




understood as long as enough key fragments are observed.  A major 
disadvantage of this approach is that unlike the small peptides, it is difficult to 
generate significant gas-phase fragmentation ions of full-length protein, 
particularly of higher molecular weight proteins.13 For example it was considered 
a heroic feat when Han and coworkers broke the ~50 kDa limit upon 
demonstrating protein fragmentation on a >200 kDa protein.14  We have chosen 
the bottom-up approach because we are not initially looking to map protein 
modifications but simply identify proteins.  Additionally, because some 
transcriptional proteins possess molecular weights near or exceeding the 
boundaries of top-down (Swi1 ~148 kDa, Snf2 ~194, Tra1 ~433), a bottom-up 
approach seemed to be a more compatible with our experiments. 
   
 B.2.  Methods used for studying proteomic samples 
 Using the various methods of protein separation of complex mixtures 
coupled with different mass spectrometers the following methods have been 
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Link et. al. (1999) 
Washburn et. al. 
(2001) 
Table 3-2:  Strategies for proteomic analysis discussed in this sections. 
 
B.2.a Two-dimensional polyacrylamide-gel electrophoresis followed by 
mass spectrometry  
 One method used to resolve and detect proteins in a complex mixture is 
two-dimensional polyacrylamide-gel electrophoresis (2D PAGE) followed by 
mass spectrometry (MS).  Proteins are resolved in one dimension by isoelectric 
point (pI) and then by molecular weight (MW) in a second dimension.15 Proteins 
are typically visualized by staining the gel with an MS-compatible stain like 
Coomassie blue.  Once visualized, the stained proteins in the gel are excised and 
digested with a protease such as trypsin to generate peptide fragments that are 
then injected into a mass spectrometer for analysis.  Although this technique has 
been effective for the identification of abundant proteins in a sample, when 
evaluated for its usefulness for analyzing a more complex sample containing 
protein of varying abundance, it was not sensitive enough for identifying low 
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abundant proteins (<0.1 codon bias discussed below).16 Additionally, the manual 
excision of the protein gel slices lowers the reproducibility and high throughput of 
2D PAGE/MS analysis, something that is essential for obtaining scientific data on 
complex samples.  To evaluate the general utility of 2D PAGE/MS for proteomic 
analysis Gygi and coworkers prepared a 500 µg sample of soluble yeast 
proteins.16 They separated the proteins on a 2D PAGE and observed ~1,500 
spots on the gel.   They analyzed one 4 cm2 section where they cut 50 spots from 
the gel for MS analysis using ESI tandem mass spectrometry (MS-MS).16 
Tandem mass spectrometry is used for protein identification because in the 
instrument peptides fragment along the backbone in predictable ways, enabling 
amino acids to be identified based on the mass of the individual fragments and 
the known mass of amino acids.17,18 In MS-MS an initial full survey scan is 
followed by several product ion scans where peptides are isolated for tandem 
mass spectrum generation that permits peptide sequencing based on the 
fragmentation observed in the spectrum (Figure 3-3).  Once a peptide sequence  
 
Figure 3-3:  General MS-MS strategy for proteomic studies.  The peptide ions are first 
measured by MS (upper panel) to determine the mass of the individual peptides.  Each 
peptide is then isolated in the first mass analyzer (MS1) and moves onto the collision cell 
where they become fragmented.  These fragments are directed to the second mass analyzer 





p ysical connections between proteins that had been thought to function 
in independent pathways. With the aim of mapping mitochondrial protein 
complexes that contain the pro-apoptotic protein Bcl-2 antagonist of cell 
death (BAD), they developed a gentle and efficient enrichment method 
to isolate these complexes from mouse liver mitochondria (Fig. 1a). A 
232-kDa a sembly consisting of five major proteins was identified by 
silver staining of proteins separated by polyacrylamide gel electrophoresis 
(PAGE). The prote n spots constituting this complex were then excised 
and analysed by liquid-chromatography–tandem mass spectrometry 
(LC–MS/MS). This revealed, in addition to BAD, the presence of protein 
phosphatase 1C (PP1C), cyclic-AMP-dependent protein kinase (PKA) 
and the PKA-anchoring protein WAVE1. Previous studies had impli-
cated PKA as an important regulator of BAD, i hibiting the activity of 
BAD by phosphorylating multiple serine residues21. The authors provided 
Mass-spectrometry-based proteomic experiments involve several steps 
(see Figure). A peptide mixture can be obtained from the sample of 
interest by proteolytic digestion of a protein mixture or of a gel band or 
spot, following separation by electrophoresis. These peptides are then 
introduced into a one-dimensional (LC) or multi-dimensional (LC/LC) 
liquid-chromatography system. After separation, they are eluted into 
an electrospray ionization tandem mass spectrometer. The mass-to-
charge ratios of the peptide ions are measured first by mass spectrom try 
(upper panels; ions pass unperturbed through the first mass analyser and 
collision cell) to determine the molecular mass of each peptide. Then, 
each peptide ion is isolated in the first ass analyser (MS 1) and directed 
into a collision cell, where it collides with neutral gas molecules (for 
example, helium) and becomes fragmented (lower panels). The mass-to-
charge ratios of the resultant fragments are measured in the second mass 
analyser (MS 2), producing a tandem mass spectrum (shown for the 
peptide ion indicated with a white rectangle in the upper panel) and, after 
computer analysis, an amino-acid sequence for each peptide. These steps 
are described in further detail below.
Sample preparation
Two general strategies are often used to prepare proteins. Proteins 
that have been enriched or obtained as part of an experiment can be 
fractionated by SDS–polyacrylamide gel electrophoresis (SDS–PAGE). 
Individual bands can be removed and analysed, or an entire lane can be 
excised and divided into 10–15 slices. Proteins in the gel slices are then 
digested in situ with trypsin, and the peptides are extracted. Extracted 
peptides are then analysed by mass spectrometry. Protein mixtures 
can also be digested directly in solution. A protein mixture is denatured 
by using chaotropes and then digested — sometimes by a two-step 
procedure that involves proteases, such as the endoprotease LysC 
followed by trypsin — to generate a peptide mixture that is suitable for 
mass-spectrometry analysis. In general, trypsin digestion is preferred to 
generate peptides with an arginine or lysine residue at the C terminus, but 
other types of enzyme, including nonspecific proteases, have also been 
used78. 
Liquid chromatography
Before peptide mixtures are introduced into the mass spectrometer, 
they are fractionated in-line with the instrument. The most common 
method of fractionation is reversed-phase liquid chromatography, 
which separates peptides according to their hydrophobicity. To 
achieve the best sensitivity and efficiency of separation, microcolumns 
(< 100 !m in length) with a small diameter tip (for example, 5 !m) are 
typically used. The electrospray ionization that takes place in the mass 
spectrometer acts like a concentration-dependent detector; therefore, 
the introduction of peptides in narrow peaks improves detection limits, 
and low flow rates (in the order of nL min–1) are used to achieve this. As 
peptide mixtures become more complex, the introduction of a second 
dimension of separation can improve the resolution of separation. A 
good choice for a second dimension is strong cation-exchange (SCX) 
liquid chromatography, which separates peptides mainly on the basis 
of positive charges. SCX can be used off-line, and then each fraction 
is analysed by reversed-phase high-pressure liquid chromatography, 
followed by mass spectrometry. Alternatively, both the reversed-phase 
and SCX resins can be packed into a single column, and, by introducing 
buffers in series, a two-dimensional separation can be achieved before 
mass-spectrometry analysis. 
Electrospray ionization
A potential is placed on the liquid flowing from the liquid-chromatography 
column through a fused silica column or needle, causing the solution 
to spray. The spray contains fine droplets that encompass the sample. 
The droplets are desolvated as they enter the mass spectrometer, by 
applying heat to generate ions. The efficiency of ionization depends on 
the chemical properties of each molecule. 
Mass-spectrometry analysis
Mass spectrometers measure the mass-to-charge ratio of an ion. This is 
carried out by manipulating ions in electric and/or magnetic fields or by 
measuring their time of flight (TOF). In addition to determining the mass-
to-charge ratio, the intensity of the signal obtained reflects the abundance 
of the ion. The abundance of ions can vary with the ionization, so samples 
can be labelled with stable isotopes to determine quantitatively the ratio 
of peptides from different ‘states’ (by measuring the mass-to-charge 
ratio and abundance). Various mass analysers are used in proteomic 
experiments, including ion-trap mass spectrometers, quadrupole/TOF 
hybrids, ion-trap/orbitrap hybrids and ion-trap/ion-cyclotron-resonance 
(FTMS) hybrids. Some types of mass analyser can measure the mass-to-
charge ratio with high resolution (up to 150,000 m/"m, where m denotes 
mass) and high mass accuracy (to < 1 part per million).
Box 1 | Fundamentals of mass-spectrometry-based proteomic experiments
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peptide ion indicated with a white rectangle in the upper panel) and, after 
computer analysis, an amino-acid sequence for each peptide. These steps 
are described in further detail b low.
Sample preparation
Two general strategies are often used to prepare proteins. Proteins 
that have been enriched or obtained as part of an experiment can be 
fractionated by SDS–polyacrylamide gel electrophoresis (SDS–PAGE). 
Individual bands can be removed and analysed, or an entire lane can be 
excised and divided into 10–15 slices. Proteins in the gel slices are then 
digested in situ with trypsin, and the peptides are extracted. Extracted 
peptides are then analysed by mass spectrometry. Protein mixtures 
can also be digested directly in solution. A protein mixture is denatured 
by using chaotropes and then digested — sometimes by a two-step 
procedure that involves proteas s, such as the endopr tea e LysC 
followed by trypsin — to generate a peptide mixture that is suitable for 
mass-spectrometry analysis. In general, trypsin digestion is preferred to 
generate peptides with an arginine or lysine residue at the C terminus, but 
other types of enzyme, including nonspecific proteases, have also been 
used78. 
Liquid chromatography
Before peptide mixtures are introduced into the mass spectrometer, 
they are fractionated in-line with the instrument. The most common 
method of fractionation is reversed-phase liquid chromatography, 
which separates peptides accordi g to their hydrophobicity. To 
achieve the best sensitivity and efficiency of separation, microcolu ns 
(< 100 !m in length) with a small diameter tip (for example, 5 !m) are 
typically used. The electrospr y ioniz ti  that takes place in the mass 
spectrometer acts like a concentration-depe dent detector; therefore, 
the introduction of peptides in narrow peaks improves detection limits, 
and low flow rates (in the order of nL min–1) are used to achieve this. As 
peptide mixtures become more complex, the introduction of a second 
dimension of separation can improve the resolution of separation. A 
good choice for a second dimension is strong cation-exchange (SCX) 
liquid chro atography, which separates peptides mainly on the basis 
of positive charges. SCX can be used off-line, and then each fraction 
is analysed by reversed-phase high-pressure liquid chromatography, 
followed by mass spectrometry. Alternatively, both the reversed-phase 
and SCX r sins can be acked into  single column, and, by introducing 
buffers in series, a two-dimensional separation can be achieved before 
mass-spectrometry analysis. 
Electrospray ionization
A potential is placed on the liquid flowing from the liquid-chromatography 
column through a fused silica column or needle, causing the solution 
to spray. The spray contains fine droplets that encompass the sample. 
The droplets are desolvated as they enter the mass spectrometer, by 
applying heat to generate ions. The efficiency of ionization depends on 
the chemical properties of each molecule. 
Mass-spectrometry analysis
Mass spectrometers measure the mass-to-charge ratio of an ion. This is 
carried out by manipulating ions in electric and/or magnetic fields or by 
measuring their time of flight (TOF). In addi ion to determining the mass-
to-charge ratio, the intensity of the sig al obtained reflects the abundance 
of the ion. The abund ce of ions can v ry with the ionization, so samples 
can be labelled with stable isotopes to determine quantitatively the r tio 
of peptides from different ‘states’ (by measuring the mass-to-charge 
ratio and abundance). Various mass analysers are used in proteomic 
experiments, including ion-trap mass spectrometers, quadrupole/TOF 
hybrids, ion-trap/orbitrap hybrids and ion-trap/ion-cyclotron-resonance 
(FTMS) hybrids. Some types of mass analyser can measure the mass-to-
charge ratio with high resolution (up to 150,000 m/"m, where m denotes 
mass) and high mass accuracy (to < 1 part per million).
Box 1 | Fundamentals of mass-spectrometry-based proteomic experiments
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physical connecti ns betw en protein  that had been th ught to function 
in independent pathways. With the aim of mapping mitochondrial protein 
complexes that contain the pro-apoptotic protein Bcl-2 antagonist of cell 
death (BAD), they developed a gentle and efficient enrichment method 
to isolate these complexes from mouse liver mitochondria (Fig. 1a). A 
232-kDa assembly consisting of five major proteins was identified by 
silver staining of proteins separated by polyacrylamide gel electrophoresis 
(PAGE). The protein spots constituting this complex were then excised 
and analysed by liquid-chromatography–tandem mass spectrometry 
(LC–MS/MS). This revealed, in addition to BAD, the presence of protein 
phosphatase 1C (PP1C), cyclic-AMP-dependent protein kinase (PKA) 
and the PKA-anchoring protein WAVE1. Previous studies had impli-
cated PKA as an important regulator of BAD, inhibiting the activity of 
BAD by phosphorylating multiple serine residues21. The authors provided 
Mass-spectrometry-based proteomic experim nts inv lv  several steps 
(see F gure). A peptide mixture can b  obtai d from he sample of 
int rest by prot olytic digestion of a otein mixture or of a gel band or 
spot, following separation by el ctro horesis. T se p ptid s are then 
intr duced into  one-dimension l (LC) or m lti-dimensional (LC/LC) 
liquid-chromatography system. After separation, they are eluted into 
an electrospray ionization tandem mass spectrometer. The mass-to-
charge ratios of the peptide ions are measured first by ass sp ctrometry 
(upper panels; ions pass unperturbed through the first mass analyser and 
collision cell) to determine the molecular mass of each peptide. Then, 
each peptide ion is isolated in the first mass analyser (MS 1) and directed 
into a collision cell, where it collides with neutral gas molecules (for 
example, helium) and becomes fragmented (lower panels). The mass-to-
charge ratios of the resultant fragments are measured in the second mass 
analyser (MS 2), producing a tandem mass spectrum (shown for the 
peptide ion indicated with a white rectangle in the upper panel) and, after 
computer analysis, an amino-acid sequence for each peptide. These steps 
are described in further detail below.
Sample preparation
Two g neral strategies are oft n u ed to prepare roteins. Proteins 
th  have been enriched or obtained as pa t of an xperiment can be
fractionated by SDS–polyacrylamide gel lect ophoresis (SDS–PAGE). 
Individual bands can be removed and analysed, or an entire lane ca  be 
xcised and divided into 10–15 slices. Proteins in the g l slices re then 
digested in situ with trypsin, and the peptides are extracted. Extracted 
peptides are then analysed by mass spectrometry. Protein mixtures 
can also be digested directly in solution. A protein mixture is denatured 
by using chaotropes and then digested — sometimes by a two-step 
procedure that involves proteases, such as the endoprotease LysC 
followed by trypsin — to generate a peptide mixture that is suitable for 
mass-spectrometry analysis. In general, trypsin digestion is preferred to 
generate peptides with an arginine or lysine residue at the C terminus, but 
other types of enzyme, including nonspecific proteases, have also been 
used78. 
Liquid chromatography
Before peptide mixtures are introduced into the mass spectrometer, 
they are fractionated in-line with the instrument. The most co mon 
method of fracti ation is reversed-phase liquid chromatography, 
whic  separates eptides according to th ir hydr phobicity. To 
achieve th  best s nsitivity and efficiency of sep ration, microcolu ns 
(< 100 !m in length) with a small diameter tip (for example, 5 !m) are 
typically sed. The electro pray ionization that takes plac  in the mass 
spectrome er acts like a c nc ntration-depen ent detector; therefore, 
the introduction of peptides in narrow peaks improves detection limits, 
and low flow rates (in the order of nL min–1) are used to achieve this. As 
p ptide mixtures becom  more complex, he introduction of a second 
dimension of separation can improve the resolution of separation. A 
good choice for a second dimension is strong cation-exchange (SCX) 
liquid chromatography, which separates peptides mainly on the basis 
of positive charges. SCX can be used off-line, and then each fraction 
is analysed by reversed-phase high-pressure liquid chromatography, 
followed by mass spectrometry. Alternatively, both the reversed-phase 
and SCX resins can be packed into a single column, and, by introducing 
buffers in series, a two-dimensional separation can be achieved before 
mass-spectrometry analysis. 
Electrospray ionization
A potential is placed on the liquid flowing from the liquid-chromatography 
column t rough a fused silica column or needle, causing the solution 
to spray. The spray contains fine drople s that encompass the sample. 
The droplets are desolvated as they nter the mass spectrom ter, by 
applying heat t  generate ions. The effici ncy of ionization depends on 
the chemical properties of each molecule. 
Mass-spectrometry analysis
Mass spectrometers measure the mass-to-charge ratio of an ion. This is 
carried out by manipulating ions in electric and/or magnetic fields or by 
measuring their time of flight (TOF). In addition to determining the mass-
to-charge ratio, the intensity of the signal obtained reflects the abundance 
of the ion. The abundance of ions can vary with the ionization, so samples 
can be labelled with stable isotopes to determine quantitatively the ratio 
of peptides from different ‘states’ (by measuring the mass-to-charge 
ratio and abundance). Various mass analysers are used in proteomic 
experiments, including ion-trap mass spectrometers, quadrupole/TOF 
hybrids, ion-trap/orbitrap hybrids and ion-trap/ion-cyclotron-resonance 
(FTMS) hybrids. Some types of mass analyser can measure the mass-to-
charge ratio with high resolution (up to 150,000 m/"m, where m denotes 
mass) and high mass acc racy (t   1 art per million).
Box 1 | Fundamentals of mass-spectrometry-based proteomic experiments































NATURE|Vol 450|13 December 2007INSIGHT REVIEW
 
physical connections between proteins that had been thought to function 
in independent pathways. With the aim of mapping mitochondrial protein 
complexes that contain the pro-apoptotic protein Bcl-2 antagonist of cell 
death (BAD), they developed a gentle and efficient enrichment method 
to isolate th se complexes from mou e liver mitocho dria (Fig. 1a). A 
232-kDa assembly consisting of five aj r proteins was ide tified by 
silver staining of proteins separated by polyacrylamide gel electroph resis 
(PAGE). The protein spots constituting this complex were then excised 
and analysed by liquid-chromatography–tandem mass spectrometry 
(LC–MS/MS). This revealed, in addition to BAD, the presence of protein 
phosphatase 1C (PP1C), cyclic-AMP-dependent protein kinase (PKA) 
and the PKA-anchoring protein WAVE1. Previous studi s had im li-
cate PKA as a  im ortant regulator of B D, inhib ting the activity of 
BAD by phosphorylating multiple serine residues2 . The auth rs provided 
Mass-spectrometry-based proteomic experiments involve several steps 
(see Figure). A peptide mixture can be obtained from the sample of 
interest by proteolytic digestion of a protein m xture or of a gel band or 
spot, followi g separation by electroph resis. These peptid s are th n 
introduced into a one-dimensional (LC) o  ulti-dimensional (LC/LC) 
liquid-chromatography system. After separation, they are eluted i to 
an electrospray ionization tandem mass spectrometer. The mass-to-
charge ratios of the peptide ions re meas red first by mass spectromet y 
(upper panels; ions pass unperturbed through the first ma s analyser and 
collision cell) to determine the molecular mass of each peptide. Then, 
each peptide ion is isolated in the first mass analyser (MS 1) and directed 
into a collision cell, where it collides ith n u al gas mol cules (for
example, helium) and becomes fragmented (low r panels). The mass-to-
charge ratios of the result nt fragments are m asured in the second ma s 
analyser (MS 2), producing a tandem mass spectrum (shown for the 
peptide ion indicated with a white rectangle in the upper panel) and, after 
computer analysis, an amino-acid sequence for each peptide. The  steps 
are described in further detail below.
Sample preparation
Two general strategies are often u ed to prepare prot ins. Proteins 
that have been enriched or obtained as part of an experiment can be 
fractionated by SDS–p lyacrylami e gel electrophoresis (SDS–PAGE). 
Individual bands can be removed  analys d, or an entire lane can be 
excised and divid d into 10–15 slices. Protei s in the gel slices are then 
digested in situ with trypsin, and the peptid s are extract d. Extracted 
peptides are th n analysed by m ss spectr metry. Protein mixtur s 
can also be digested directly i  solution. A protein mixture is den tured 
by using chaotropes and then digested — sometimes by a two-step 
procedure that involves proteases, such as the endoprotease Ly C 
followed by trypsin — to generate a peptide mixture that is suitable for 
mass-spectrometry nalysis. In general, trypsin dig stion is preferred to 
generate peptides with an rg nine or ly ine residu  at t e C terminus, but 
other types of enzyme, including nonspecific proteases, have also been 
used78. 
Liquid chromatography
Before peptide mixtures are introduced into the mass spectrometer, 
they are fractionated in-line with the instrument. The most common 
method of fractionation is reversed-phase liquid chromatography, 
which separates peptides according to their hydrophobicity. To 
achieve the best sensitivity and efficiency of separation, microcolumns 
(< 100 !m in length) ith a small diamet r tip (for example, 5 !m) are 
typically used. Th  el ctr spray ionizat  that tak s plac  in the mass 
spectrometer acts like a conc ntration-d penden  detector; therefore, 
the introduction of peptides in narrow p aks improves detection limits, 
and low flow rates (in the order of nL min–1) are used to ac ieve t is. As 
peptide mixtures become or  complex, the introduction of a second 
dimension f separation can improve the resolution of s p ration. A 
good choice for a second dimension is strong cation-exchange (SCX) 
liqui  chromatography, which separat s peptides mainly n the basis 
of positive charges. SCX ca  be used off-line, nd then each fraction 
is analysed by rev rsed-phase high-pressure liquid chromatography, 
followed by mass spectrometry. Alternatively, both the reversed-phase 
and SCX resins can be packed into a single column, and, by introducing 
buffers in series, a two-dimensional s p ration can be achieved before 
mass-spectrometry a alysis. 
Electrospray ionizati n
A potential is lac d on th  liquid flowing fro  the liquid-chromatography 
column through a fused silica column or eedl , causing the solution 
to spray. The spray contains fine droplets that e compass the sample. 
The droplets are desolvated as they enter the mass spectrometer, by 
applying heat to gener e ions. The efficiency of ionization depends on 
th  chemical prop rti s of eac  molecule. 
Mass-spectrometry analysis
Mass spectrometers mea ur  the mas -to-c arge ratio of an ion. This is 
carried out by ma ipulating ions in electric nd/or magnetic fields or by 
me suring their time of flight (TOF). In addition to d termi ing the mass-
to-charge ratio, the intensity of the signal obtained reflects the abundance 
of t e ion. The abundance of ions can vary with the ionization, s  samples 
can be labelled with t ble isotopes to d term e quantitatively the ratio 
of peptides from different ‘states’ (by measuring the mass-to-charge 
ratio and abundance). Various mass analysers are used in proteomic 
experiments, including ion-trap mass spectrometers, quadrupole/TOF 
hybrids, ion-trap/orbitrap hybrids and ion-trap/ion-cyclotron-resonance 
(FTMS) hybrids. Some types of mass analyser can measure the mass-to-
charge ratio with high resolution (up to 150,000 m/"m, where m denotes 
mass) and high mass accuracy (to < 1 part per million).
Box 1 | Fundamentals of mass-spectrometry-based proteomic experiments






































is obtained a database search is carried out to identify the protein from which the 
peptide comes from.17 They evaluated the sensitivity of using 2D PAGE with 
MS/MS based on the codon bias values.  Codon bias values have been 
established for proteins and is defined as the extent to which a gene uses a 
subset of optimal codons with a scale of 0.0-1.0.20 Higher expressed proteins 
have codon bias values of >0.2.  In yeast about half of the proteins have a codon 
bias value of <0.1 and of the proteins identified in their study none of them had a 
codon bias value <0.1.16 They concluded that 2D PAGE followed by MS/MS is 
not a reliable technique for detecting low abundant proteins and in order to do so 
a much larger protein sample must be prepared to identify these proteins using 
this method.   One limitation of 2D PAGE is sample capacity for loading onto a 
2D PAGE gel.   If a larger sample is required for low abundant proteins to be 
detected than is able to be loaded onto a 2D PAGE then sample capacity may be 
the limiting factor for analyzing these proteins with this method.  Also, if an entire 
analysis of all proteins in the gel would have been carried out (~1,500 spots) it 
would have been extremely time consuming and very low throughput.  Perhaps 
this is the reason why they only chose a 4cm2 area to analyze.  A low throughput 
technique with little success at identifying low abundant proteins is not conducive 
for large protein mixtures with low abundant proteins and therefore other 
strategies must be used. 
 
B.2.b.  Two-dimensional liquid chromatography  
 Other researchers explored different ways to resolve protein mixtures 
before they are analyzed by MS (Table 3-2). In particular, it was desirable to 
improve the 2D PAGE system by reducing the sample capacity limitations, 
increase throughput and sensitivity.  To this end, 2D-liquid-chromatography 
followed by MS was developed. One advantage of liquid-phase chromatography 
over 2D PAGE for resolving proteins is that it has a high loading capacity (can be 
up to 50 times more than 2D PAGE).4-6,21 In an effort to improve throughput and 
sensitivity Wall et. al. separated proteins from human erythroleukemia cell line 
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lysate first by isoelectric focusing and then by nonporous reversed-phase high 
throughput liquid chromatography (HPLC), and analyzed these proteins by 
matrix-assisted laser desorption/ionization time-of-flight MS (MALDI-TOF MS). 
They were able to resolve ~700 bands with a rapid gradient and ~1000 bands 
with a longer gradient but were only able to identify 38 different proteins.6 They 
report an improved resolution of low mass and basic proteins over 2D PAGE 
protein separation they were not able to identify a significant amount of proteins 
(38 out of ~700).  This method is, however, an improvement in throughput and 
sample capacity over 2D PAGE.   
 Another important aspect for improving systems for protein resolution and 
detection is whether the method used is off-line or on-line.  This is an important 
consideration because it is related to throughput.   Off-line is when the sample is 
handled after the resolving step and before it is injected into the mass 
spectrometer (MALDI is an example of this) and on-line is when the there is no 
handling of the sample from the resolving step to injecting into the mass 
spectrometer (Figure 3-4).  The latter was used by Opiteck and coworkers who  
       
Figure 3-4:  Example of off-line (top) and on-line (bottom) MS approaches.  Off-line requires 
sample handling in between protein separation and the mass spectrometer.  There is no 
sample handling once the sample is injected into the protein separation apparatus.22 





















developed a fully automated 2D liquid chromatography MS system.5 The proteins 
were separated by cation-exchange chromatography (CE) and reversed-phase 
HPLC and then detected by an electrospray mass spectrometer (ESI-MS).5 On-
line systems are higher throughput than off-line systems and they are less prone 
to sample loss.  Despite the advantages of this method, Opiteck and coworkers 
were able to identify proteins in a protein mixture containing 10 known proteins, 
but when E. coli lysate was analyzed they report one protein with a database 
search indicating the mass corresponds to 38 proteins within 2% of its molecular 
weight.5 Later the same group modified their method by resolving the protein 
mixture by size-exclusion liquid chromatography followed by reversed-phase 
HPLC and analyzed the proteins by either MALDI-TOF MS or ESI-MS.4 They 
identified 14 of the ~450 proteins isolated from E. coli lysates by MALDI-TOF MS 
and Edman sequencing.4 Overall, their method was high throughput, but it lacked 
the resolution that 2D gels posses, a direct interface to the mass spectrometer 
and automated protein identification technology.4    
 
B.2.c Two-dimensional liquid chromatography followed by MS-MS  
 Perhaps the best strategy for characterizing complex proteomes was 
achieved by the Yates research group (Figure 3-4 (on-line)).  Using a fully 
integrated method comprised of 2D liquid-chromatography followed by tandem 
mass spectrometry they were able to identify >100 proteins of a yeast lysate in a 
single run.7 They loaded trypsin-digested proteins onto a biphasic 2D 
microcapillary column.  The peptide sample mixture was separated in the column 
by strong cation exchange (SCX) and reverse-phase (RP-HPLC).  Once on the 
SCX resin the peptides was displaced through a salt step gradient onto the RP-
HPLC resin where they were eluted directly onto an ESI-MS/MS.  Before the next 
salt step in the SCX column the RP-HPLC resin was equilibrated, prepared for a 
new fraction of peptides.7 Peptide sequences were analyzed by the SEQUEST 
software to identify proteins.  
 61 
 Further optimization by the Yates lab lead to increased utility and 
applicability of their front running technology, termed multidimensional protein 
identification technology (MudPIT), for detecting proteins in a complex mixture.  
Applying their method to a large-scale analysis of the yeast proteome they were 
able to identify 1,484 proteins, the most of anyone at the time.23 This highly 
unbiased method yielded proteins identified from all subcellular compartments.  
They were able to capture proteins with extreme isoelectric points (pI), molecular 
weight, abundance and hydrophobicity.23 In particular they evaluated their 
method in terms being able to identify low abundant proteins.  To this end they 
looked at the codon adaptation index (CAI) of the proteins they were able to 
identify. CAI, similar to codon bias index, is defined as value that corresponds to 
cellular protein abundance and is the relative adaptiveness of the codon usage of 
a gene towards the codon usage of highly expressed genes.24 If a protein is 
coded with the most frequently used codons then it has a higher CAI value.  CAI 
values range from 0.0-1.0 where 0.0-0.2 is related to low cellular protein 
abundance and values closer to 1.0 are associated with higher cellular protein 
abundance. It has been reported that 83% of the ~6,000 genes in the yeast 
genome have CAI levels between 0.0-0.2.23 When the authors analyzed the 
proteins identified by their method in terms of their CAI, they identified proteins 
that have a CAI <0.2.23 In this large-scale study 53.3% of the proteins had a CAI 
value <0.2, a major feat as other studies on yeast proteomes have had limited 
success at identifying proteins with this characteristic.25-27 Importantly, they report 
identifying 45 transcription factors. Amongst them were SNF5, SWI6 and SWI4, 
proteins that are found in the SWI/SNF complex with CAIs ranging from 012-
0.15.23 Based on the CAI analysis of their data, MudPIT may be applied for the 
study of biological processes involving low abundant proteins such as 
transcription. 
 In summary, recent advances in mass spectrometry for analyzing complex 
protein samples have reduced the limitations of past methods.   The Yates 
laboratory has shown the utility of their method by collaborating with researchers 
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to help solve biological problems surrounding protein-protein interactions.28-30 
Due to their proven success, a facility at Scripps Research Institute termed the 
Center for Physiological Proteomics was opened that uses MudPIT.  MudPIT has 
been used to detect low abundant proteins, a characteristic required for studying 
transcription proteins therefore is of much interest to reaching our goal of 
identifying the direct targets of Gal4 TAD.   In vivo photo-crosslinking followed by 
Western blot allowed us to identify a known binding partner of Gal4, Gal80, with 
little perturbation to the function of the activator proving this method is useful for 
capturing transcription related proteins.  Moving forward, we needed a less 
biased and limiting method than Western blot for identifying the direct targets of 
Gal4.  Because MudPIT is a technique possessing remarkable sensitivity for 
identifying low abundant proteins we decided to utilize this method for analyzing 
our crosslinked protein samples.  
 
C.  Preparing an in vivo photo-crosslinked sample for mass spectrometric 
analysis 
 Using in vivo crosslinking followed by MS, our initial goal was to observe 
and confirm the Gal4-Gal80 interaction that was observed on our Western blot.  
Characterizing Gal4-Gal80 interaction with these techniques would confirm the 
possibility of using MS for identifying other protein targets of Gal4. Before a 
sample could be submitted for mass spectrometric analysis an extensive 
optimization of a protein purification protocol was required for generating a MS 
sample with minimal nonspecific/low binding proteins that would be carried 
through the purification process. One challenging aspect of transcription proteins 
with relation to obtaining MS data, was their low abundance issue meaning that 
high yeast culture volumes were required for identifying the proteins of interest 
with MS (Table 3-1).31 Additionally, it was improbable that all of the copies of a 
particular protein target in the cell would be localized to the required proximity of 
Gal4 TAD for pBpa crosslinking, and, if they were, it was known that pBpa 
crosslinking was not 100% efficient due to required geometries and amino acid 
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preference which meant that only a fraction of the already low abundant potential 
protein targets in the cell would be captured by crosslinking.32,33  TADsʼ 
intrinsically unstructured character and multipartner binding profile made purifying 
crosslinked products for MS difficult as potentially many nonspecific proteins 
could interact with the TAD.34 
 Many steps were optimized in the protein purification for preparing a MS 
sample containing low abundance crosslinked proteins (Figure 3-5). The initial  
 
Figure 3-5:  LexA-Gal4-FLAG-6X-His construct used in the MS experiments (top).  Steps in 
optimizing a method for preparing a crosslinking protein sample (boxes). 
 
optimization experiments were designed to reduce the nonspecific/low affinity 
proteins present in the sample.  To this end, a sample of full-length wild-type 
(WT) LexA-Gal4 protein without pBpa and without irradiation was used.   
Because WT LexA-Gal4 is expressed at higher levels (~5 fold) than Gal4 with 
pBpa incorporated, this allowed the use of smaller culture sizes.  If WT LexA-




















1. Use wild-type LexA-Gal4 to optimize conditions and determine 
scale of culture based on protein yields after purification 
 
Gal4(840-881)LexA(1-202) Flag 6X-His
2.  Optimize lysis conditions and wash buffers 
for purification with affinity columns 
 
3.  Optimize steps and order of purification using two affinity 
columns used (Nickel and FLAG resins) to maximize yield and 
minimize nonspecific/low affinity proteins in the final sample 
 
4.  Reassess the culture size needed for LexA-
Gal4 with pBpa incorporated 
5.  Prepare final samples and test 
different MS strategies 
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pBpa would as well. For purification purposes the LexA-Gal4 protein had both a 
FLAG and 6x-His epitope tag on the C-terminus.   
 
C.1. Optimizing yeast lysing conditions and wash buffers 
 Throughout the optimization different yeast lysing methods were tested as 
yeast require more rigorous lysing methods than other eukaryotic cells or 
bacteria due to their robust cell wall.  In previous experiments with yeast in our 
lab a mechanical method for lysing was used and included glass beads and a 
vortex.  This protocol was limited to small culture sizes as the vortex only holds 
1.5 mL tubes.  When preparing samples for MS it was estimated that the culture 
size would be several orders of magnitude larger than one compatible with the 
method described.  After trying a microfluidizer with little success (meaning whole 
yeast cells were visualized under a microscope after several times through the 
instrument) we found that lysing using a combination of incubation with Zymolase 
(US Biological), a reagent containing an enzyme (β-1,3-glucan 
laminaripentaohydrolase) used to break down yeast cell walls, followed by 
treatment with glass beads in either a vortexer or a bead beater resulted in a 
more complete lysis based on the amount of protein observed on a gel.35 The 
vortexer can hold 1.5mL microfuge tubes and the bead beater has either a 15 or 
50 mL chamber (with a water ice bath chamber that surrounds it) that is placed 
on top of a rotating blade.  Both bead lysing apparati can be controlled in terms of 
duration and pausing times, both of which were optimized as well.  It was 
important to optimize the amount of time the cells were agitated versus paused 
especially with the bead beater because it was used on the bench top and the 
yeast were in direct contact with the blade, thus becoming heated upon use.  In 
the bead beater samples became quite hot if there are not frequent pauses, 
which was not desirable for protein stability.  Ultimately short 15 second 
agitations with 2 minute pausing in the bead beater was used for lysing large 
yeast pellets.  
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 To test different combinations of lysis buffer and wash buffer, five 1L 
cultures of yeast expressing WT LexA-Gal4 protein were grown to test five 
different combinations (Table 3-3 and Figure 3-6).  The protein was purified once  
 Lysis buffers  
I 
100 mM PBS pH 7.0 
  
10% glycerol 
10 mM imidazole  
0.01% NP-40 
10 mM B-me 
II 
100 mM PBS pH 7.0 
150 mM NaCl 
10% glycerol  




100 mM PBS pH 7.0 
350 mM NaCl  
10% glycerol  
20 mM imidazole 
1.0% tween-20  
10 mM B-me  
1M Guanidine-HCl 
 Wash buffers  
I 
100 mM PBS pH 7.0  
 
4M Guanidine-HCl 
20 mM imidazole 
0.1% tween-20 
 10% glycerol  
10 mM B-me  
 
II 
100 mM PBS pH 7.0 
150mM NaCl  
4M Guanidine-HCl 
30 mM imidazole  
1.0% tween-20  
10% glycerol 
10 mM B-me  
 
III 
100 mM PBS pH 7.0 
350 mM NaCl 
5M Guanidine-HCl 
50 mM imidazole 
1.0% tween-20 
10% glycerol 
 10 mM B-me 
 
Table 3-3:  Lysis and wash buffers with different stringency (1<2<3) used in the initial 
optimization.   
 
Figure 3-6:  Gel showing the results of different lysis and wash conditions of purifying WT 
LexA-Gal4-FLAG-6X-His with Ni NTA resin.  Each lane is purified WT LexA-Gal4-FLAG-6X-
His from 1L of yeast expressing this protein.  The gel is strained with Sypro ruby which has a 





















Figure 3-6:  Gel showing the results of di ferent lysis and ash con iti  for purifying WT 
LexA-Gal4-FLAG-6X-His with Ni NTA resin.  Each lane is purified  - l -
His from 1L of yeast expre sing this protein.  The gel is st i  it  y r  ruby hich has a 
detection limit of 1 ng.32  
 
Gel Lane Lysis buffer Wash buffer 
A II III 
B III III 
C II II 
D III II 
E I I 
Full-length WT LexA-Gal4-FLAG-6X-His 
      A    B    C    D     E 
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with nickel (Ni NTA) resin to determine what conditions were best for lysing. The 
wash buffers compatible with Ni NTA resin used were based on what had been 
used with success in our lab previously and the handbook provided by Sigma 
that outlined the reagent compatibilities (see Methods for details).  Choice of 
wash buffer was critical because if a wash buffer was incompatible or too 
stringent, the His epitope tagged protein would be lost over the course of the 
wash step and too weak a wash buffer could result in high amounts of 
nonspecific/low affinity proteins stuck to the protein or the Ni NTA resin.  The 
wash buffers used ranged from low stringency to very high stringency (Table 3-
3).  A lysis buffer was also important because it was in this buffer that the lysate 
was interacting with the Ni NTA resin therefore minimizing nonspecific binding 
from the beginning would help in the wash step.  It was determined in this study 
(Figure 3-6) that lane one had the best lysis buffer/wash combination because it 
had reduced nonspecific bands yet the intensity of the LexA+Gal4 band was not 
reduced.  Further, when one of the most stringent buffers was absent (lane 3) the 
greatest of nonspecific proteins were observed.  Moving forward with this 
information it was clear that due to the high volume of nonspecific bands with a 
single purification in the samples a second affinity purification was an order. 
 
C.2 Two affinity columns for purifying crosslinked proteins 
 Two different affinity columns, Ni NTA and FLAG, were used to purify 
proteins from a complex protein mixture to reduce the nonspecific proteins in the 
sample.  First the yeast lysate containing WT LexA-Gal4 was bound to FLAG 
beads which had FLAG antibody conjugated to them, beads were washed, 
protein was eluted and then bound to the Ni NTA resin, again proteins were 
washed and eluted off to achieve a final pure protein sample.  Figure 3-7 shows 
the product from the described purification from 6L of yeast culture.  In this 
experiment one band was observed at the correct molecular weight of WT LexA-
Gal4 when silver-stained, conditions that have a detection limit of >0.8 ng.36 This  
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Figure 3-7:  Silver stained gel of WT LexA-Gal4 purified with Ni NTA and FLAG affinity resin 
from 6L of yeast.  
 
result showed two things: (1) the FLAG+Ni NTA dual purification protocol worked, 
as there were very few, if any, nonspecific bands viewed even with the highly 
sensitive stain; (2) although 6L of yeast expressing WT LexA-Gal4 protein was 
visualized well on the sensitive silver stain larger cultures would be required 
when working with the more poorly expressed protein, LexA-Gal4 with pBpa 
incorporated.   
 
C.3 Purifying Gal4 with p-benzoyl-L-phenylalanine incorporated 
 With a purification procedure in place, the next step was to carry out a 
similar experiment with protein containing pBpa.  A major concern moving 
forward were that the yields seen with WT LexA-Gal4 were not extraordinary 
considering a 6L sample was prepared.  This indicated that when working with 
the pBpa incorporated LexA-Gal4 protein higher culture sizes would be needed 
to not only see the full-length protein on a gel but to see the crosslinked products 
which are at even lower yield.  Being able to observe the purified Gal4 protein 
containing pBpa and crosslinked products in a stained gel was the gauge for 
obtaining successful MS data.  With this in mind, the goal of the next experiment 
was to understand how much protein was being expressed based on the ability to 
visualize the proteins with stains that have different detection limits.  To this end, 
6L yeast culture expressing LexA-Gal4 with pBpa incorporated into position 849 
WT Lex-Gal4 
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mutant (Phe849pBpa mutant) was crosslinked, purified and run on a gel 
alongside a 6L sample of not crosslinked WT LexA-Gal4 to compare purity and 
abundance (Figure 3-8).  Position Phe849 was chosen because this site showed 
the most crosslinked products in the photo-crosslinking experiments, an 
important aspect to consider when low protein concentration is a concern (see 
Figure 2-8).  The  
 
Figure 3-8:  Silver Stained gel (left) and Western blot (right) of the same samples showing 
purification of 6L of either WT LexA-Gal4 –pBpa –UV (lane 1) and LexA-Gal4 Phe849pBpa  
+pBpa +UV.  This experiment shows that the purification is clean and that the crosslinked 
products are not very concentrated as they are not very visible considering the sensitivity of 
the silver stain is >0.8 ng.36  The Western confirms than the higher molecular weight bands 
in the silver stained gel contain LexA-Gal4 protein.                                                    
 
samples were analyzed by Western blot and three types of staining methods: 
Coomassie, SYPRO ruby and silver stain with different detection limits (5ng, .25-
1ng, and >0.8 ng respectively) and with varying MS compatibility.36 From the data 
shown in Figure 3-8 it was concluded that the crosslinked bands were seen most 
clearly in the silver stain which was not MS compatible although Invitrogen does 
make a MS compatible stain however when tested produced a high background.  
In both the Coomassie stain and Sypro stain, the full-length protein was 
visualized in both the WT and Phe849pBpa mutant samples but the crosslinked 
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the silver stain matched with the Western blot bands nicely indicating that indeed 
the higher MW bands viewed in the silver stain were crosslinked products and 
not just nonspecific bands.  That did not rule out the possibility that some 
nonspecific proteins were present and that they could share the molecular weight 
of a crosslinked target showing up as overlapping bands on the silver stained gel 
but because the WT LexA-Gal4 showed negligible higher MW nonspecific bands 
indicated that this was not a clear problem.  
 
 C.4   Gel electrophoresis followed by mass spectrometric analysis  
As a starting point for MS analysis the University of Michiganʼs Michigan 
Proteome Consortium facility was used. A 2D gel was run to resolve protein 
mixtures and stained protein spots were excised from the gel; these samples 
were then digested and subjected to MS-MS by MALDI-TOF/TOF.  A sample was 
prepared with a goal of minimally identifying the full-length Gal4 Phe849pBpa 
protein and the Gal4+Gal80 crosslinked product.  Discussions with a staff 
member at the University of Michiganʼs Michigan Proteome Consortium indicated 
that for their MS-MS analysis ideally the proteins needed to be visualized under 
Coomassie stain.  Because 6L culture of irradiated yeast expressing LexA-Gal4-
849/pBpa produced crosslinked products that were only minimally observed by 
Coomassie stain and the more sensitive SYPRO stain, a 12L yeast culture 
expressing the LexA-Gal4-849/pBpa protein was irradiated and prepared for 
submission to the Michigan Proteome Consortium for 2D gel resolution followed 
by MS-MS analysis.  Upon staining the 2D gel with Sypro ruby at the facility there 
were few spots on the gel.  It may be that our proteins are just not stained well 
with SYPRO Ruby, although this would be surprising because it binds to basic 
amino acids and the polypeptide backbone.37   In our lab we restained the gel 
with a MS-compatible silver stain (less sensitive than sypro ruby) resulting in an 
enhancement (Figure 3-9).  One concentrated spot in the center appeared near  
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Figure 3-9:  Silver stained 2D gel of purified crosslinked LexA-Gal4 Phe849pBpa mutant 
purified from 12L of yeast.  Red boxes indicate spots cut from gel for MS-MS analysis. 
 
the MW of full-length Gal4 Phe849pBpa protein.  From this 2D gel four spots 
were cut out at the facility and analyzed by MS-MS.  They were not able to 
identify proteins in any of the samples tested.   
 To further define the technical hurdles, a second sample was prepared for 
submission to the facility.   The goal of this experiment was to simply detect the 
full-length Gal4 Phe849pBpa.  If the technique was not sensitive enough to 
detect the most abundant protein in the protein mixture then it could never be 
used to detect lower abundant crosslinked proteins.  This time 6L of yeast 
expressing Gal4 Phe849pBpa were irradiated, purified and run on a 1D gel.  Only 
the full-length Gal4 Phe849pBpa (not crosslinked protein) was excised from the 
gel for MS/MS analysis. From this experiment the facility was able to identify our 
protein in the sample but only 5 tryptic peptides were identified, certainly a 
concern.   
 The lack of promising data obtained at the Michigan Proteome Consortium 
precipitated the search outside the University of Michigan for facilities that have a 
more high throughput, sensitive technique.  Samples were analyzed at Michigan 
State University and the Rockefeller University; however, little additional signal 




Proteomics at Scripps Research Institute was established where samples are 
analyze by MudPIT as described above. Samples from 6-12L yeast cultures were 
prepared using a modified protocol from above where the major change being 
the inversion of the order of the affinity purification columns (Figure 3-10).  Here 
the sample was first exposed to Ni NTA resin and then to FLAG beads.  Using 
this purification strategy samples were prepared and send for analysis.  
 
Figure 3-10:  Method for preparing a crosslinked LexA-Gal4 Phe849pBpa sample for 
MudPIT analysis. 
 
D.  Multidimensional Protein Identification Technology (MudPIT) for 
identifying protein partners of Gal4 
 The first sample prepared for submission to the Center for Physiological 
Proteomics for MudPIT analysis was crosslinked Gal4 Phe849pBpa.  To assess 
the MudPIT method for detecting our proteins, the yeast were grown in glucose 
so as to capture the Gal4-Gal80 interaction.  A 12L yeast culture expressing Gal4 
Phe849pBpa was irradiated, purified and ~1/3 of the purified protein sample was 
run on a 1D gel and silver stained with silver stain that is not MS compatible 
because past experiments showed this stain give the best visualization of the 
proteins.  On the same gel another ~1/3 of the samples was run and not stained.  
The unstained gel was superimposed on the silver-stained gel to guide excision.  
If LexA-Gal4 Phe849pBpa and a target protein are both identified in an excised 
gel slice at the correct molecular weight corresponding to a crosslinked product 
between the two them this will strength the evidence that they are direct protein 
partners.   The remaining 1/3 of the solution sample that was not run on the gel 
was also submitted. A disadvantage of cutting bands from a gel is that there is 














However, one disadvantage surrounding the solution sample is that it is not 
known if the proteins identified would be present at the correct molecular weight 
corresponding to a crosslinked product with LexA-Gal4 if run on a gel; therefore 
further verification of proteins identified is required to confirm that it is a direct 
target.  
One complicating aspect of analyzing the results from these experiments 
is that it is difficult to identify peptide sequences with the program used that are 
composed of a part of LexA-Gal4 Phe849pBpa, pBpa and part of the crosslinked 
protein target.  It is challenging because the program used, SEQUEST, does not 
recognize a mass corresponding pBpa; even if it was incorporated into the 
program, the peptide fragment would contain parts of two different proteins 
complicating the database search. We are working the proteomic facility at 
Scripps to incorporate these aspects into the analysis but, thus far they have not 
been able to do it in a straightforward manner.   
 Results from this from the initial study (Figure 3-11) showed that in the  
solution sample, Gal80 was observed and with significant sequence coverage 
(54.0%).  Additionally, 45 unique peptides with 168 peptides total of LexA-Gal4 
Phe849pBpa were identified generating 60.4% sequence coverage, a 
considerable improvement from the previous method used (only 5 unique 
peptides identified). Of the other proteins identified, those involved in translational 
processes made-up  ~17% of the all proteins in the irradiated sample.  This could 
be from pBpa crosslinking occurring as the protein is being translated or because 
these proteins are high abundance proteins that happen to interact with Gal4 




     
Figure 3-11: Number of unique and total peptides identified for Gal4 Phe849pBpa and Gal80 
with and without UV using MudPIT. 
 
Next, a control experiment of 6L yeast expressing Gal4 Phe849pBpa in 
glucose without irradiation was carried out to investigate whether or not protein 
binding partners such as Gal80 would be absent.  Not surprising, this was the 
case (Figure 3-11).  Additionally, another irradiated control experiment was done 
where only the tRNA/synthetase plasmid was present in the yeast and no Gal4 
Phe849pBpa expression plasmid.  This experiment was used for detecting the 
nonspecific/low binding proteins that are artifacts of the purification process 
independent from the Gal4 Phe849pBpa protein.  From this data about ~62% 
fewer proteins were identified in this sample than in the Gal4 Phe849pBpa 
sample that was not irradiated.  Indicating that little nonspecific/low affinity 
proteins were pulled through the process and ones that were can be used to 
understand the experimental data when LexA-Gal4 Phe849pBpa was present. 
 
E.  Using Multidimensional protein identification technology for identifying 
targets beyond Gal80 
 Using MudPIT, Gal4 and Gal80 were observed in crosslinked samples, 





























protein partner of Gal4 in vivo.  Towards capturing protein targets of Gal4 when 
transcription is occurring crosslinking experments were carried out in the 
presence of galactose and prepared for MudPIT analysis.  Two samples, both of 
Gal4 Phe849pBpa where one was irradiated (12L) and other was (6L) not were 
prepared and submitted to the MS facility.  Figure 3-12 and Table 3-4 outlines the 
transcription proteins identified that were present only in the sample that was 
irradiated.  None of them were identified in the sample that was not irradiated.   
 The nine proteins identified are components of six different complexes that 
are recruited to the DNA during transcription and two of the proteins are not in 











Table 3-4:  Proteins identified by MuDPIT of crosslinked LexA-Gal4 Phe849pBpa in the 
presence of galactose. 
 
Some of the proteins found were not surprising such as Tra1, a component of 
SAGA, a complex with histone acetyltransferase function.  Through various 
strategies, discussed in Chapter 1, this complex has been thought of a front 
runner in the search for direct binding partners.38,39 Likewise, Swi1 a component 
of the SWI/SNF complex that remodels chromatin through their  
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Figure 3-12:  Potential targets of Gal4 and the amount of peptides identified from 
crosslinked Gal4 Phe849pBpa in the presence of galactose. 
 
ATPase capabilities has been suggested as partners of amphipathic activators 
before (Chapter 1).40,41 Both possess enzymatic activity, aiding in chromatin 
remodeling and are not members of the general transcriptional machinery.     
Another protein identified in this study was Mlp2, a component of the inner 
nuclear basket of the nuclear pore.42 A study found that Mlp2 (and Mlp1) interacts 
with SAGA, the complex mentioned above, and is thought to colocalize to DNA 
with Gal4 shown through ChIP.43 Interestingly they also found that Mlp2 (and 
Mlp1) interacts with the GAL upstream activating sequence (UAS) which is the 
region of the GAL gene that SAGA interacts.42 The MudPIT data further strengths 
these past studies of nuclear pore proteins being localized to the GAL UAS.  
Further mechanistic details of how a component of the nuclear pore could be 
localized to the GAL UAS region and crosslinked with Gal4 could be another area 
of research to explore in transcription regulation.  
Additionally, the proteins Ccr4 and Mot2 were identified.  They are part of 
the CCR4-NOT complex that participates in many transcription processes such 
as, contacting and regulating TFIID function, contacting SAGA and is thought to 
contribute to mRNA deadenylation.44 Due to the diverse functions of this 



















Number of peptides identified for potential 
targets of Gal4 using MudPIT!
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complex, involved in regulating transcription both positively and negatively, not all 
of the components are well characterized. 
Ctr9, a protein identified, is a member of the Paf complex which is a five 
subunit complex that is thought to associate with RNA polymerase II and aid in 
transcription elongation.45 Like the CCR4-NOT complex the Paf complex was not 
typically on the radar for interacting directly with Gal4.  Between these two 
protein complexes it appears that proteins with diverse functionality are being 
identified with this approach and ones that were not thought of as leading targets 
of Gal4 before. 
Ssl2, a component of TFIIH, is a DNA helicase that is involved in 
transcription initiation and nucleotide-excision repair was identified.46 Although it 
is involved in basic transcription perhaps it was specifically targeted to DNA as a 
result of the UV light that the cells were exposed during the crosslinking process.  
Considering the function of this protein if may be difficult study the role that this 
target has in Gal4 activated transcription under the crosslinking conditions used. 
Finally, two proteins that are not associated with a complex were identified 
Abf1 and Hrr25.  Abf1 is thought to carry out several functions including DNA 
replication, transcription activation and chromatin remodeling.47,48 Additionally, it 
is able to bind DNA in sequence specific manner and in fact can bind to its own 
promoter and repress transcription.47,48 Hrr25 is a protein kinase and is thought to 
have a role in the transcriptional processes in response from DNA damage.49 It is 
also is thought to interact with the C-terminal domain of RNA polymerase II and 
phosphorylate Swi6, a component of the Swi/Snf complex.49 Neither one of these 
proteins have historical evidence of interacting the Gal4 and would be a new 
finding once verified. 
 
E.1 Analyzing proteins identified in crosslinked samples 
 One of the challenging aspects of analyzing the mass spectrometric data 
was that many proteins, those related to transcriptional and those that were not, 
were identified in the experiments (see Appendix).  To determine which proteins 
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identified were relevant over other proteins an analysis of all of the proteins 
identified in all of the samples submitted for MudPIT analysis was applied (Table 
3-4 and Appendix).   
Sample Culture Size Sugar Source UV 
Gal4 Phe849pBpa 6L Glucose No 
Gal4 Phe849pBpa 6L Glucose Yes 
Gal4 Phe849pBpa 6L Galactose No 
Gal4 Phe849pBpa 6L Galactose Yes 
Gal4 Phe849pBpa 12L Galactose Yes 
Only tRNa/synthetase no Gal4 
Phe849pBpa present 
6L Glucose Yes 
Table 3-5:  Samples prepared for MudPIT analysis. 
Only proteins that were functionally related to transcription and only present in 
irradiated samples grown in either galactose or found in both galactose and 
glucose were deemed potential targets of Gal4.  Other proteins that were not 
related to transcription could interact with Gal4 and could potentially have 
unknown functions related to regulating Gal4 function in the cell however, 
because the goal was to identify direct protein targets that are functionally 
relevant to Gal4 activated transcription the above proteins were thought to be the 
most likely candidates. 
 
E.2  A limitation in the MudPIT analysis 
 One major limitation in the MudPIT analysis was that peptides that contain 
a portion of Gal4 covalently attached, through pBpa, to a portion of the target 
protein could not be detected with the SEQUEST software used to analyszed the 
peptide samples.  This would require the software to recognize two different 
proteins are present in one peptide and that the mass of the nonnatural amino 
acid pBpa to be understood as a potential mass that is possible in the sample 
mixture.  Due to the complexity of this it is was not possible for the Center for 
Physiological Proteomics to observe these peptides.  This identification would be 
definitive evidence of the proteins being direct targets of Gal4.  Until this type of 
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analysis is developed other methods, described in the next section must be used 
to verify proteins identified as direct targets of Gal4.        
 
E.3  Future MudPIT studies 
In summary, these results have strengthened the evidence that Gal4 has a 
multiprotein binding profile and that these proteins come from complexes with 
diverse functions. Further several of the proteins are novel potential targets of 
Gal4. When comparing the MS results with a Western blot of crosslinked 
samples of LexA-Gal4 with pBpa incorporated at various positions in the 
presence of galactose, many more protein bands were observed than the nine 
found with MudPIT (Figure 3-13).  Of particular interest is a band that is near the 
molecular weight  
 
 
Figure 3-13:  Crosslinking experiment with LexA-Gal4-FLAG with pBpa incorporated at 
different positions along Gal4 TAD.  LexA-Gal4 crosslinked to Med15 (~150 kDa) could 
possibly be bands in the red box. 
of Gal4 crosslinked to Med15, a protein of the mediator that has been thought to 
be a direct target (~150 kDa).38,39 Because of the presence of this band and the 
many other bands the next experiment planned is to scale-up the culture size to 
50L so that low abundance proteins that may have been missed in the first 
experiment could be identified. 
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 Overall, we were able to show that in vivo crosslinking with Gal4 coupled 
with MudPIT is a useful technique for identifying transcription proteins which have 
a history of being extremely difficult to study.  Additional experiments are planned 
to further verify and resolve the protein targets of Gal4.  Potential targets 
identified by the MS data will be verified through Western blotting and protein 
deletions in yeast.  Additionally, this method will be used to identify targets of 
other amphipathic activators, like GCN4 and this data will be compared to Gal4 to 
understand the shared and unique targets of each activator, information that will 
be useful for understanding fundamental transcriptional mechanistic questions.  
 
F.  Methods 
General peptide synthesis for FLAG peptide 
 Standard FMOC solid phase peptide synthesis was used to make the 
FLAG peptide DYKDDDDK.  The resin was purchase from Peptides international 
and all of the FMOC-protected amino acids were purchased from Peptides 
International or Chem Impex International.  HOBt and HBTU were purchased 
from CPC Scientific.  The synthesis was carried out on an Advanced 
ChemTech90 synthesizer using establish protocols. N-Methyl-2-pyrrolidone 
(NMP), Dimethylformamide (DMF), N,N-Diisopropylethylamine (DIEA), piperidine, 
pyridine, and acetic anhydride were purchase from Fisher Scientific and used 
without purifying.  The peptide was purified to homogenerity using reversed-
phase HPLC on a C18 column with a gradient solvent system (buffer A: 0.1% 
TFA, buffer B: CH3CN). 
Growing cultures for crosslinking experiments 
The protocol for growing the yeast and irradiating them is similar to the 
experiments in Chapter 2.  The modifications to the protocol are the following. 
LS41 yeast were transformed with a plasmid coding WT LexA-Gal4 or LexA-Gal4 
Phe849pBpa-FLAG-6X-His mutant plasmid and pSNRtRNA-pBpaRS.  A single 
colony is picked for inoculation of a 5mL starter culture of as described in 
Chapter 2.  Some of the starter culture is used to inoculate a 1L yeast cultures 
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which were grown in SC media lacking histidine, tryptophan and uracil and 
containing 2% glucose and 1mM pBpa (dissolved in 10mL of 1M NaOH) and 
10mL of 1M HCl.   Cultures were grown to an OD660 0.8.  Cultures were 
harvested by centrifugation for 15 minutes at 6000 rpm and at 4°C.  Samples that 
were going to be irradiated were resuspended in SC media lacking Histidine, 
Tryptophan and Uracil and containing 2% glucose and were placed under the UV 
lamp (Eurosolar 15 W UV lamp) for 1 hour with a cooling pack underneath the 
sample.  Following irradiation samples were pelleted by centrifugation at 4°C at 
4500 rpm for 5 minutes.  They were then washed once with 100mM PBS buffer 
and pelleted again in similar manner.  Cultures that were not irradiated were 
washed once with 100mM PBS buffer and pelleted.  All cultures were stored at    
-80°C until lysed.  
Sample lysis and purification for MudPIT  
Pelleted yeast cultures are removed from -80°C and thawed on ice or in a water 
bath on the bench top. ~2X EDTA-free protease inhibitor tablets (Roche) was 
added to the lysis buffer (100mM PBS, 150 mM NaCl, 10% glycerol, 0.5% NP-40, 
10mM B-me). Each pellet containing 3L of yeast culture is resuspended in 10mL 
of lysis buffer (adjust amount accordingly for different culture sizes).  1000 units 
of Zymolase 20T (US Biologicals) is dissolved in 1mL of lysis buffer and 0.5mL  
is added to each 3L resuspeded pellet (50mg/3L yeast pelleted culture or 
~15mg/1L).  Let suspension rotate slowly at 30°C for 30-45 minutes.  During this 
time glass beads and the 15mL or 50mL lysis bead beater chamber (Biospec  
Products) are pre-chilled in a freezer -80°C.  After incubating with Zymolase cool 
culture on ice for a few minutes.  Add yeast to lysis bead beater chamber and 
add glass beads to fill ~3/4 to top of meniscus.  Total time bead beater is turned 
on for lysis is 3 minutes with 15 seconds turned on with 2 minutes rest in 
between.  Decant yeast lysis bead slurry (add extra lysis buffer to make sure all 
beads are removed from chamber) into 50mL tubes and centrifuge at 4500rpm 
for 5 minutes at 4°C.  Decant lysate into a clean 50mL tube and pour the beads 
into 1.5mL microfuge tubes.  Poke a hole in the bottom of the 1.5mL tube with a 
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flamed sterile needle (19G) and place into new 1.5mL microfuge tube and 
centrifuge both tubes together at 5000rpm for 1 minute at 4°C.  Collect the 
supernatant in the lower tube and add it to the lysate already in the in the 50mL 
tube.  Centrifuge all of the lysate in the 50mL tube at 9000rpm for 5 minutes at 
4°C.  Decant the supernatant into a new 50mL tube and centrifuge again at 
9000rpm for 5 minutes at 4°C.  Repeat until there is virtually no pellet observed.  
Wash 300µL of Ni NTA beads (Sigma-Aldrich) 3 times in 100mM PBS buffer at 
3000rpm for 3 minutes at 4°C and add to lysate along with 10mM B-me.  Rotate 
and incubate with Ni NTA beads for 1 hour at 4°C.  After incubation centrifuge Ni 
NTA beads 3000rpm for 3 minutes at 4°C, remove the lysate and transfer Ni NTA 
beads to a 15mL tube.  Wash the Ni NTA beads 6 times in 5mL of wash buffer 
(100mM PBS, 350NaCl, 10% glycerol, 3M Guanidine-HCl, 30mM imidazole, 
1.0% tween-20, 10mM B-me) and 2 times in 5mL of 100mM PBS buffer 
centrifuging at 3000rpm for 3 minutes at 4°C each time and decanting buffer.  
Transfer Ni NTA beads to a 1.5mL microfuge tube and elute the protein in 500µL 
elution buffer (100mM PBS, 500mM imidazole, 0.5% tween-20) three times with 
10 minute incubations each time rotating at 4°C.  The 1.5mL eluant is then buffer 
exchanged in a centrifugal concentrator (Vivaspin 500) with a 10,000 molecular 
weight cut-off and a polyethersulfone membrane (PES) by first concentrating the 
eluant to ~50-100µL at 10,000 rpm at 4°C and then adding 500µL of 100mM PBS 
buffer and repeat two more times bringing the volume down to 100ul and adding 
500ul of 100mM PBS buffer diluting the imidazole for preparation for incubation 
with anti-FLAG M2 agarose beads (Sigma).  After the third time bringing the 
elution volume down to ~50-100ul bring the final sample volume up to 500ul with 
PBS.  Wash 200µl the anti-FLAG M2 agarose beads (Sigma) three times with 
100mM PBS in a 1.5mL microfuge tube at 3000 rpm for 3 minutes at 4°C.  Add 
the eluant to the FLAG beads and incubate at 4°C rotating for 2 hours.  After 
incubation centrifuge the FLAG beads at 3000rmp for 3 minutes at 4°C and 
remove the supernatant.  Wash FLAG beads in 1mL wash buffer (100mM PBS, 
350mM NaCl, 10% glycerol, 1.0% NP-40) ten times and two times in 100mM 
 82 
PBS centrifuging at 3000rpm for 3 minutes at 4°C.  Make a FLAG elution buffer 
consisting of a solution of 10mg/mL purified FLAG peptide (DYKDDDDK) in a 
buffer containing 500µl lysis buffer (see above) and 500ul 100mM PBS.  Elute 
the protein from the FLAG beads in ~300µl of FLAG elution buffer three times (2 
30 minute incubations at 4°C rotating and a final one overnight rotating and 
incubating at 4°C) and collecting the eluant each time after centrifuging at 3000 
rpm for 3 minutes at 4°C.  Upon collecting the final elution immediately begin 
concentrating the eluant in a centrifugal concentrator (Vivaspin 500) with a 
10,000 molecular weigh cut-off and PES membrane.  Buffer exchange the 
sample into a MS compatible buffer by bringing the volume down to ~50-100µl 
and adding 500µl of the exchange buffer (50mM Ammonium Acetate or 50mM 
PBS) three times.  The final volume of the sample is  ~30ul.  Flash freeze the 
sample and place in the freezer (-20°C) until shipping on dry ice.    
Lysis buffers and Wash buffers use for optimization 
1L yeast cultures samples were thawed and resuspended in one of the following 
lysis buffers containing EDTA free protease inhibitor (Roche).  Lysis buffer I:  
100mM PBS pH 7.0, 0.01% NP-40, 10% glycerol, 10mM imidazole, 10mM B-me 
Lysis buffer II: 100mM PBS pH 7.0, 150 mM NaCl, 10mM imidazole, 10% 
glycerol, 0.5% tween-20, 10mM B-me Lysis buffer III:  100mM PBS, 350 mM 
NaCl, 20mM imidazole, 10% glycerol, 1.0% tween-20, 10mM B-me, 1M 
Guanidine-HCl.  Cells were lysed by a incubation with Zymolase enzyme 
followed by glass beads for 30 minutes, 10 minute pause followed by another 15 
minute vortex.  Following an incubation with Ni NTA (Sigma) beads the beads 
were washed 6 times with one of the following wash buffers. Wash buffer I:  
100mM PBS pH 7.0, 0.1% tween-20, 10% glycerol, 10 mM B-me, 4M Guanidine-
HCl, 20 mM imidazole.  Wash buffer II:  100 mM PBS pH 7.0, 150mM NaCl, 
10mM B-me, 1.0% tween-20, 4M Guanidine-HCl, 30mM imidazole, 10% glycerol.  
Wash buffer III:  100mM PBS pH 7.0, 350 mM NaCl, 10mM B-me, 1.0% tween-
20, 5M Guanidine-HCl, 50mM imidazole, 10% glycerol.  Proteins were eluted 
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form the Ni NTA resin in 100mM PBS buffer containing 500mM imidazole and 
0.5% tween-20, separated on a 1D gel and stained with Sypro ruby. 
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A comparative analysis of photoactivatable crosslinking moieties  
 
A.  Project Focus 
 Protein-protein interactions (PPIs) are essential for carrying out and 
maintaining cellular processes.1-3 Alteration of PPIs changes the signaling events 
and the biological processes they are regulating, making them major contributors 
to the initiation and persistance of diseases like cancer.2,4 As a result, there has 
been enormous effort exerted by the chemical, biological and medical 
communities aimed at identifying and characterizing PPIs that play a role in 
disease processes with the longer-term goal of discovering new therapeutic 
targets.3 As outlined in the previous chapters, PPIs that regulate transcription 
initiation comprise one such class and thus have been our focus of study.  
Photocrosslinking has long been an important tool to capture and 
characterize PPIs in vitro and in their native context and the ability to genetically 
incorporate two unnatural amino acids with photoactivatable functionality, p-
benzoyl-L-phenylalanine (pBpa) and p-azido-L-phenylalanine (pAzpa) has further 
enhanced its utility.5-7 8,9  However, little attention has been paid to the inherent 
reactivities and selectivities of these unnatural amino acids in spite of the 
profound influence these characteristics will likely have on experimental 
outcome.10 Here I compare the known reaction pathways for pBpa and pAzpa to 
predict the utility of these photocrosslinkers in studying PPIs in terms of their 
likely amino acid preferences.  In addition, I analyze these preferences in the 
context of the known potential for the most preferred amino acids to reside at the 
surface/interface of proteins.  These preferences are illustrated in a direct 
comparison of pBpa and pAzpa crosslinking in vivo.  pBpa and pAzpa 
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crosslinking is compared at the Gal4-Gal80 interface and shows that placing the 
crosslinker at different positions results in unique crosslinking profiles.  
Additionally,  placing a different crosslinker in the same position in Gal4 forms 
crosslinks to Gal80 when pAzpa is present and is attenuated for pBpa.  This 
information will be particularly useful for designing future experiments in 
capturing the direct protein targets of TADs and is a general consideration for 
studying PPIs with crosslinkers in vivo.  
 
B.  Background   
B.1  Photocrosslinking with transcriptional activators 
 Photo-crosslinking to study the targets of transcriptional activators has 
been used by many groups in an in vitro context.  Most commonly, the strategy 
employs an aryl azide as the crosslinking moiety.7-9 One crosslinking strategy 
that has been used by the Hahn research group involves attaching N-((2-
pyridyldithio) ethyl)-4-azidosalicylamide (125I-PEAS) through a disulfide linkage to 
cysteines (Figure 4-1).4,8,9   Once attached to a protein and UV light is applied,  
  
 
Figure 4-1:  Scheme of crosslinking with 125I-PEAS.   
 
crosslinks are formed with neighboring biomolecules.  After crosslinking, a 
reducing agent is added, reducing the disulfide bond, releasing the crosslinked 
products and leaving the targets isotopically labeled for further analysis.  Hahn 
and coworkers applied this crosslinking method to identify the targets of both 
Gal4 and GCN4 in vitro.  Both TADs used in their study do not naturally contain 





















TAD.  Only one cysteine was mutated at a time so the labeling was site-specific.  
The labeled proteins were localized on DNA in vitro in the presence of purified 
preinition complex (PICs). This was a significant study that resulted in the 
identifcation of multiple direct targets of each activator (Gal11, Tra1, Taf12) in 
PIC); however, there are limitations to the PEAS crosslinking strategy .8,9   One is 
that the crosslinking moiety on 125I-PEAS is 14 Å from the α carbon of the 
cysteine to which it is attached when fully extended.  This means that it is 
possible that crosslinks to proteins that are not making direct contact with the 
TAD it is attached could be occuring.11 Another downfall of this crosslinking 
strategy is that it is not performed in a cellular context but in the presence of a 
much simpler environment, purified PICs. Further, as discussed later in this 
Chapter, the chemical reactivity of the phenyl azide moiety may not be optimal for 
capturing a full complement of binding partners. 
 Also using a related aryl azide crosslinking moiety, Sulfo-SBED, Workman 
and coworkers carried out photo-crosslinking label transfer assays to identify 
direct targets of GCN4 (Figure 4-2).7  Sulfo-SBED is a crosslinking moiety that is 
conjugated to proteins through the lysines on the TAD and contains a 
photoreactive aryl azide, a disulfide bond and a biotin label.  Upon UV irradiation 
crosslinks are formed via the aryl azide, DTT is added to disrupt the disulfide 
bond thereby removing the activator and leaving the biotin handle on the target. 
This is then used for Western blotting with a streptavidin antibody for detection of 
crosslinked targets (Figure 4-2).  Using this method they performed in vitro 
crosslinking experiments between GCN4 and purified Swi/Snf complex.  From 
these experiments they report that several components of this complex are 
targets of GCN4 (Swi1, Snf5, Swi2/Snf2).7 Like 125I-PEAS crosslinking method, 
Sulfo-SBED has some disadvantages.  One aspect is that Sulfo-SBED labeling is 
not site-specific which means that all nine of the lysines in the GCN4 TAD can be  
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Figure 4-2:  Sulfo-SBED crosslinking strategy.  Left, organization of aryl azide conjugated to 
Biotin (for Western blot analysis) and sulfo-NHS (conjugates to lysine) through a disulfide 
bond.  Right, photo-crosslinking label transfer scheme with a transcriptional activator and the 
Swi/Snf complex.7  Reproduced with permission. 
 
labeled.  Multiple modifications could have the problem of affecting the 
interactions and function of Gcn4.  Further because they used full-length GCN4, 
all of the lysines throughout the protein were potentially labeled. In this instance, 
it is difficult to know which portion of the protein was contributing to the 
crosslinking.7.   
 In summary, previous methods used to identify targets of transcriptional 
activators using aryl azide crosslinking have been carried out in vitro and a 
number of activator binding partners have been identified. However, the 
conclusions that can be drawn are limited due to the positioning and reactivity of 
the crossllinking moiety employed.  The in vivo crosslinking strategy discussed in 
Chapter 2 has clear advantages over those previously used in that the 
crosslinker is incorporated site specifically and, further, the crosslinking reactions 
are carried out in the cellular setting. In addition, as discussed in the subsequent 
section, the reactivity of the photocrosslinking moiety can have a profound affect 
on the suite of binding partners identified through crosslinking experiments. 
 
lysines within the GST portion of the fusion protein was lead-
ing to the biotin-labeled products, we performed the experi-
ment with GST alone and found that it does not significantly
cross-link to any SWI/SNF subunits (Fig. 2D). The GST-Hap4
is biotin labeled (doublet at ca. 80 kDa) upon irradiation with
UV light due to the dimerization of the GST portion of this
fusion protein (Fig. 2C, compare lanes 1 and 2 to lanes 3 and
4). This background precluded the detection of possible acti-
vator targets in this region of the gel.
To determine whether a different yeast acidic activator con-
tacts the same subunits within SWI/SNF or has unique subunit
targets, we conjugated full-length Gcn4 with the lysine-specific
cross-linking reagent. Gcn4 contains nine lysines within its
acidic activation domain. We found that Snf5, Swi1, and Swi2/
Snf2 were biotin labeled when UV cross-linked with conju-
gated Gcn4 (Fig. 3A, lane 4), which is the same result that we
found with GST-Hap4. Again, the photo-cross-linked products
were dependent on UV exposure (Fig. 3A, compare lanes 2
and 4) and the presence of the SWI/SNF complex (Fig. 3A,
compare lanes 3 and 4). Gcn4 contains a leucine zipper domain
that allows dimerization, leading to the background biotin la-
beling of Gcn4 itself. The membranes were stripped and im-
FIG. 2. Interaction of Snf5, Swi1, and Swi2/Snf2 in the context of intact SWI/SNF with Hap4. (A) Diagram of the photo-cross-linking reagent
Sulfo-SBED. (B) Schematic of the photo-cross-linking experiments. Photo-cross-linking experiments were performed with purified SWI/SNF
complex and an activator that was previously conjugated with Sulfo-SBED. Where indicated, the reaction mixtures were exposed to UV light (312
nm) at 6 cm for 8 min at room temper ture. The activator was separated from interacting SWI/SNF ubunits upon the addition of DTT, which
reduces the disulfide bond. (C) Snf5, Swi1, and Swi2/Snf2 are cross-linked by GST-Hap4. The photo-cross-linking reaction mixtures were run on
an SDS–4 to 15% gradient polyacrylamide gel. The proteins were transferred to PVDF membrane and immunoblotted with streptavidin-HRP or
the indicated SWI/SNF-specific antibodies. The asterisks indicate photo-cross-linked SWI/SNF subunits. (D) SWI/SNF subunits are not cross-
linked by GST alone. The photo-cross-linking experiment was performed as described for panels B and C.
1618 NEELY ET AL. MOL. CELL. BIOL.
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B.2  p-benzoyl-L-phenylalanine and p-azido-L-phenylalanine reactive 
mechanisms and amino acid preferences  
 Two photoactivatible nonnatural amino acids have been successfully 
incorporated into proteins in vivo (S. cerevisiae), pBpa and pAzpa, using 
nonsense suppression technology.12 In Chapter 2, I showed that pBpa can be 
incorporated into positions along the Gal4 TAD and that in vivo crosslinking was 
feasible.  Here I will discuss the reactive mechanisms of both pBpa and pAzpa 
and with what amino acids they prefer to react, information that effects the 




Figure 4-3:  pAzpa and pBpa reactive mechanisms for crosslinking.  A.  pAzpa mechanism.  
B. pBpa mechanism.4,10,13   
 
 B.2.a p-benzoyl-L-phenylalanine 
 pBpa forms a diradical upon UV irradiation at 350-365 nm where it then is 
able to insert into C-H bonds found in protein backbones and amino acid side 
chains (Figure 4-3).   In the absence of any orientational preferences it reacts 
with the following carbons in decreasing order NCHx > -SCHx > methine > 
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where it will react at distances beyond the 3.1 Å reactive radius.15 This is should 
be considered when analyzing data as the selectivity of Met in pBpa crosslinking 
may reduce the precision of crosslinking direct targets.  In an early study by 
DeGrado and coworkers using pBpa crosslinking with biomolecules two model α-
helical peptides were synthesized containing pBpa at two different positions 
(Figure 4-4).16 In the presence of calmodulin both peptides preferentially labeled  
                              
Figure 4-4:  Ball and stick model of Calmodulin (left) and the 17 residue α-helical peptide 
(right).  Met-144 and Met-71 that become crosslinked with the peptide are labeled in the 
picture with filled dots and the filled dots on the peptide indicate where pBpa was placed in 
the experiments.  Only one pBpa at a time was present in each peptide tested.16 Reproduced 
with permission. 
 
two different methionines located in the hydrophobic cavity on calmondulin 
showing the selectivity of pBpa for methionine.16 It is also important to consider 
the geometric requirements of pBpa for efficient crosslinking.  Even in the 
presence of amino acids that are preferred by pBpa, crosslinking may not occur 
due to geometric constraints as it was determined that the ideal angle of pBpa 
diradical attack is 108.9º and the attack occurs almost in-plane (Figure 4-5).14 
One advantage of pBpa crosslinking is that the diradical can be maintained up to 
120 µs where it either inserts into a C-H bond or relaxes back down to the initial 
state where it can be excited again aiding in the crosslinking efficiency.10 For 
example, if a protein-protein interaction is not captured during the first excitation 
due to distance or improper geometries from protein conformation perhaps during 
a second excitation the protein-protein interaction would be captured.   
14576 Photolabeling of Calrnodulin 
and in  high  yield with proteins. The amino acid is extremely 
stable to the conditions of peptide synthesis and can be 
incorporated into peptides using either Boc or  Fmoc proted- 
ing schemes. The atomic positions on a protein most  likely to 
react with the  triplet  state of the Bpa  residue  may  be inferred 
from the mechanism of insertion (Scheme I), which  involves 
hydrogen abstraction in  the  first  and  rate limiting step (21). 
Particularly reactive C-H bonds include tertiary  centers (e.g. 
the CY-H bond of leucine or the CB-H bond of valine) and 
bonds adjacent to heteroatoms (C"-H bonds, or bonds adja-. 
cent to  the thioether of methionine). In  the case of methionine 
it is possible that  the reaction may  occur through the inter- 
mediacy of a radical anion/cation pair (21) involving the 
thioether, which  may account for the high reactivity of Met- 
71 and Met-144. In addition, computer-aided model building 
illustrates a large increase in solvent accessibility for 4 me- 
thionines in each of the hydrophobic patches upon calcium 
binding to calmodulin (32). Since the model peptides bind 
calmodulin in a calcium-dependent manner (Le. when these 
methionine residues are exposed) this may account for the 
observation that in these experiments only methionine resi- 
dues are labeled. The specificity of labeling of Met-71 and 
Met-144 is illustrated, however,  by the observation that  the 
methionine residues immediately adjacent to 71 and 144 ( i e .  
72 and 145) are  not labeled at all. Recently, the Bpa residue 
has also been used to label CAMP-dependent protein kinase 
(26). A peptide inhibitor of the enzyme incorporating this 
amino acid  was found to photolabel a glycine and a methionine 
residue,  previously  localized to this enzyme's active site. In 
this work as well as  that reported here, the precise atomic 
positions of attachment were not determined. Our observation 
that digestion of the radiolabeled photoadducts gives multiple 
separable radioactive peptides with identical amino acid se- 
quences and mass spectra would indicate that there are mul- 
tiple atomic positions of attachment and/or that multiple 
stereoisomers are formed. 
The crystal structure of calmodulin (33, 34) shows two, 
homologous domains connected by a long, central helix  (Fig. 
6). The C-terminal domain contains an exceedingly hydro- 
phobic cavity large enough to accommodate the Bpa or other 
bulky, hydrophobic residue (Fig. 7). Consistent with this 
structure when the Bpa residue occupied the  third position of 
the mod lpeptide or MLC kinase peptide, the sole residue on 
calmodulin that was  modified  was Met-144 which is located 
in this cavity. This might acc unt for the fact that the 
4 
FIG. 6. Ball and stick diagram of calmodulin. For comparison, 
a 17-residue helical peptide is shown next to  the calmodulin structure. 
Only Ca carbons are shown, and  the residues photolabeled (residues 
71 and 144 of calmodulin, 3 and 13 of the peptide) are indicated as 
filled circles. The calmodulin structure  is redrawn from Ref. 35. 
FIG. 7. Computer graphics illustration of the region sur- 
rounding Met-144. Calmodulin coordinates are from the 2.2 A 
structure described by Babu and co-workers (42). The molecular 
surface illustrated here was generated using the Connolly algorithm 
(43) and has been color-coded as follows: hydrophobic residues green, 
acidic residues red, basic residues blue, neutral polar residues and 
glycine white. The tryptophan residue docked in  the hydrophic cleft 
has been colored yellow. Met-144 is located at  the bottom right of the 
figure with its side chain extending up into  the hydrophic pocket in 
the C-terminal domain. 
substitution of a tryptophan at  the  third position of our model 
peptide results in a 10-fold increase in its affinity for calmod- 
ulin. A tryptophan residue often occupies a homologous  po- 
sition in  natural peptides such as  the MLC kinase peptide 
described here (Table I, Ref. 2). 
The Bpa-13 peptide labels Met-71 and Met-144 in about a 
1O:l ratio, indicating that  it has two  possible binding orien- 
tations although the orientation placing the Bpa residue to- 
ward the N-terminal lobe is substantially preferred. Met-71 
is homologous to Met-144 in the amino acid sequence of 
calmodulin (31) and is a part of a hydrophobic cavity similar 
to  that of the C-terminal domain although the cavity appears 
to be less well defiied  than on the C-terminal domain. As 
noted earlier, both Met-71 and Met-144 have been predicted 
to experience a large increase in  their solvent accessibilities 
when apo-calmodulin binds four Ca2+ ions (32), consistent 
with our observation that these peptides bind to and specifi- 
cally label calmodulin only in the presence of excess Ca2+ 
(20) .2 
As illustrated in Fig.  6, the primary sites of insertion for 
the Bpa-3 and Bpa-13 peptides are about 30 A distant in 
space (C"-C"), although the two photoprotes  are separated 
by  only about three helical turns (about 15 A) in  the calmod- 
ulin-binding peptide. Even if the peptide were bound in a 
totally extended conformation, it does not appear to be steri- 
cally reasonable to bridge the two sites because of unfavorable 




Figure 4-5:  Geometric constraints for pBpa hydrogen abstraction for C-H insertion.14 
Reproduced with permission. 
 
B.2.b. p-azido-L-phenylalanine 
 The amino acid preference for pAzpa crosslinking is less clear because of 
its more complex crosslinking mechanism compared to pBpa (Figure 4-3, Table 
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1. nitrene inserts into the 
aryl C-H (also other C-H 
containing sidechains) 
 
2. N-H insertion possible 
with the rearranged 
product and nitrene 
 
 
3.  O-H insertion possible 
with the rearranged 
product and nitrene 
 
4. S-H insertion possible 
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      Table 4-1:  Amino acid reactivity preference of pBpa and pAzpa crosslinking. 
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cyclisation of BzBz-esters 
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proximity in the transition state, and only minimal motion is 
required to fulfill the stereoelectronic requirements for bond 
format ion. 
Flexibility and Proximity as Factors in Photoprobe Design. 
Intramolecular BP photochemistry with long fl xible chai s 
provides multiple sites for attack (Winnik, 1981). On the 
basis of modeling and experimental data, the r active volume 
of the BP moiety was approximated as a sphere with a radius 
of 3.1 A centered on the ketone oxygen (Scheme 2), and the 
overall process is controlled by rotational accessibility. 
Intermolecular reactions are very slow, are completely dif- 
fusion-controlled, and lack regioselection. However, in model 
reactions that employ hydrogen bonds or ion pairs as organizing 
forces, selective attack was observed. For example, when 
symmetrical BP-3,3’-dicarboxylic acid or a related positively 
charged BP derivative (Scheme 2) was photolyzed in the 
presence of a long-chain dicarboxylic acid (Breslow, 1980), 
the H-abstraction occurred from the internal methylenes of 
thediacid substrate. The incorporation of two binding points 
into the long-chain substrate restricted its motion relative to 
the photochemical BP probe, just as ligands show reduced 
conformational mobility when bound to an enzyme or a 
receptor active site. In the excited state, the BP ring system 
is required to be nearly planar, imparting significant rigidity. 
This rigid system can be extended with rigid linkers to 
reposition the photophore and thereby alter the efficiency and 
site of the resulting attachment. For biochemical studies, the 
section of linker size and orientation is crucial, since the 
primary goal is to label the binding site for the ligand while 
minimizing nonspecific modifications. Typically, the BP 
photophore in biochemical probes would be coupled to active 
ligands via linkers bearing either moderately flexible (1-3 
CH2 units, 0, NH) or moderately rigid ( C 4 ,  COO) 
functionalities. In conclusion, BP photochemistry in bio- 
chemical systems is most regioselective when the flexibility 
is limited to only that which is necessary to achieve efficient 
H-a bst ract ion. 
Regioelectronic Control: The Role of Fine- Tuning. The 
factors controlling BP photoreactivity impart macroscopic 
recombination ph\C/Ph -4 
I‘ f O.” 
geometric control; the geometry of the attack imparts the 
microscopic geometric control, with preferred angles of attack 
providing the fine-tuning. Regiochemical and stereoelectronic 
control results from the preferred molecular orbital geometry 
of the photochemically excited triplet. The conformation of 
the n l r *  triplet state is close to planarity; the half-filled 
n-orbital es in this ideal pl ne, while the #-orbital is 
perpendicular to it (Scheme 2). 
Ab initio calculations determined an idealized transition- 
state model, in which the C@H angle of the biradical 
attack was found to be 108.9O, the O-H-CCH bonds were 
almost collinear, and the attack occurred in-plane (Severance 
et al., 1987). Although the observed values deviate slightly 
from that model (Wagner et al., 1994), they still represent a 
significant geometric control. Radical recombination may 
then serve to impart a second stereoelectronic control, since 
the recombination requires the porbitals to be collinear for 
maximum overlap. Finally, the radicals can approach from 
either face, giving either a racemic or diastereomeric mixture 
in a chiral environment. 
Reactivity and Substituent Effects. Apart from the 
geometric factors, the reactivity and the efficiency of covalent 
attachment strongly depend on the chemical and electronic 
environment of the photophore and the H-donor moiety (Turro, 
1978). The strength of the bond being broken in the H-donor 
and the relative stabilities of the resulting alkyl radicals are 
the major determining factors. In general, the homolytic 
cleavage of C-H bonds, induced by the triplet biradical, is 
favored over the 0-H bonds. In the case of N-H bonds, the 
electrophilic excited state abstracts an electron first, and this 
event is followed by the H-abstraction from the adjacent C-H 
group, as described earlier (Scheme 1). 
In biological systems, the most effective H-donors include 
backbone C-H bonds in amino acids, polypeptides, and 
carbo ydrates. Methylene groups of lipids and amino acid 
side chains also provide abstractable hydrogens. In the absence 
of any orientational preference, the reactivity order for C-H 
bonds is >NCH, > -SCH, > methine > C=CCH2 > -CH2- 
> -CH3. Particularly reactive sites include the electron- 
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inserts into both C-H or heteroatom-H bonds.10 If however, insertion does not 
occur during the ~10-4 excitation (determined for simple nitrenes in a polystyrene 
matrix) it will rearrange to a more stable ketenimine.10,18 Once rearranged it 
reactions with nucleophiles.10   To determine which occurs more frequently 
crosslinks with the nitrene for C-H or heteroatom-H bond insertion or by the 
ketenimine with nucleophiles Brunner and Richards designed an experiment to 
answer this question.19-22   In their study they used a synthetic phospholipid 
bilayer with phenyl azide attached to the fatty acyl chain with the polypeptide 
antibiotic gramicidin A present.20 The peptide has an established orientation in 
the membrane with the residues Gly, Ala, Leu and Val in the center of the bilayer 
where the aryl azide is located and the residues Leu and Trp near the lipid polar 
heads.19,21 From the photo-crosslinking reaction they observed mostly crosslinks 
with Trp, the only residue with a nucleophilic side chain in gramicidin.20 This 
experiment suggests that the majority of aryl azide crosslinking takes place 
between the more stable ketenimine and nucleophilic side chains in biological 
molecules.  One disadvantage of pAzpa as a crosslinker is that because it reacts 
with nucleophiles, water commonly reacts with the ketenimine intermediate, 
decreasing the crosslinking efficiency.  Another disadvantage of pAzpa compared 
to pBpa is the unlike pBpa, that can relax back its initial state after excitation 
state and be excited again, pAzpa has one chance for reactivity at the excited 
state before it rearranges.  Also, because a lower wavelength may be required 
for crosslinking with pAzpa (~254 nm for no substitutions on the phenyl ring as 
substitutions have been shown to increase the wavelength used for excitation) 
than pBpa (~365 nm) more damage to biomolecules can occur.10,23 Overall, pBpa 
appears to have more advantages over pAzpa in terms of potential efficiency and 





B.3 Frequency of preferred amino acids for p-benzoyl-L-phenylalanine and 
p-azido-L-phenylalanine crosslinking at protein interfaces 
 In an effort to understand the role of individual amino acid residues in 
PPIs, much effort has been focused on characterizing the protein-protein 
interface by size and shape, complementarity between surfaces, residue 
propensities, hydrophobicity, hydrogen bonding and electrostatic interactions.24 
Of the many factors affecting two proteins interacting one is particularly important 
when considering the use of, pBpa or pAzpa for photo-crosslinking, the 
propensity of residues found at the interface of PPIs.25,26 To exemplify this Ofran 
and coworkers performed a comprehensive study on residue composition at six 
different types of protein-protein interfaces.26 They included 1812 proteins in their 
study and found that there is a significant difference between each of the protein-
protein interfaces that they looked at (Figure 4-6).  Here they compared residues  
         
Figure 4-6:  Frequency of amino acids at six different interfaces.  The SWISS-PROT 
database was used as background.  If a residue is found more frequently at the interface 
than its frequency in SWISS-PROT this is represented by a positive bar.  If a residue is found 
less frequently this is represented by a negative bar.  Equal representation at interface and 
database results in a zero bar.26 Reproduced with permission. 
 
found at interfaces to the overall amino acid composition of all proteins in SWISS-
PROT, a database of protein sequences, as background.26 In this way if an 
(Table 2: note that all values on the diagonal are
substantially higher than the off-diagonal counts).
In terms of the most coarse-grained separation,
the sequence compositions differed most strongly
between internal and external interfaces (Table 1S
in Supplementary Material). The least-distinct
types were (a) domain–domain interfaces that
overlapped with intra-domain interfaces and (b)
hetero-obligomers that resembled domain–domain
interfaces remarkably often (off-diagonal elements
in Table 2). The former was not surprising, since
domain–domain interfaces are formed between
residues on the same chain, and thus are likely to
be similar to intra-domain contacts. On the other
hand, we can view domain–domain interfaces as
permanent interactions between independently
folded units. Therefore, we may expect them to be
similar to hetero-obligomers, which by definition,
associate independently folded chains. Transient
interfaces between identical chains (homo-
complexes) constituted the seemingly most distinct
interface type. The fact that our method could
distinguish automatically between the interfaces
of different chains of the same protein (hetero-
obligomers) and different chains of different
proteins (hetero-complexes) indicated strongly
that the success of our data-mining approach in
distinguishing complexes from obligomers was
not restricted to the expert-curated data sets.
All interfaces differed in residue composition
from background and surface
We used the residue compositions of all proteins
in SWISS-PROT as the background to compare the
compositions between the six interface types. We
found that the composition of all interface types
differed substantially from the composition of
SWISS-PROT (Figure 1; Table 2S in Supplementary
Material shows that this difference was highly sig-
nificant). Nonetheless, our results showed why
some studies report a strong correlation between
the propensities of residues in internal and external
interactions.7,8 Most residues show similar trends
in internal contacts and many other types of inter-
faces (Figure 1(b)). Indeed, we observed very
strong correlations (equation (3)) between the
amino acid residue distributions in all interface
types (r .0.8 in all pairwise comparisons) except
for homo-complexes. Furthermore, all interface
types were highly correlated to the distribution of
amino acid residues in SWISS-PROT (r .0.8).
Nevertheless, the find-self procedure indicated
substantial differences between these distributions,
suggesting that the correlation coefficients were
not sensitive enough for this comparison. All inter-
faces differed significantly from exposed residues
(Table 3). Interestingly, about 1.3% of all the
internal residues were found not to be in any non-
trivial contact by our definition of contact. Most of
these were at the ends of chains. When we added
these “free” residues as a separate class, we found
that they again differed significantly from all other
classes.
Similarities and differences in and to the
literature for composition
Some studies report substantial differences
between internal and external interfaces,22 while
others report a high level of similarity.8 Xu et al.
conclude from the differences they found that
internal contacts are facilitated by other than
external mechanisms.22 The substantial differences
Figure 1. Amino acid composition of six interface types. The propensities of all residues found in SWISS-PROTwere
used as background. If the frequency of an amino acid is similar to its frequency in SWISS-PROT, the height of the bar
is close to zero. Over-representation results in a positive bar, and under-representation results in a negative bar. The
amino cid residues are identified by their one-letter code, orted by biophysical featu es.
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amino acid is found more frequently at an interface than in the database as a 
whole then this results in that amino acid having a high propensity for being in 
that interface.  Using the hetero-complex data to assess the amino acid 
propensities found in the type of protein-protein interfaces of transcription 
proteins the following amino acids are found more frequently at the interface than 
compared to all residues found in SWISS-PROT Trp>Tyr>Arg>Phe,His>Gln>Met.  
The rest of the amino acids were either equal to or less than all residues found in 
SWISS-PROT.26 Using this information and what is known about pBpa and 
pAzpa photo-crosslinking we can analyze the utility of each crosslinker in protein-
protein interfaces for capturing transcription proteins.  Based on this, pBpa 
crosslinking in hetero-complex interfaces should not be limited by the absence of 
preferred amino acids for bond formation since methionine is one of the most 
frequently found amino acids at the interface.  When relating the residue 
preference of pAzpa to those with the highest propensity in the protein-protein 
interface (discussed above) it is clear that in the context of hetero-complexes 
photo-crosslinking through the more likely ketenimine is possible.  The most 
frequently found residue at these interfaces, Trp, posesses a nucleophillic side 
chain. 
  Overall, both pBpa and pAzpa are useful for probing protein-protein 
interfaces and capturing interactions whether known or yet to be discovered.  For 
crosslinking transcription proteins, based on the propensity of amino acids found 
in hetero-complexes, there is evidence that both pBpa and pAzpa have the 
necessary amino acids present at the protein-protein interface for crosslinking to 
occur.  If a protein-protein interaction is known then having a clear understanding 
of the amino acids present at the interface can be useful for selection and 
placement of a photo-crosslinker.  If the protein binding partners are not known 
the best way to probe these systems is by electing to use both crosslinkers as 
one may capture an interaction that the other may not due to the amino acid 




C. Amino acid propensity within transcription proteins 
 By looking at the residues involved in a well characterized PPI between a 
transcriptional activator and a known protein partner and by understanding the 
residue propensity of amino acids, preferred for pBpa or pAzpa crosslinking, in 
proposed targets of the amphipathic class of TADs (Chapter 1) one could predict 
if these interactions could be captured through photo-crosslinking.  The residues 
involved in the well-characterized interaction of the transactivation domain of the 
p53 tumor suppressor and its transcriptional repressor MDM2 are (Phe19, Trp23, 
Leu26 and Met50, Leu54, Leu57, Gly58, Ile61, Met62, Tyr67, His73, Val75, 
Phe91, Val93, His96, Ile99, and Tyr100 respectively (Figure 4-7).27 Based on this 
information an experiment designed with pBpa as a crosslinking moiety placed 
on p53 would be predicted to result in efficient crosslinking as two methionines 
are located at the interface. Conversely, when designing a similar experiment 
with pAzpa as the crosslinker perhaps incorporating in into the MDM2 protein 
would more likely result in crosslinked products as tryptophan is buried in the 
MDM2 cleft.27 This is just one example of utilizing what is known about 
crosslinking moieties and residues found at the interface of a TAD and its direct 
protein partner.  This same rational can be applied to study other PPIs involved in 
other biological processes.  
 
Figure 4-7:  Structure of p53 peptide with MDM2.  Residues at the interface are labeled p53 
(yellow) and MDM2 (blue).27 Reproduced with permission. 
Overall structure of the MDM2-p53 
complex. The MDM2 NH2-terminal do- 
main forms a structure reminiscent of a 
twisted trough, having a cleft lined with 
hydrophobic amino acids (Fig. 2). The cleft 
is composed of two helices forming the 
sides, two shorter helices that make up the 
bottom, and a pair of three-stranded 1 
sheets that cap each end (Fig. 2A). The p53 
peptide forms an amphipathic ox helix of 
about 2.5 turns (Fig. 2), which is followed 
by an extended region of three residues. 
The primary contacts from p53 are made by 
its ox helix, which binds the MDM2 cleft 
with its hydrophobic face and buries all but 
one of its five hydrophobic amino acids at 
the interface. 
The key to the interface is a triad of 
hydrophobic and aromatic amino acids of 
p53-Phe19, Trp23, and Leu26-which in- 
serts deep into the MDM2 cleft (Fig. 2C). 
These amino acids are invariant across spe- 
cies (24). The interface relies extensively 
on van der Waals contacts and the steric 
complementarity between the MDM2 cleft 
and the hydrophobic face of the p53 helix 
as these interactions are augmented by only 
two ntermolecular hydrogen bonds. 
The structure, in conjunction with bio- 
chemical studies, reveals the mechanism of 
p53 inhibition by MDM2. Mutagenesis 
studies have impli ated several hydropho- 
bic amino acids on the amphipathic helix of 
p53 in transactivation (24), probably be- 
cause of their binding to the TATA box- 
binding pr tein-associated factors (TAFs) 
(30). MDM2 makes extensive contacts to 
these hydrophobic p 3 residues, shielding 
them from the solvent and preventing their 
access to the TAFs. 
Structure of MDM2. The MDM2 do- 
main contains a structural repetition. It has 
two portions, 45 and 38 amino acids long, 
with similar structures (residues 26 to 70 
and 71 to 108) that are related by an ap- 
proximate dyed axis of symmetry (Figs. 2A 
and 3). The sequence similarity of the two 
halves is low (11 percent identity), except 
Fig. 3. The MDM2 NH2-ter- 
minal domain contains two C 04 a2' 95 
structurally similar portions 
related by an approximate 108 13' 106 I 2 89 02' 
dyad axis of pseudosymme- 
try. In this topological dia- 26 P1 30-- c\al 77 1' 
gram of the secondary struc- \ \ \ \81 
ture elements of MDM2, the N 9 48 6 3 68v 
residues at the start and the 
end of each secondary 50 65) 
structure element are indi- 
cated. The structural ele- 
ments of the second repeat are distinguished from those of the first repeat by the 'prime' symbol. 
Fig. 4. The p53 peptide (in yellow) forms an amphipathic helix whose hydro- 
phobic face binds the MDM2 cleft (in blue). The cleft is formed by the ca2 helix, 
on one side, and the middle p sheet, on the other side, and is lined with 
hydrophobic and aromatic amino acids (or both). (A) The helical p53 amino 
acids show and emphasize the amphipathic nature of the a helix, where blue 
and red spheres indicate nitrogen and oxygen atoms, respectively, and the 
carbon atoms are in yellow. View is looking down the helix axis, as in Fig. 2C. 
for a general conservation of hydrophobic 
residues. The repeat structure consists s - 
quentially of a 1 strand, an ot helix, a 1 
strand, a longer ot helix, and a 1 strand (Fig. 
3). The two helices of the repeat, which 
pack at an angle of -70°, and the first two 
1 strands, which form a 1 sheet, come 
tog ther to form a small globular structure 
with a hydrophobic core. 
One side of this globular repeat structure 
is hydrophobic, and the two repeats come 
together and pack across their hydrophobic 
sides forming a cleft at their interface (Fig. 
2). Their short helices (al and aol') pack in 
an antiparallel fashion to form the bottom 
of the cleft, their long helices (or2 and a2') 
form the sides of the cleft, and their 1 
strands form two 1 sheets at opposite ends 
of the cleft that cap the ends (Figs. 2 and 3). 
One 13 sheet contains the NH2- and 
COOH-termini of the polypeptide, and we 
refer to it as the terminal 13 sheet to distin- 
guish it from the 1 sheet that occurs in the 
middle of the polypeptide (middle 13 sheet). 
The cleft is about 25 A long, 10 A wide 
near the surface but narrowing toward the 
bottom, and up to 10 A deep. The cleft has 
two layers of hydrophobic amino acids. One 
layer forms a hydrophobic core that seals 
the bottom of the cleft and an additional 
layer forms the hydrophobic lining of the 
cleft. 
Although the two repeats have similar 
tertiary structures, the MDM2 cleft is asym- 
metric. One portion, which corresponds to 
about three-quarters of the length of the 
cleft and is the site where the p53 o helix 
makes its primary contacts, resembles a 
For simplicity, only the p53 amino acids are labeled, although the MDM2 amino 
acids at the interface are also shown. The backbone regions of p53 and MDM2 
are colored in a darker tone, and the two intermolecular hydrogen bonds at the 
interface are shown as red dotted lines. (B) The interface in an orientation 
rotated 90° about the vertical axis of (A). The MDM2 ao2 helix is below the plane 
of the figure, its p sheet is above the plane, and p53 is between the two. Only 
the interacting amino acids at the interface are shown, and they are labeled. 





 An examination of the amino acid propensity in proteins that have been 
suggested as targets of amphipathic TADs, discussed in Chapter 1, can be 
useful for determining the probability of crosslinking success.  To this end, I have 
carried out an amino acid analysis on 10 proteins, 9 of which have been 
suggested as potential targets of amphipathic TADs and one is a known partner 
of Gal4, Gal80.  I looked at the overall propensity of four residues in these 
proteins Met, Trp, His and Leu (Table 4-2).  Met abundance was studied because 
it is the residue that is preferred for pBpa crosslinking.  Trp and His were chosen 
because of their nucleophilicity, preferred for pAzpa, and because they are 
amongst the residues thought to be most prevalent at hetero-complex protein 
interfaces (discussed above).  Experimentally, Leu is a residue that is not 
typically thought of as being one of the highest reactive amino acids with either 
pBpa or pAzpa so it was used as a comparison.  What was observed from this 
study was that Met, Trp and His were all considerably less abundant that the less 
reactive Leu.  Met was more abundant that Trp and His and in the 10 proteins 
studied there were ~2.5 times more Mets than Trps. Based on this information, it 
could be concluded that photo-crosslinking with pBpa would result in more 
protein crosslinks because there are more Mets. Because the amino acids that 
are more reactive are not the found in excess throughout the protein indicates 
that during irradiation the reactions are not occurring because there is an over 
abundant amount of the highly reactive residues but that they are capturing a 









Transcription proteins/potential targets of TADs from other 
studies 
 % Met*  %Trp %His %Leu 
Med15 3.05 0.46 1.2 6.38 
Swi1 1.29 0.38 0.99 10.65 
Snf2 2.41 0.65 2.17 9.57 
Taf12 1.67 0.74 0.93 6.31 
Tra1 2.4 1.1 2.22 13.09 
Snf5 1.55 0.55 1.99 7.85 
GCN5 3.42 0.68 2.05 7.06 
TFB1 2.8 0.47 2.18 9.5 
ADA2 2.07 0.92 2.76 8.99 
GAL80 2.3 0.69 2.3 9.2 
Average 2.296 0.664 1.879 8.86 
Standard 
Deviation 0.676694581 0.219959592 0.618105529 2.083165327 
*includes 
n-terminal 
Met     
     
Arbitrary 
Proteins     
HSP82 1.83 0.71 0.56 9.31 
COQ5 3.26 0.98 1.95 7.82 
mps2 0.52 1.29 1.29 8.79 
bud1 2.21 0.37 0.74 7.72 
Average 1.955 0.8375 1.135 8.41 
Standard 
Deviation 1.13179798 0.391524797 0.625806147 0.666820816 




MudPIT     
CCR4 2.62 1.19 3.11 10.99 
mlp2 1.61 0.42 1.07 11.26 
mot2 1.36 0.34 3.58 6.64 
ssl2 2.85 0.71 2.37 7.59 
abf1 1.5 0.27 5.34 6.29 
ctr9 1.86 0.93 2.14 12.44 
hrr25 2.63 0.81 2.83 9.51 
Average 2.061428571 0.667142857 2.92 9.245714286 
Standard 
Deviation 0.620307144 0.339249873 1.333516654 2.43723106 
Table 4-2:  Percent Met, Trp, His and Leu in transcription proteins, arbitrary proteins and 
potential targets of Gal4 identified by MudPIT. 
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 Next, I looked at the protein composition of the potential protein targets of 
Gal4 that were identified by MudPIT in Chapter 3 (Table 4-2).  Like the analysis 
of the proteins described above Met, Trp and His were less abundant than Leu.  
What was different in these proteins was that there was more His than Met.  With 
this information pAzpa may be a better crosslinker for capturing these 
interactions.  Finally, because in vivo crosslinking is useful for studying proteins 
beyond transcription I also looked at the composition of unrelated arbitrary yeast 
proteins spanning a heat shock protein to a mitochondrial protein for 
understanding the utility of this technique for studying other biological processes.  
Of this small collection of proteins I found a similar trend as with the transcription 
proteins where Met, Trp and His represented significantly less than Leu and that 
there are more Met than His and Trp.  Overall, it appears that pBpa would be the 
more efficient crosslinker for capturing PPIs base on the amino acid composition; 
however pAzpa should not be dismissed as there are some interactions that may 
be missed by dismissing this crosslinker. 
 
D.  In vivo crosslinking with p-benzoyl-L-phenylalanine and p-azido-L-
phenylalanine at the Gal4-Gal80 interface 
 The Gal4-Gal80 interaction has been well characterized through structural 
studies, protein mutagenesis and by in vivo crosslinking.28-30 In Chapter 2 the 
interaction was further characterized by showing an extending binding surface 
demonstrated by a crosslinked product corresponding to the correct MW of Gal4-
Gal80.30 One observation from this experiment was that crosslinking efficiency 
varied at the Gal4-Gal80 crosslinked product when pBpa was incorporated at 
different positions along the Gal4 TAD even at positions important for maintaining 
the Gal4-Gal80 interaction.29 It was hypothesized that by incorporating pAzpa 
into the positions on Gal4 that produced little crosslinking with Gal80 the 
interaction could be captured.   
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 Shown in Figure 4-8, crosslinking at 10 positions produces varying 
amounts of crosslinked Gal4-Gal80.  Particularly perplexing is that although Gal4 
(851-871) has been shown to comprise the Gal80 binding site residue Phe856  
       
Figure 4-8:  In vivo photo-crosslinking with pBpa incorporated at 10 positions along the Gal4 
TAD.  The red box highlights the a crosslinked band corresponding to the molecular weight 
of Gal4-Gal80.30   
 
within this region produced little crosslinking to Gal80 and residues outside of this 
region crosslinked better with Gal80 than Phe856.29,30 Interestingly, this residue 
has been shown to be critical for maintaining Gal4-Gal80 interaction because 
mutating Phe856 to cysteine resulted in a disruption in the interaction.29 The lack 
of crosslinking was not due to a disruption in the Gal4-Gal80 interaction from 
pBpa being incorporated into Phe856 as transcription remained repressed in the 
presence of glucose, an indicator of Gal80 maintaining contact with Gal4 by 
repressing transcription.30 Further, the lack of crosslinking at this position is not 
due to reduced pBpa incorporation at this site as it was show in Chapter 2 that 
incorporation efficiency at this site was equal to or more than other residues that 
crosslinked more efficientaly with Gal80 (Figure 4-8 compare Phe856 to 
Phe869). Thoden et. al. solved the structure of Kluyveromyces lactis (K. lactis) 
Gal4-Gal80 co-crystallized where the Gal4 peptide of K. lactis is thought to mimic 
the structure of S. cerevisiae Gal4.28 They used a 22 residue K. lactis Gal4 TAD 
peptide that has ~68% sequence homology with Gal4 from S. Cereviseae (Figure 
4-9).  Fortunately, Phe856 (S. cerevisiae residue numbering) is shared between 
the two organisms.  From the co-crystalized complex they report that Phe856 lies  














                                        
Figure 4-9:  Structure of Gal4 peptide in complex with Gal80.  Red and yellow highlights the 
Gal4 peptide (yellow are residues used in this study except 867) and gray represents Gal80 
both from K. lactis.  The residue numbering is from S. cerevisiae. PDB ID 3EIK.28 
Reproduced with permission. 
 
in a hydrophobic patch consisting of two valines and it is suggested that there 
Phe856 participates in a stacking interactions with the side chain of a histidine.28 
Considering the side chain preference for pBpa crosslinking those particularly 
reactive residues, like methionine, are not present.  Another reason that pBpa 
crosslinking does not occur at this site could be due to unfavorable geometries 
for C-H insertion between those present.   
 We hypothesized that pAzpa could be incorporated at positions along the 
Gal4 TAD to probe the Gal4-Gal80 interaction and perhaps produce crosslinking 
of Gal4-Gal80 where pBpa could not.  To this end four residues on Gal4 TAD 
were chosen for comparison with pBpa crosslinking at similar incorporation sites 
and crosslinking conditions (Phe849, Phe856, Thr859, Met861).  Phe849 was 
one of mutants that formed the most amount of pBpa crosslinks with Gal80.  To 
test a site with the most amount of crosslinks with a different crosslinker would 
show the difference in crosslinking efficiency between two crosslinkers at a site 
already known to be permissive to a point mutation.  When pBpa was 
incorporated into Phe856 low crosslinking efficiency was observed.  pAzpa may 
capture this interaction when incorporated into Phe856 especially since it is 
nearby a histidine.  There are two ways the pAzpa may form crosslinking with 
Gal80 at this position through either the excited nitrene, that inserts into C-H and 
heteratom-H bonds or the more stable ketenimine may insert into the nucleophilic 
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Given the central role of protein-protein interactions in biologi-
cal functions, the development of methods for the discovery and
characterization of such interactions has been of paramount
importance in the scientific community.1 Ideally these methods are
compatible with live-cell studies so that protein-protein interactions
can be investigated in their native context. Toward that end, recent
advances in nonsense suppression technology have enabled the site-
specific incorporation of amino acids bearing moieties for photo-
activatable cross-linking reactions into proteins in bacteria, yeast,
and human cells.2 However, there have been few applications of
this technology in eukaryotes, perhaps due to challenges in obtaining
efficient incorporation of the nonnatural amino acids as well a
limited knowledge about the impact of these changes on structure
and function.3 Here we demonstrate an enhanced tRNA/synthetase
system for efficient incorporation in vivo (S. cereVisiae) of the
photoactivatable amino acid p-benzoyl-L-phenylalanine (pBpa)
throughout the transcriptional activation domain of the prototypical
eukaryotic transcriptional activator Gal4. The pBpa-containing
proteins maintain the key functions of Gal4, suggesting that this
nonnatural amino acid has minimal impact on a critical binding
surface within the protein. In vivo cross-linking with these mutants
captured a key binding partner of Gal4, Gal80, and defi ed he
binding interface of this complex beyond that predicted by
conventional approaches. More broadly, this strategy should be
suitable for the characterization and discovery of transcription factor
binding partners in the native cellular environment.
The multipartner binding profile and intrinsically disordered
nature of the transcriptional activation domains (TADs) of amphi-
pathic activators produce significant roadblocks in studies of the
function and structure of these essential proteins.4,5 The most well-
studied member of this family, Gal4, is a yeast transcriptional
activator that regulates the GAL genes, whose products are required
for galactose catabolism.6,7 As a result, Gal4 is highly sensitive to
the nutrient environment, such that only under galactose growth
conditions does it function as an activator. The environmental
sensitivity of Gal4 is largely regulated via a strong (nanomolar KD)
interaction between the repressor Gal80 and a portion of the
carboxy-terminal transcriptional activation domain of Gal4.7-9
Conventional mutagenesis and structural studies suggest t at the
middle region of the transcriptional activation domain (amino acids
851-871) comprises the binding site for Gal80, yet the Gal4•Gal80
complex impacts the function of the entire activation domain
(840-881) (Figure 1).9-11 We hypothesized that in vivo cross-
linking would provide molecular-level detail regarding this impor-
tant regulatory interaction. In addition to the interaction with Gal80,
the Gal4 TAD engages in a set of interactions with coactivators in
the transcriptional machinery to stimulate transcription under
restrictive growth conditions (galactose).5,8-14 Thus, the impact
of pBpa mutations on the binding modes and function of Gal4 can
be assessed by xamining transcriptional ctivity under restrictive
and permissive growth conditions.
As has been detailed previously, the nonsense suppression
strategy ty ically utilizes the amber stop codon to encode the
nonnatural amino acid.2,15,16 Thus, to investigate the effect of
p-benzoyl-L-phenylalanine incorporation on the binding and function
of the Gal4 TAD, 10 individual Gal4 mutants were created in which
amber stop c dons (TAG) replaced the natural codons at specified
positions within this sequence; in addition to the sequence encoding
the mutant Gal4 TAD, each plasmid bears the sequence for the
LexA DNA binding domain (Figure 2a). Six of the positions within
Gal4(840-881) (W840, Y846, F849, F856, Y867, F869) are
hydrophobic aromatic residues at which replacement with pBpa
might be expected to have minimal impact. In contrast to this were
positions T852, T859, and D871, all of which are polar residues.
These plasmids were introduced into S. cereVisiae along with a
plasmid encoding a mutant E. coli tRNA/synthetase pair (tRNATyr-
CUA/TyrRS) for pBpa as previously reported.16 However, very low
yields of full-length protein were observed by Western blot analysis,
likely due to low expression levels of the mature tRNA (Figure
2b). To address this, a yeast polIII promoter (SNR52) was inserted
upstream of the E. coli tRNATyrCUA which enables the efficient
expression of functional E. coli tRNATyrCUA in yeast.17 We first
examined the Phe849pBpa mutant and observed that expression
increased from undetectable to >20% of unmodified LexA+
Gal4(840-881) (Figure 2b and c). Significantly, read-through in the
absence of pBpa was minimal, consistent with previous reports.16
Next, we examined the functional impact of incorporating pBpa
into LexA+Gal4(840-881) using quantitative !-galactosidase
assays. Truncation of protein synthesis at residue 849 would result
in a protein with little transcriptional activity;12 thus activity
† Department of Chemistry, University of Michigan.
‡ Program in Chemical Biology, University of Michigan.
§ Department of Medicinal Chemistry, University of Michigan.
| The Salk Institute.
Figure 1. (a) Structure of a short region of the Gal4 TAD (red and gold)
bound to the inhibitor protein Gal80 (gray). Fou of the ami o acids replaced
with pBpa in this study are highlighted in gold. Labels correspond to S.
cereVisiae numbering. PDB ID 3E1K.11 (b) Structure of p-benzoyl-L-
phenylalanine (pBpa).
Published on Web 09/18/2009
10.1021/ja904378z CCC: $40.75 ! 2009 American Chemical Society14240 9 J. AM. CHEM. SOC. 2009, 131, 14240–14242
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side chain.  Thr859 was chosen because it is the closest residue mutated in the 
initial pBpa study to Phe856 to study the changes in crosslinking in nearby 
position.  Met861 was chosen because the structural information suggests that it 
participates in intramolecular stacking with Tyr865 (Gal4 TAD S. Cerevisiae 
residue numbering) which would suggest that crosslinking to Gal80 could be 
reduced at this position due to this intramolecular interaction although pBpa was 
able to form crosslinks at this position.28 At these four residues on Gal4 pAzpa 
was incorporated and photo-crosslinked in vivo (Figure 4-10).  Incorporation was 
possible at all residues tested with little read-through.  An exciting result was that 
pAzpa crosslinking at position Phe856 produced a band corresponding to the 
MW of Gal4-Gal80 crosslinked product.  Additionally, of the four residues that 
were irradiated position 856 produced the most prominent crosslinked band at 
that MW, the opposite of what was observed with pBpa crosslinking at the same 
positions.  Interestingly, Phe849, the position with the most crosslinking to Gal80 
by pBpa was exceedingly reduced in pAzpa crosslinking at the same position.  It 
is not certain but the reduced crosslinking to Gal80 at position Met861 could be a 
result of pAzpa crosslinking at this position to the Tyr865 due to its nucleophilic 
character.  
 














                    
Figure 4-10:  Incorporation and in vivo photo-crosslinking with pAzpa in Gal4.  Top panel, 
pAzpa is incorporated into F849, F856, T859, M861. Bottom panel, photo-crosslinking  
results in varying abundance of crosslinked Gal4-Gal80 corresponding to 80 kDa molecular 
weight (red box) a different band patterns.  Position F856 is shows more crosslinked product 
with pAzpa than pBpa crosslinking at the same position. 
 
 In conclusion, pAzpa was able to capture a Gal4-Gal80 interaction that 
pBpa was not (at Phe856) when placed under similar conditions. Additionally, 
crosslinking at position Phe849 to Gal80 was significantly less than what is 
observed with pBpa crosslinking.  This is also true for Thr859 and Met861.  
































































































Gal80 interaction at more of the positions tested than pAzpa.  Further, an 
experimental observation is that pAzpa incorporation is lower and that the 
crosslinking appears less efficient overall in the system studied than pBpa.  
When testing for incorporated pAzpa ~0.5 more OD is collected and a 25% larger 
sample is loaded onto the gel in order to observe incorporated protein.  It is not 
clear if the reduction in crosslinking is from lower yields in pAzpa incorporated 
protein.  It was observed that a more sensitive substrate was needed for 
developing the Western blots for observing crosslinked product, an indicator of 
low protein abundance.  In summary, careful thought should be placed into 
experimental design for crosslinking in biological systems from the type of 
crosslinking moiety to the position of the selected moiety.  If for example pBpa 
was only placed at Phe856 little crosslinking would be observed with Gal80.  The 
best way to capture biomolecular interactions is by placing the crosslinker at 
various positions.  In this way, one can study the binding surface in terms of 
residues interacting directly with the protein.  Incorporating a crosslinker at 
different positions may capture proteins that are interacting with only a small 
portion of that protein and it could be missed if a few residues are used in the 
study.  Additionally, a thorough study would incorporate more than one 
crosslinking moiety for capturing interactions missed by the other moiety. 
 
E. Methods 
LS41 [JPY9::pZZ41, Matα his3Δ200 leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 gal4 
URA::pZZ41] yeast was used for all experiments. pAzpa was purchased from 
Bachem.  
 
Table of Plasmids used in this study 
 
Plasmid name Function 
pLexAGal4 Expresses LexA(1-202)+Gal4(840-
881)+FLAG tag 
pLexAGal4 849TAG, pLexAGal4 856TAG, 
pLexAGal4 859TAG, pLexAGal4 861TAG 
Express LexA(1-202)+Gal4(840-
881)+FLAG tag with a TAG 
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replacing the codon of the existing 
amino acid 
pSNRtRNA-pAzpaRS  Expresses tRNA under the control 
of the SNR52 promoter and 
contains synthetase specific for 
pAzpa 
 
Incorporation of pAzpa into LexA(1-202)+Gal4(840-881)  
LS41 yeast were transformed with various pLexAGal4 TAG mutant plasmids and 
pSNRtRNA-pAzpaRS. Individual colonies were grown in 5 mL SC media 
containing 2% glucose but lacking uracil, histidine and tryptophan for selection. 
The cultures were incubated overnight at 30°C and agitated at 250 rpm. 
Following incubation, these cultures were used to inoculate 5 mL cultures of SC 
media containing 2% glucose, with or without 2 mM pAzpa (dissolved in 50 μL of 
1M NaOH), and 50 mL 1M HCl which were subsequently incubated overnight at 
30°C with agitation to an OD660 of 0.8-1.2. 3 ODs of cells were isolated, washed 
with 100mM PBS water, flash freezed and stored at -80 °C. The samples were 
lysed in 10 µL 4x NuPAGE LDS Sample buffer (Invitrogen), 15 µL Lysis Buffer 
(50 mM Tris-Acetate, pH 7.9, 150 mM KOAc, 20% glycerol, 0.2% Tween-20, 2 
mM b-mercaptoethanol, 2 mM MgOAc) 5 µL 1M DTT and analyzed using 
Western blot with the anti-FLAG(M2) antibody (Sigma). 
In vivo cross-linking 
To perform in vivo cross-linking, individual colonies of each pLexAGal4 TAG 
mutant were grown in 5 mL SC media containing 2% glucose but lacking uracil, 
histidine and tryptophan for selection. The cultures were incubated overnight at 
30 °C and agitated at 250 rpm. Following incubation, these cultures were used to 
inoculate 50 mL cultures of SC media containing 2% glucose, with 2 mM pAzpa 
(dissolved in 0.5 mL of 1M NaOH), and 0.5 mL 1M HCl, which were subsequently 
incubated overnight at 30 °C with agitation to an OD660 of 0.8-1.0. For each 
mutant, 50 ODs of cells were isolated, washed with sterile 100mM PBS and 
either resuspended in 2 mL of SC media containing 2% glucose but lacking 
uracil, histidine and tryptophan and irradiated for 1 h with 365 nm light (Eurosolar 
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15 W UV lamp) with cooling or immediately flash freezed and stored at -80 °C. 
Following irradiation, all the cells were pelleted and stored at -80 °C until lysis. 
For lysis, cells were resuspended in 600 mL Lysis buffer (50 mM Hepes-KOH pH 
7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 
2X Complete Mini, EDTA Free Protease Inhibitor (Roche) and lysed using glass 
beads by vortexing at 4 °C. Subsequently, the lysate was pelleted and the 
supernatant incubated with 10 µL of LexA antibody (N-19, Santa Cruz 
Biotechnologies) for 2 h at 4 °C for immunoprecipitation. The protein bound to the 
antibody was isolated by incubation for 1 h with ~40 mL of prewashed protein G 
magneticbeads (Dynal Corporation, Invitrogen, Carlsbad, CA) at 4 oC. The beads 
were washed 3X with 1 mL Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 
0.5% NP-40, 1% Na-Deoxycholate and 1 mM EDTA) and stored dry at -20 oC. 
The protein was eluted from the beads by heating at 95 oC for 10 min in NuPAGE 
LDS Sample buffer  (Invitrogen, Carlsbad, CA) containing DTT and probed using 
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 This body of work has demonstrated the development and implementation 
of in vivo photo-crosslinking for studying PPIs between a transcriptional activator 
Gal4 and its known target Gal80. Additionally, the initial mass spectrometry 
experiments identified potentially new targets.  With additional experimentation 
this technique could be used to map the entire network of PPIs that take place 
during transcription.  Another interesting aspect of crosslinking revealed was the 
idea of incorporating different crosslinking moieties, pBpa or pAzpa, into similar 
protein sites for understanding the potential binding site at the interface of two 
proteins.   Overall these techniques are generally useful for not only identifying 
unknown partners of Gal4 TAD but for studying and identifying PPIs involved in 
other biological processes.  Outlined here are future ongoing areas of research 
using photo-crosslinking to study PPIs in cellular environments.    
 
A.  In vivo crosslinking in a histone deacetylase, Rpd3 
 Histone deacetylases (HDACs) are primarily responsible for removing the 
acetyl group from lysine side chains that has been placed on by histone 
acetyltransferases (HATs) found in histone proteins.1 Histones in the octomeric 
form are called nucleosomes which DNA wraps around and is further compact 
into chromatin.  Removing the acetyl group on lysines of histones generates a 
positive charge that allows it to interact with the negatively charged phosphate 
backbone of DNA thereby increasing the histone-DNA interaction and making it 
more difficult for chromatin to be relaxed, an action associated with activated 
transcription.2 A balance between aceteylation and decetylation of histone lysines 
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is thought to be important for regulating gene expression.3   Because 
dysregulation is associated with diseases such as cancer inhibitors of HDACs 
have been developed.3 In fact the HDAC inhibitor, suberoylanilide hydroxamic 
acid (SAHA), has been approved for the treatment of cutaneous T cell 
lymphoma.4 Although HDACs principally modify lysines on histones there are 
many other potential non-histone substrates of these proteins, such as NF-kB 
and androgen receptor, have been thought to have increased acetylation upon 
addition of HDAC inhibitors.5-7  
In collaboration with Noah Wolfson in the laboratory of Dr. Carol Fierke we 
will use in vivo photo-crosslinking for characterizing substrates of the yeast 
homologue, Rpd3, of mammalian Class I HDACs which are primarily localized in 
the nucleus.2 Once these substrates have been identified a more detailed look at 
the factors that affect substrate specificity (amino acid sequence, structural 
preference etc.) will be studied.   
 Rpd3 has been shown in vitro to deacetylated lysines found in H2A, H2B, 
H3 and H4 with the exception of K16.8 To identify other substrates of Rpd3 in 
vivo three sites were selected for pBpa incorporation (Figure 5-1) based on the 
structure characterize by Vannini et. al. of the mammalian homologue HDAC8 in 
complex with a substrate (a p53 derived diaceteylated peptide with a fluorogenic 
coumarin group at its carboxyl terminus or a hydroxamate inhibitor) and on 
homology maps base on that structure.9 HDAC8 shares 43% sequence identity 
and 65% sequence similarity to Rpd3 and is used for structural studies because 
unlike other HDACS HDAC8 is found functional as a singular protein instead of a 
multiprotein complex.1,9   Before applying in vivo crosslinking to this system first 
pBpa was shown to incorporate into Rpd3 with little read-through (Figure 5-1, top 
panel).  In a crosslinking experiment all positions with pBpa incorporated 
crosslinked products are observed.  It appears in this initial study that each 
position tested has a unique crosslinking product protein pattern which can be 
indicative of different protein targets captured at different positions.  The next 
step in this project is to incorporate pBpa into more sites along pRpd3 and to  
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Figure 5-1:  Incorporation and in vivo photo-crosslinking pBpa in Rpb3.  Top panel, pBpa is 
incorporated into three position in Rpd3. Bottom panel, crosslinking with pBpa incorporated 



























































carry out crosslinking in the presence of an HDAC inhibitor to eliminate 
crosslinked bands that are not actual substrates but are proteins in complex with 
Rpd3.  Another interesting set of crosslinking experiments can be designed to 
map the substrate binding site once they have been identified by placing pBpa at 
various distances from the substrate to see if crosslinking is still possible.  In this 
way an extensive binding site can be characterized for individual substrates.  The 
long term goal of this project is to use the yeast model for mapping the substrates 
of HDACs in human cells.       
 
B. Photo-crosslinking with transcriptional activation domains in 
mammalian cells 
 Characterizing the direct protein targets of the prototypical amphipathic 
transcriptional activator Gal4 in yeast is used as a model for understanding the 
protein interactions of other transcriptional activators of the same class in other 
cellular contexts.  To this end, a project in our laboratory (carried out by Conor 
Doss) aims at using the similar crosslinking approach carried out in yeast in 
mammalian cells for detecting protein partners of Gal4 TAD.  After optimizing the 
conditions required for incorporating a crosslinker into the well studied Gal4 TAD 
a mammalian transcriptional activator will be used for mapping the transcriptional 
proteins in a mammalian cells.  This information will be useful for understanding 
fundamental transcriptional mechanistic questions and for designing therapeutics 
that can inhibit the PPIs between a TAD and its direct protein targets that lead to 
aberrant gene expression in diseases like diabetes and cancer. 
 
C. Studying the amino acid preference with photo-crosslinkers 
 As discussed in Chapter 4 the amino acid preference for pBpa is known 
yet it is not clear what this means in terms of specificity for crosslinking with 
proteins.  In Gal4 TAD (840-881) there is one methionine (Met861), the preferred 
residue for pBpa crosslinking.10 At this residue we have incorporated pBpa and 
have shown that it crosslinks to Gal80 indicating that at this position the two 
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proteins are at an acceptable distance for pBpa crosslinking.  What has not been 
tested is the importance of methionine in pBpa crosslinking between Gal4-Gal80 
when pBpa is incorporated along Gal80.  To study this the lone methionine in 
Gal4 can be mutated to phenylalanine, the closest residue resembling pBpa of 
the natural amino acids, to ensure that the contact with Gal80 could still be made 
and the effect of methionine in pBpa crosslinking efficiency could be observed.  
Although this experiment would initially be carried out in a cell a more simplified 
in vitro experiment can be designed with peptides of Gal80 and Gal4 coupled 
with mass spectrometric analysis for quantifying the crosslinking efficiency.   
 
D. Additional experiments for verifying direct targets of Gal4 identified by 
mass spectrometry 
 Once all the potential targets have been identified with MudPIT further 
verification with additional methods will be applied since samples were submitted 
in solution to maximize proteins identified.  Another sensitive and quantitative MS 
method termed selected reaction monitoring (SRM) can be used to verify direct 
targets.  SRM is applied when a protein is known and therefore the focus of the 
MS-MS is on detecting the known peptide fragments.11 It is a more biased 
approach but is useful for focusing on verifying a protein that is known to be 
present in a sample.  To aid in identifying crosslinked peptides in the more 
focused SRM experiments isotopically labeled pBpa can also be used to aid in 
identifying crosslinked peptide fragments, one of the challenges with MS analysis 
since part of the sequence is from one protein and another in a different protein.  
Beyond MS methods for verifying protein targets, confirmation with Western blots 
can be straightforward if the protein has a commercially available antibody.  If 
this is not the case a yeast strain with an epitope tag associated with the protein 
of interest can be used integrated into the genome.  This allows for the natural 
expression level of the protein in the cell and easy probing of a Western blot with 
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Data from MudPIT analysis  
 
This appendix consists of all the MudPIT mass spectrometric data 
discussed in Chapter 3.  Table A-1 outlines the conditions for each sample 
prepared and Table A-2 shows the data (the proteins identified and the number 
of peptides in each experiment that were observed for each protein).  Those 
highlighted in yellow represent the proteins that were only present in crosslinked 
samples in and are related to transcription.  These are thought to be potential 
targets of Gal4. 
Sample Culture Size Sugar Source UV 
Gal4 Phe849pBpa 6L Glucose No 
Gal4 Phe849pBpa 6L Glucose Yes 
Gal4 Phe849pBpa 6L Galactose No 
Gal4 Phe849pBpa 6L Galactose Yes 
Gal4 Phe849pBpa 12L Galactose Yes 
Only tRNa/synthetase no Gal4 
Phe849pBpa present 
6L Glucose Yes 
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Glu no UV 
6L 
LEXAGAL4 - no description 255 108 168 88 0 131 
YAL003W - EFB1  0 0 0 34 0 0 
YAL005C - SSA1  10 8 4 94 0 3 
YAL012W - CYS3  0 0 0 6 0 0 
YAL016W - TPD3  0 0 0 3 0 0 
YAL021C - CCR4  0 12 0 0 0 0 
YAL038W - CDC19  2 18 10 48 0 11 
YAL042W - ERV46  0 5 0 2 0 0 
YAL044C - GCV3  0 0 0 10 0 0 
YAL060W - BDH1  17 13 0 8 0 0 
YAL061W - BDH2  0 6 0 0 0 0 
YBL002W - HTB2  0 0 0 10 0 0 
YBL003C - HTA2  0 0 0 4 0 0 
YBL005W-B - YBL005W-B  0 45 0 0 0 0 
YBL015W - ACH1  0 0 0 4 0 0 
YBL024W - NCL1  0 0 0 2 0 0 
YBL027W - RPL19B  3 4 0 11 0 0 
YBL030C - PET9  3 7 0 9 0 0 
YBL039C - URA7  0 2 0 0 0 0 
YBL045C - COR1  0 0 0 3 0 0 
YBL058W - SHP1  0 0 0 4 0 0 
YBL064C - PRX1  0 0 0 3 0 0 
YBL066C - SEF1  3 31 0 3 0 8 
YBL069W - AST1  0 3 0 0 0 0 
YBL072C - RPS8A  0 0 0 6 0 0 
YBL076C - ILS1  0 3 3 6 0 2 
YBL085W - BOI1  0 0 0 0 0 3 
YBL086C - YBL086C  2 0 0 0 0 0 
YBL087C - RPL23A  0 0 0 8 0 0 
YBL092W - RPL32  0 0 0 2 0 0 
YBL099W - ATP1  0 2 0 11 0 0 
YBR009C - HHF1  0 0 0 3 0 0 
YBR011C - IPP1  0 0 0 13 0 0 
YBR012W-B - YBR012W-B  87 45 49 0 0 26 
YBR025C - OLA1  0 2 0 3 0 0 
YBR031W - RPL4A  0 0 0 23 0 0 
YBR035C - PDX3  0 0 0 2 0 0 
YBR039W - ATP3  0 0 0 2 0 0 
YBR048W - RPS11B  0 0 0 5 0 0 
YBR072W - HSP26  0 0 0 9 0 0 
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YBR079C - RPG1  0 0 0 2 0 0 
YBR084C-A - RPL19A  3 4 0 11 0 0 
YBR092C - PHO3  0 0 0 4 0 0 
YBR106W - PHO88  0 0 0 3 0 0 
YBR109C - CMD1  0 0 0 6 0 0 
YBR118W - TEF2  91 29 20 107 4 11 
YBR121C - GRS1  0 0 0 3 0 0 
YBR126C - TPS1  0 4 0 0 0 0 
YBR127C - VMA2  0 0 0 21 0 0 
YBR129C - OPY1  32 72 16 34 12 66 
YBR135W - CKS1  9 17 5 2 4 8 
YBR149W - ARA1  0 0 0 7 0 0 
YBR181C - RPS6B  0 0 0 6 0 0 
YBR189W - RPS9B  0 0 0 4 0 0 
YBR191W - RPL21A  0 0 0 2 0 0 
YBR196C - PGI1  0 2 0 21 0 0 
YBR218C - PYC2  0 13 2 5 0 0 
YBR221C - PDB1  0 0 0 2 0 0 
YBR238C - YBR238C  52 24 35 15 3 57 
YBR248C - HIS7  0 0 0 2 0 0 
YBR249C - ARO4  0 2 0 7 0 0 
YBR255W - MTC4  13 9 7 5 0 4 
YBR263W - SHM1  0 3 0 3 0 0 
YBR275C - RIF1  2 2 0 0 0 0 
YBR286W - APE3  0 0 0 6 0 0 
YCL009C - ILV6  2 20 2 17 0 3 
YCL018W - LEU2  0 0 0 31 0 0 
YCL019W - YCL019W  0 15 0 0 0 0 
YCL030C - HIS4  0 0 0 15 0 0 
YCL035C - GRX1  0 0 0 4 0 0 
YCL037C - SRO9  167 163 29 139 46 196 
YCL039W - GID7  0 2 0 0 0 0 
YCL040W - GLK1  0 3 0 11 0 0 
YCL043C - PDI1  0 0 0 6 0 0 
YCR004C - YCP4  0 0 0 2 0 0 
YCR012W - PGK1  0 6 4 97 0 2 
YCR031C - RPS14A  0 0 0 7 0 0 
YCR053W - THR4  0 0 0 17 0 0 
YCR088W - ABP1  0 0 0 3 0 0 
YDL004W - ATP16  0 0 0 6 0 0 
YDL022W - GPD1  0 9 0 7 0 0 
YDL025C - YDL025C  16 9 0 12 0 31 
YDL051W - LHP1  0 0 0 3 0 0 
YDL055C - PSA1  0 0 0 7 0 0 
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YDL061C - RPS29B  0 0 0 3 0 0 
YDL065C - PEX19  0 0 0 2 0 0 
YDL066W - IDP1  0 0 0 4 0 0 
YDL075W - RPL31A  0 0 0 6 0 0 
YDL081C - RPP1A  0 0 0 7 0 0 
YDL082W - RPL13A  0 0 0 6 0 0 
YDL083C - RPS16B  0 2 0 7 0 0 
YDL084W - SUB2  0 0 0 6 0 0 
YDL095W - PMT1  0 3 0 0 0 0 
YDL099W - BUG1  0 0 0 2 0 0 
YDL124W - YDL124W  0 0 0 4 0 0 
YDL126C - CDC48  0 0 0 7 0 0 
YDL131W - LYS21  8 0 4 5 0 0 
YDL140C - RPO21  0 4 0 0 0 2 
YDL145C - COP1  4 10 2 4 0 0 
YDL160C - DHH1  0 0 0 0 0 3 
YDL171C - GLT1  0 2 0 0 0 0 
YDL182W - LYS20  0 8 4 5 0 0 
YDL185W - TFP1  0 4 0 12 0 0 
YDL192W - ARF1  0 2 0 5 0 0 
YDL195W - SEC31  0 0 0 4 0 0 
YDL201W - TRM8  0 2 0 0 0 0 
YDL223C - HBT1  0 7 0 0 0 2 
YDL229W - SSB1  3 0 0 41 0 0 
YDL237W - AIM6  0 5 0 0 0 0 
YDR002W - YRB1  0 0 0 6 0 0 
YDR012W - RPL4B  0 0 0 22 0 0 
YDR023W - SES1  0 0 0 8 0 0 
YDR025W - RPS11A  0 0 0 5 0 0 
YDR034C-D - YDR034C-D  0 15 0 0 0 0 
YDR035W - ARO3  0 0 0 3 0 0 
YDR037W - KRS1  0 0 0 10 0 0 
YDR050C - TPI1  0 0 0 33 0 0 
YDR051C - DET1  0 3 0 0 0 0 
YDR064W - RPS13  0 0 0 4 0 0 
YDR098C-B - YDR098C-B  0 0 0 0 9 0 
YDR122W - KIN1  0 2 0 0 0 0 
YDR127W - ARO1  5 2 0 4 0 0 
YDR148C - KGD2  0 0 0 5 0 0 
YDR150W - NUM1  0 0 0 2 0 0 
YDR155C - CPR1  0 4 0 22 0 0 
YDR164C - SEC1  0 2 0 0 0 0 
YDR171W - HSP42  0 3 0 0 0 0 
YDR172W - SUP35  3 2 4 0 0 0 
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YDR210C-D - YDR210C-D  0 0 47 0 9 0 
YDR224C - HTB1  0 0 0 10 0 0 
YDR225W - HTA1  0 0 0 4 0 0 
YDR226W - ADK1  0 0 0 11 0 0 
YDR232W - HEM1  10 12 3 6 0 4 
YDR258C - HSP78  0 0 0 2 0 0 
YDR261C-D - YDR261C-D  0 0 47 0 9 0 
YDR261W-B - YDR261W-B  18 14 0 0 0 0 
YDR298C - ATP5  0 0 0 5 0 0 
YDR300C - PRO1  0 2 0 0 0 0 
YDR304C - CPR5  0 0 0 7 0 0 
YDR316W-B - YDR316W-B  84 0 47 0 9 0 
YDR342C - HXT7  0 5 0 6 0 0 
YDR343C - HXT6  0 5 0 0 0 0 
YDR353W - TRR1  0 0 0 7 0 0 
YDR354W - TRP4  0 3 0 0 0 0 
YDR382W - RPP2B  0 0 0 6 0 0 
YDR385W - EFT2  0 9 4 55 0 0 
YDR394W - RPT3  0 0 0 2 0 0 
YDR418W - RPL12B  0 0 0 17 0 0 
YDR429C - TIF35  0 0 0 2 0 0 
YDR432W - NPL3  35 261 9 42 53 51 
YDR447C - RPS17B  0 0 0 7 0 0 
YDR450W - RPS18A  0 3 4 6 0 0 
YDR454C - GUK1  0 0 0 2 0 0 
YDR457W - TOM1  0 4 0 0 0 2 
YDR471W - RPL27B  0 0 0 7 0 0 
YDR475C - JIP4  6 14 0 3 0 10 
YDR477W - SNF1  79 61 19 24 4 70 
YDR481C - PHO8  11 69 9 15 6 25 
YDR487C - RIB3  0 0 0 3 0 0 
YDR502C - SAM2  0 0 0 4 0 0 
YDR510W - SMT3  0 0 0 2 0 0 
YDR513W - GRX2  0 0 0 4 0 0 
YDR529C - QCR7  0 0 0 5 0 0 
YDR533C - HSP31  0 0 0 3 0 0 
YEL024W - RIP1  0 0 0 2 0 0 
YEL030W - ECM10  0 0 0 6 0 0 
YEL034W - HYP2  0 0 0 12 0 0 
YEL054C - RPL12A  0 0 0 17 0 0 
YEL060C - PRB1  0 3 0 0 0 0 
YEL071W - DLD3  0 0 2 0 0 0 
YER003C - PMI40  0 0 0 8 0 0 
YER009W - NTF2  0 0 0 2 0 0 
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YER018C - SPC25  2 4 0 0 0 0 
YER025W - GCD11  0 0 0 3 0 0 
YER043C - SAH1  0 5 0 18 0 2 
YER062C - HOR2  0 0 0 3 0 0 
YER067W - YER067W  30 63 0 19 8 22 
YER068W - MOT2  0 8 3 0 0 0 
YER074W - RPS24A  0 0 0 8 0 0 
YER086W - ILV1  2 11 6 6 3 5 
YER088C - DOT6  13 5 0 2 6 5 
YER090W - TRP2  0 5 0 3 0 0 
YER091C - MET6  0 0 0 27 0 0 
YER094C - PUP3  0 0 0 4 0 0 
YER101C - AST2  0 4 0 0 0 0 
YER102W - RPS8B  0 0 0 6 0 0 
YER103W - SSA4  0 0 0 25 0 0 
YER113C - TMN3  0 0 0 2 0 0 
YER117W - RPL23B  0 0 0 8 0 0 
YER120W - SCS2  0 0 0 3 0 0 
YER131W - RPS26B  0 0 0 4 0 0 
YER132C - PMD1  4 3 4 0 0 5 
YER138C - YER138C  0 45 49 57 0 26 
YER151C - UBP3  0 3 0 0 0 2 
YER155C - BEM2  9 9 0 7 0 6 
YER160C - YER160C  87 45 49 0 0 26 
YER165W - PAB1  0 3 0 14 0 0 
YER177W - BMH1  0 0 0 16 0 0 
YER183C - FAU1  2 0 0 0 0 0 
YFL002W-A - YFL002W-A  0 15 0 0 0 0 
YFL007W - BLM10  3 4 2 0 0 0 
YFL014W - HSP12  0 0 0 2 0 0 
YFL018C - LPD1  0 0 0 7 0 0 
YFL034C-A - RPL22B  0 0 0 2 0 0 
YFL039C - ACT1  3 10 0 22 0 9 
YFL045C - SEC53  0 0 0 2 0 0 
YFR004W - RPN11  0 0 0 2 0 0 
YFR015C - GSY1  9 11 0 4 0 0 
YFR024C-A - LSB3  0 0 0 3 0 0 
YFR028C - CDC14  0 3 0 2 0 0 
YFR031C-A - RPL2A  6 8 0 14 0 0 
YFR033C - QCR6  0 0 0 2 0 0 
YFR044C - DUG1  0 0 0 5 0 0 
YFR052W - RPN12  0 0 0 2 0 0 
YFR053C - HXK1  0 8 0 45 0 0 
YGL008C - PMA1  0 0 0 20 0 0 
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YGL009C - LEU1  0 0 0 10 0 0 
YGL026C - TRP5  6 14 4 16 0 0 
YGL030W - RPL30  0 0 0 7 0 0 
YGL031C - RPL24A  0 0 0 3 0 0 
YGL037C - PNC1  5 39 3 13 7 9 
YGL040C - HEM2  0 0 0 2 0 0 
YGL043W - DST1  0 0 0 2 0 0 
YGL056C - SDS23  0 8 0 2 0 0 
YGL062W - PYC1  0 13 2 5 0 0 
YGL068W - MNP1  0 0 0 3 0 0 
YGL076C - RPL7A  2 5 0 9 0 0 
YGL103W - RPL28  6 12 8 5 0 6 
YGL105W - ARC1  0 0 0 10 0 0 
YGL106W - MLC1  0 0 0 6 0 0 
YGL120C - PRP43  0 3 0 0 0 0 
YGL123W - RPS2  0 0 0 11 0 0 
YGL135W - RPL1B  0 0 0 7 0 0 
YGL137W - SEC27  0 0 0 2 0 0 
YGL147C - RPL9A  0 5 2 5 0 0 
YGL148W - ARO2  2 6 3 8 3 2 
YGL157W - YGL157W  0 0 6 0 0 0 
YGL173C - KEM1  2 19 4 4 0 3 
YGL178W - MPT5  0 6 0 0 0 6 
YGL187C - COX4  0 3 0 6 0 0 
YGL189C - RPS26A  0 0 0 4 0 0 
YGL202W - ARO8  0 5 0 3 0 0 
YGL206C - CHC1  0 0 0 2 0 0 
YGL234W - ADE5,7  0 0 0 4 0 0 
YGL242C - YGL242C  0 0 0 5 0 0 
YGL245W - GUS1  0 2 0 11 0 0 
YGL253W - HXK2  0 4 0 14 0 0 
YGR010W - NMA2  3 0 0 0 0 0 
YGR019W - UGA1  0 2 0 0 0 0 
YGR034W - RPL26B  0 0 0 3 0 0 
YGR037C - ACB1  0 0 0 12 0 0 
YGR038C-B - YGR038C-B  0 0 0 0 9 0 
YGR061C - ADE6  0 0 0 5 0 0 
YGR080W - TWF1  0 0 0 2 0 0 
YGR085C - RPL11B  0 0 0 2 0 0 
YGR086C - PIL1  0 0 0 12 0 0 
YGR094W - VAS1  0 0 0 5 0 0 
YGR116W - SPT6  6 23 0 8 0 3 
YGR118W - RPS23A  0 0 0 5 0 0 
YGR124W - ASN2  301 139 218 103 17 138 
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YGR148C - RPL24B  0 0 0 3 0 0 
YGR155W - CYS4  0 0 0 17 0 0 
YGR159C - NSR1  0 0 0 3 0 0 
YGR161C-D - YGR161C-D  0 45 0 0 0 0 
YGR161W-B - YGR161W-B  0 15 0 0 0 0 
YGR185C - TYS1  0 0 0 3 0 0 
YGR192C - TDH3  20 21 10 132 5 15 
YGR194C - XKS1  0 9 0 0 0 0 
YGR204W - ADE3  0 0 0 2 0 0 
YGR209C - TRX2  0 0 0 3 0 0 
YGR214W - RPS0A  0 2 0 0 0 0 
YGR234W - YHB1  0 0 0 7 0 0 
YGR240C - PFK1  4 15 4 15 0 2 
YGR254W - ENO1  0 0 0 66 0 2 
YGR264C - MES1  0 0 0 3 0 0 
YGR266W - YGR266W  3 8 0 4 0 0 
YGR271W - SLH1  0 0 0 2 0 0 
YGR277C - CAB4  0 3 0 0 0 0 
YGR279C - SCW4  0 0 0 7 0 0 
YGR282C - BGL2  0 0 0 7 0 0 
YGR285C - ZUO1  0 0 0 9 0 0 
YHL001W - RPL14B  0 0 0 15 0 0 
YHL015W - RPS20  0 0 0 3 0 0 
YHL018W - YHL018W  12 26 0 4 0 9 
YHL023C - RMD11  0 5 0 0 0 6 
YHL033C - RPL8A  0 0 0 11 0 0 
YHL034C - SBP1  0 0 0 14 0 0 
YHR005C-A - TIM10  0 0 0 2 0 0 
YHR007C - ERG11  0 2 0 0 0 0 
YHR008C - SOD2  0 0 0 4 0 0 
YHR010W - RPL27A  0 0 0 7 0 0 
YHR018C - ARG4  0 0 0 2 0 0 
YHR019C - DED81  0 3 0 5 0 0 
YHR033W - YHR033W  0 3 0 0 0 0 
YHR051W - COX6  0 0 0 4 0 0 
YHR064C - SSZ1  0 0 0 9 0 0 
YHR070W - TRM5  2 4 0 0 0 0 
YHR073W - OSH3  0 3 0 0 0 0 
YHR087W - RTC3  0 0 0 4 0 0 
YHR097C - YHR097C  0 14 0 0 3 15 
YHR099W - TRA1  0 2 0 0 0 0 
YHR106W - TRR2  0 0 0 2 0 0 
YHR108W - GGA2  0 0 0 2 0 0 
YHR135C - YCK1  0 46 0 0 4 12 
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YHR146W - CRP1  0 0 0 2 0 0 
YHR174W - ENO2  2 3 5 129 0 2 
YHR179W - OYE2  0 0 0 6 0 0 
YHR183W - GND1  0 8 0 18 0 0 
YHR193C - EGD2  0 0 0 12 0 0 
YHR203C - RPS4B  0 3 0 18 0 0 
YHR205W - SCH9  5 7 4 3 0 12 
YHR208W - BAT1  0 0 0 11 0 0 
YHR214C-B - YHR214C-B  0 45 0 0 0 0 
YHR216W - IMD2  0 0 0 4 0 0 
YIL002C - INP51  0 0 0 0 0 3 
YIL018W - RPL2B  6 8 0 14 0 0 
YIL033C - BCY1  0 0 0 2 0 0 
YIL041W - GVP36  0 0 0 2 0 0 
YIL051C - MMF1  0 0 0 3 0 0 
YIL053W - RHR2  0 0 0 9 0 0 
YIL057C - YIL057C  0 2 0 0 0 0 
YIL062C - ARC15  0 0 0 3 0 0 
YIL069C - RPS24B  0 0 0 8 0 0 
YIL070C - MAM33  0 0 0 6 0 0 
YIL078W - THS1  0 4 0 0 0 0 
YIL109C - SEC24  0 3 0 0 0 0 
YIL125W - KGD1  0 10 0 8 0 0 
YIL137C - TMA108  0 15 0 3 0 2 
YIL138C - TPM2  0 0 0 2 0 0 
YIL143C - SSL2  0 3 0 0 0 0 
YIL149C - MLP2  0 2 0 0 0 0 
YIL162W - SUC2  0 0 0 2 0 0 
YIR037W - HYR1  0 0 0 2 0 0 
YJL005W - CYR1  0 2 0 0 0 0 
YJL020C - BBC1  7 28 3 8 3 8 
YJL026W - RNR2  2 2 0 2 0 0 
YJL034W - KAR2  0 0 0 6 0 0 
YJL041W - NSP1  0 0 0 4 0 0 
YJL042W - MHP1  0 0 0 0 0 3 
YJL045W - YJL045W  14 5 0 0 0 0 
YJL052W - TDH1  0 8 0 25 0 0 
YJL056C - ZAP1  0 0 0 0 0 2 
YJL080C - SCP160  0 0 0 6 0 0 
YJL083W - TAX4  3 4 4 0 0 2 
YJL130C - URA2  6 39 15 17 0 12 
YJL136C - RPS21B  0 0 0 10 0 0 
YJL138C - TIF2  0 2 0 20 0 0 
YJL158C - CIS3  0 0 0 2 0 0 
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YJL159W - HSP150  0 0 0 2 0 0 
YJL172W - CPS1  0 7 2 0 0 0 
YJL177W - RPL17B  0 0 0 7 0 0 
YJL190C - RPS22A  0 0 0 7 0 0 
YJL191W - RPS14B  0 0 0 7 0 0 
YJR009C - TDH2  0 14 0 44 0 0 
YJR016C - ILV3  0 0 0 4 0 0 
YJR019C - TES1  113 36 20 26 0 9 
YJR033C - RAV1  0 2 0 0 0 0 
YJR035W - RAD26  0 6 0 0 0 0 
YJR045C - SSC1  0 0 0 29 0 0 
YJR048W - CYC1  0 0 0 6 0 0 
YJR059W - PTK2  0 2 0 0 0 0 
YJR069C - HAM1  0 0 0 3 0 0 
YJR077C - MIR1  0 0 0 5 0 0 
YJR082C - EAF6  0 4 0 0 0 2 
YJR091C - JSN1  0 3 0 0 0 0 
YJR104C - SOD1  0 0 0 19 0 0 
YJR105W - ADO1  0 0 0 8 0 0 
YJR109C - CPA2  0 9 0 13 0 0 
YJR121W - ATP2  0 3 0 32 3 0 
YJR123W - RPS5  0 0 0 15 0 0 
YJR139C - HOM6  0 0 0 12 0 0 
YJR145C - RPS4A  0 3 0 18 0 0 
YKL006W - RPL14A  0 0 0 15 0 0 
YKL016C - ATP7  0 0 0 6 0 0 
YKL032C - IXR1  0 4 0 0 0 0 
YKL035W - UGP1  5 3 0 3 0 0 
YKL060C - FBA1  2 4 0 66 0 0 
YKL067W - YNK1  0 0 0 4 0 0 
YKL080W - VMA5  0 0 0 6 0 0 
YKL081W - TEF4  0 2 0 8 0 0 
YKL085W - MDH1  0 0 0 22 0 0 
YKL104C - GFA1  0 3 0 2 0 0 
YKL112W - ABF1  4 10 2 0 0 0 
YKL129C - MYO3  5 10 2 6 0 6 
YKL142W - MRP8  0 0 0 5 0 0 
YKL148C - SDH1  33 17 0 15 0 0 
YKL150W - MCR1  0 0 0 4 0 0 
YKL152C - GPM1  0 2 0 41 0 0 
YKL164C - PIR1  0 0 0 2 0 0 
YKL168C - KKQ8  2 0 0 0 0 0 
YKL175W - ZRT3  0 2 0 0 0 0 
YKL180W - RPL17A  0 0 0 7 0 0 
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YKL182W - FAS1  0 10 0 17 0 0 
YKL191W - DPH2  0 2 0 0 0 0 
YKL210W - UBA1  0 0 0 2 0 0 
YKL211C - TRP3  0 2 0 0 0 2 
YKL212W - SAC1  0 18 0 3 0 0 
YKL213C - DOA1  2 2 0 0 0 0 
YKR016W - AIM28  0 0 0 3 0 0 
YKR048C - NAP1  0 0 0 4 0 0 
YKR057W - RPS21A  0 0 0 11 0 0 
YKR059W - TIF1  0 2 0 20 0 0 
YKR098C - UBP11  7 9 0 6 0 7 
YLL013C - PUF3  0 4 0 0 0 3 
YLL018C - DPS1  0 8 0 10 0 0 
YLL021W - SPA2  4 3 5 0 0 0 
YLL024C - SSA2  9 0 4 84 0 3 
YLL026W - HSP104  0 0 0 4 0 0 
YLL041C - SDH2  0 2 0 0 0 0 
YLL045C - RPL8B  0 0 0 12 0 0 
YLL050C - COF1  0 0 0 11 0 0 
YLR017W - MEU1  0 3 2 0 0 0 
YLR027C - AAT2  0 0 0 4 0 0 
YLR028C - ADE16  0 0 0 3 0 0 
YLR029C - RPL15A  0 0 0 5 0 0 
YLR038C - COX12  0 0 0 2 0 0 
YLR043C - TRX1  0 0 0 2 0 0 
YLR044C - PDC1  5 23 20 74 0 16 
YLR048W - RPS0B  0 2 0 10 0 0 
YLR058C - SHM2  8 18 24 17 0 28 
YLR061W - RPL22A  0 0 0 7 0 0 
YLR075W - RPL10  0 2 0 13 0 0 
YLR096W - KIN2  0 7 0 0 0 0 
YLR109W - AHP1  0 0 0 12 0 0 
YLR134W - PDC5  0 0 0 13 0 0 
YLR150W - STM1  0 0 0 7 0 0 
YLR153C - ACS2  12 15 8 14 0 13 
YLR157C-B - YLR157C-B  0 0 0 0 9 0 
YLR167W - RPS31  0 0 0 17 0 0 
YLR175W - CBF5  0 0 0 3 0 0 
YLR180W - SAM1  0 0 0 6 0 0 
YLR192C - HCR1  0 0 0 6 0 0 
YLR195C - NMT1  0 4 3 0 0 0 
YLR197W - NOP56  0 0 0 5 0 0 
YLR200W - YKE2  0 0 0 3 0 0 
YLR216C - CPR6  0 0 0 4 0 0 
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YLR249W - YEF3  8 20 2 20 2 0 
YLR250W - SSP120  0 3 0 3 0 0 
YLR258W - GSY2  29 34 6 21 0 9 
YLR259C - HSP60  0 0 0 26 0 0 
YLR262C-A - TMA7  0 0 0 2 0 0 
YLR264W - RPS28B  0 0 0 6 0 0 
YLR293C - GSP1  0 2 0 2 0 0 
YLR295C - ATP14  0 0 0 6 0 0 
YLR301W - YLR301W  0 0 0 2 0 0 
YLR303W - MET17  2 0 0 3 0 0 
YLR304C - ACO1  0 0 0 12 0 0 
YLR325C - RPL38  0 0 0 5 0 0 
YLR328W - NMA1  22 17 3 14 2 33 
YLR340W - RPP0  0 0 0 14 0 0 
YLR344W - RPL26A  0 0 0 3 0 0 
YLR352W - YLR352W  0 2 0 0 0 0 
YLR354C - TAL1  0 0 0 5 0 0 
YLR355C - ILV5  0 0 0 22 0 0 
YLR367W - RPS22B  0 0 0 7 0 0 
YLR371W - ROM2  4 10 5 2 0 3 
YLR388W - RPS29A  0 0 0 3 0 0 
YLR406C - RPL31B  0 0 0 6 0 0 
YLR432W - IMD3  0 2 0 4 0 0 
YLR438W - CAR2  26 18 8 5 0 10 
YLR441C - RPS1A  0 0 0 10 0 0 
YML008C - ERG6  0 0 0 2 0 0 
YML017W - PSP2  23 132 9 22 7 35 
YML024W - RPS17A  0 0 0 7 0 0 
YML026C - RPS18B  0 3 4 6 0 0 
YML028W - TSA1  0 5 0 37 0 0 
YML035C - AMD1  20 25 5 9 0 0 
YML050W - AIM32  3 27 0 2 0 3 
YML051W - GAL80  12 13 30 0 0 0 
YML059C - NTE1  10 6 5 3 0 5 
YML063W - RPS1B  0 0 0 11 0 0 
YML070W - DAK1  0 0 0 2 0 0 
YML072C - TCB3  0 6 0 2 0 2 
YML073C - RPL6A  0 0 0 7 0 0 
YML074C - FPR3  0 0 0 4 0 0 
YML078W - CPR3  0 0 0 3 0 0 
YML081W - YML081W  0 0 0 0 0 3 
YML092C - PRE8  0 0 0 2 0 0 
YML100W - TSL1  0 4 0 3 0 0 
YML126C - ERG13  0 0 0 2 0 0 
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YMR012W - CLU1  20 27 11 13 3 8 
YMR029C - FAR8  0 7 0 0 0 0 
YMR062C - ECM40  0 0 0 3 0 0 
YMR083W - ADH3  3 3 0 5 0 0 
YMR087W - YMR087W  0 6 2 0 0 0 
YMR099C - YMR099C  0 2 0 2 0 0 
YMR102C - YMR102C  0 0 0 0 0 2 
YMR104C - YPK2  10 12 0 9 0 11 
YMR108W - ILV2  3 2 0 12 0 0 
YMR109W - MYO5  2 0 0 0 0 0 
YMR113W - FOL3  3 82 2 10 4 31 
YMR116C - ASC1  0 2 0 19 0 0 
YMR120C - ADE17  0 0 0 6 0 0 
YMR142C - RPL13B  0 0 0 6 0 0 
YMR143W - RPS16A  0 2 0 7 0 0 
YMR145C - NDE1  0 0 0 3 0 0 
YMR146C - TIF34  0 0 0 2 0 0 
YMR183C - SSO2  0 0 0 3 0 0 
YMR186W - HSC82  6 11 2 29 0 2 
YMR194W - RPL36A  0 0 0 3 0 0 
YMR203W - TOM40  0 0 0 4 0 0 
YMR205C - PFK2  0 5 0 8 0 0 
YMR217W - GUA1  5 15 5 12 0 4 
YMR226C - YMR226C  0 0 0 3 0 0 
YMR230W - RPS10B  0 0 0 11 0 0 
YMR237W - BCH1  3 14 3 4 0 2 
YMR242C - RPL20A  0 6 0 5 0 0 
YMR243C - ZRC1  3 3 0 0 0 0 
YMR250W - GAD1  3 9 0 2 0 0 
YMR273C - ZDS1  0 0 0 0 0 2 
YMR276W - DSK2  0 0 0 4 0 0 
YMR304W - UBP15  0 2 0 0 0 0 
YMR307W - GAS1  0 0 0 7 0 0 
YMR309C - NIP1  0 2 0 2 0 0 
YMR315W - YMR315W  0 0 0 3 0 0 
YMR318C - ADH6  0 0 0 2 0 0 
YNL007C - SIS1  0 2 0 8 0 0 
YNL009W - IDP3  0 2 0 0 0 0 
YNL015W - PBI2  0 0 0 5 0 0 
YNL030W - HHF2  0 0 0 3 0 0 
YNL036W - NCE103  0 8 0 2 0 0 
YNL037C - IDH1  0 0 0 2 0 0 
YNL055C - POR1  0 0 0 12 0 0 
YNL064C - YDJ1  4 7 8 3 0 0 
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YNL067W - RPL9B  0 5 2 5 0 0 
YNL071W - LAT1  0 0 0 5 0 0 
YNL079C - TPM1  0 0 0 10 0 0 
YNL091W - NST1  0 11 0 2 0 0 
YNL096C - RPS7B  0 0 0 5 0 0 
YNL104C - LEU4  0 0 0 4 0 0 
YNL121C - TOM70  0 0 0 3 0 0 
YNL131W - TOM22  0 0 0 4 0 0 
YNL134C - YNL134C  0 0 0 10 0 0 
YNL135C - FPR1  0 0 0 4 0 0 
YNL138W - SRV2  0 0 0 2 0 0 
YNL154C - YCK2  73 190 25 56 21 120 
YNL160W - YGP1  0 0 0 2 0 0 
YNL178W - RPS3  0 0 0 13 0 0 
YNL183C - NPR1  3 0 0 0 0 0 
YNL208W - YNL208W  0 0 0 3 0 0 
YNL209W - SSB2  3 7 0 42 0 0 
YNL220W - ADE12  0 0 0 2 0 0 
YNL244C - SUI1  0 0 0 4 0 0 
YNL301C - RPL18B  0 2 0 2 0 0 
YNL302C - RPS19B  0 2 0 15 0 0 
YNL310C - ZIM17  4 9 3 0 0 0 
YNL321W - VNX1  0 0 0 0 0 4 
YNR001C - CIT1  0 0 0 8 0 0 
YNR016C - ACC1  30 66 10 17 0 7 
YNR047W - FPK1  0 3 0 0 0 3 
YOL039W - RPP2A  0 0 0 9 0 0 
YOL040C - RPS15  0 0 0 5 0 0 
YOL044W - PEX15  0 3 0 0 0 0 
YOL051W - GAL11  0 0 0 20 0 0 
YOL058W - ARG1  0 0 0 5 0 0 
YOL059W - GPD2  24 41 15 10 8 36 
YOL081W - IRA2  0 4 2 3 0 2 
YOL086C - ADH1  7 27 7 40 3 4 
YOL087C - YOL087C  36 39 37 25 4 28 
YOL109W - ZEO1  0 0 0 2 0 0 
YOL120C - RPL18A  0 2 0 2 0 0 
YOL121C - RPS19A  0 2 0 15 0 0 
YOL123W - HRP1  0 0 0 3 0 0 
YOL127W - RPL25  0 0 0 4 0 0 
YOL139C - CDC33  0 10 0 6 0 3 
YOL145C - CTR9  0 4 0 0 0 0 
YOR007C - SGT2  0 0 0 9 0 0 
YOR017W - PET127  2 6 0 0 0 0 
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YOR020C - HSP10  0 0 0 3 0 0 
YOR021C - YOR021C  0 0 0 2 0 0 
YOR027W - STI1  3 2 0 15 0 0 
YOR063W - RPL3  3 4 4 18 0 0 
YOR070C - GYP1  0 2 0 0 0 0 
YOR096W - RPS7A  0 0 0 10 0 0 
YOR117W - RPT5  0 0 0 4 0 0 
YOR122C - PFY1  0 0 0 3 0 0 
YOR133W - EFT1  0 9 4 55 0 0 
YOR136W - IDH2  0 5 0 10 0 0 
YOR142W - LSC1  0 0 0 5 0 0 
YOR167C - RPS28A  0 0 0 6 0 0 
YOR168W - GLN4  0 0 0 2 0 0 
YOR184W - SER1  0 0 0 3 0 0 
YOR185C - GSP2  0 2 0 2 0 0 
YOR187W - TUF1  0 10 0 4 0 0 
YOR195W - SLK19  3 0 0 0 0 0 
YOR198C - BFR1  0 0 0 6 0 0 
YOR202W - HIS3  3 10 2 7 0 4 
YOR204W - DED1  0 0 0 4 0 0 
YOR230W - WTM1  0 0 0 4 0 0 
YOR267C - HRK1  11 19 11 13 5 26 
YOR276W - CAF20  19 10 0 14 0 20 
YOR285W - YOR285W  0 0 0 8 0 0 
YOR286W - AIM42  0 0 0 2 0 0 
YOR293W - RPS10A  0 0 0 11 0 0 
YOR298C-A - MBF1  0 0 0 3 0 0 
YOR310C - NOP58  0 0 0 2 0 0 
YOR312C - RPL20B  0 6 0 5 0 0 
YOR316C - COT1  0 2 0 0 0 0 
YOR317W - FAA1  0 4 0 3 0 0 
YOR332W - VMA4  0 0 0 9 0 0 
YOR335C - ALA1  0 0 0 4 0 0 
YOR369C - RPS12  0 0 0 8 0 0 
YOR374W - ALD4  0 8 0 20 0 0 
YOR375C - GDH1  0 0 0 9 0 0 
YPL004C - LSP1  0 0 0 11 0 0 
YPL016W - SWI1  7 6 8 0 0 0 
YPL037C - EGD1  0 0 0 13 0 0 
YPL059W - GRX5  0 0 0 4 0 0 
YPL061W - ALD6  0 0 0 12 0 0 
YPL063W - TIM50  0 2 0 0 0 0 
YPL078C - ATP4  0 0 0 4 0 0 
YPL079W - RPL21B  0 0 0 2 0 0 
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YPL081W - RPS9A  0 0 0 4 0 0 
YPL090C - RPS6A  0 0 0 6 0 0 
YPL091W - GLR1  0 0 0 3 0 0 
YPL106C - SSE1  0 0 0 29 0 0 
YPL131W - RPL5  0 0 0 28 0 0 
YPL154C - PEP4  0 0 0 8 0 0 
YPL160W - CDC60  0 0 0 4 0 0 
YPL198W - RPL7B  2 5 0 9 0 0 
YPL204W - HRR25  0 2 0 0 0 0 
YPL207W - TYW1  4 3 3 0 0 0 
YPL218W - SAR1  0 0 0 5 0 0 
YPL220W - RPL1A  0 0 0 7 0 0 
YPL224C - MMT2  14 19 0 8 0 4 
YPL231W - FAS2  0 4 0 17 0 0 
YPL237W - SUI3  0 0 0 2 0 0 
YPL239W - YAR1  0 0 0 3 0 0 
YPL240C - HSP82  0 0 2 27 0 0 
YPL248C - GAL4  0 0 0 54 0 0 
YPL249C-A - RPL36B  0 0 0 3 0 0 
YPL262W - FUM1  0 0 0 3 0 0 
YPR016C - TIF6  0 0 0 2 0 0 
YPR033C - HTS1  0 0 0 3 0 0 
YPR035W - GLN1  0 6 0 0 0 0 
YPR036W - VMA13  0 0 0 2 0 0 
YPR041W - TIF5  0 0 0 2 0 0 
YPR069C - SPE3  0 0 0 2 0 0 
YPR072W - NOT5  0 0 0 2 0 0 
YPR074C - TKL1  0 0 0 7 0 0 
YPR080W - TEF1  91 29 20 107 4 11 
YPR102C - RPL11A  0 0 0 2 0 0 
YPR129W - SCD6  0 0 0 2 0 0 
YPR132W - RPS23B  0 0 0 5 0 0 
YPR135W - CTF4  0 6 0 0 0 0 
YPR145W - ASN1  110 48 90 27 5 63 
YPR163C - TIF3  0 0 0 3 0 0 
YPR181C - SEC23  2 3 0 0 0 0 
YPR191W - QCR2  0 0 0 7 0 0 
 
 
 
 
